



## UNITED STATES PATENT AND TRADEMARK OFFICE

JUN 12

Commissioner for Patents, Box PCT  
United States Patent and Trademark Office  
Washington, D.C. 20231  
www.uspto.gov

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/831096 ✓	CLEMONS	P 385A PCT/US
INTERNATIONAL APPLICATION NO. PCT/US99/25766		
DAVID L. BERSTEIN ARIAD PHARMACEUTICALS INC 26 LANDSDOWNE STREET CAMBRIDGE MA 02139		
I.A. FILING DATE		PRIORITY DATE
05 NOV 99		06 NOV 98

DATE MAILED 05 JUN 2001

## NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

1. The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as  a Designated Office (37 CFR 1.494)  an Elected Office (37 CFR 1.495):

U.S. Basic National Fee.  Indication of Small Entity Status.  
 Copy of the international application.  Translation of the international application into English.  
 Oath or Declaration of inventors(s).  Translation of Article 19 amendments into English.  
 Copy of Article 19 amendments.  Other:  
 Priority Document.  
 The International Preliminary Examination Report in English and its Annexes, if any.  
 Translation of Annexes to the International Preliminary Examination Report into English.

2.  Applicant has requested early processing under 35 U.S.C. 371(f) but has not filed the following indicated items and/or the indicated items in paragraph 3 below. The Basic National Fee and the copy of the international application must be filed prior to 20 or 30 months from the priority date to avoid abandonment.

U.S. Basic National Fee.  Copy of the international application.

3. The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

a. Translation of the application into English. A processing fee will be required if submitted later than the appropriate 20 or 30 months from the priority date.  
 The current translation is defective for the reasons indicated on the attached Notice of Defective Translation.  
 Processing fee for providing the translation of the application and/or the Annexes later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(f)).  
 c. Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), properly identifying the application (preferably by the International application number and international filing date). A surcharge will be required if submitted later than the appropriate 20 or 30 months from the priority date.  
 The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT/DO/EO/917.  
 d. Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(e)). PREPAID.

4. Additional claim fees of \$\_\_\_\_\_ as a  large entity  small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due (37 CFR 1.492(g)). See attached PTO-875.

5.  Applicant has not submitted the required sequence listing pursuant to 37 CFR 1.821-1.825. See attached PCT/DO/EO/920.

**ALL OF THE ITEMS SET FORTH IN 3(a)-3(d), 4 AND 5 ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 22 OR 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

6. If box 3a or 3c is checked, a translation of the Annexes MUST be submitted no later than the time period set above or the Annexes will be cancelled. A processing fee will be required if submitted later than 20 or 30 months from the priority date.

7.  The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d)) or 30 (37 CFR 1.495(d)) months from the priority date.

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5).

*A copy of this notice MUST be returned with this response!*

Enclosed:  PCT/DO/EO/917  
 PTO-875

Notice of Defective Translation  
 PCT/DO/EO/920

Shakeel Ahmed

Telephone: 703-305-3659

## PENT COOPERATION TREA

PCT

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
 United States Patent and Trademark  
 Office  
 Box PCT  
 Washington, D.C.20231  
 ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year)
20 June 2000 (20.06.00)

International application No.
PCT/US99/25766

International filing date (day/month/year)
05 November 1999 (05.11.99)

Applicant's or agent's file reference
385A PCT
Priority date (day/month/year)
06 November 1998 (06.11.98)

Applicant
CLEMONS, Paul, A. et al

1. The designated Office is hereby notified of its election made:

in the demand filed with the International Preliminary Examining Authority on:

26 May 2000 (26.05.00)

in a notice effecting later election filed with the International Bureau on:

\_\_\_\_\_

2. The election  was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer  Juan Cruz
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference  385A PCT	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No.  PCT/US 99/25766	International filing date (day/month/year)  05/11/1999	(Earliest) Priority Date (day/month/year)  06/11/1998
Applicant  PRESIDENT AND FELLOWS OF HARVARD COLLEGE et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 6 sheets.  
 It is also accompanied by a copy of each prior art document cited in this report.

## 1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

contained in the international application in written form.

filed together with the international application in computer readable form.

furnished subsequently to this Authority in written form.

furnished subsequently to this Authority in computer readable form.

the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2.  Certain claims were found unsearchable (See Box I).3.  Unity of invention is lacking (see Box II).

## 4. With regard to the title,

the text is approved as submitted by the applicant.

the text has been established by this Authority to read as follows:

## 5. With regard to the abstract,

the text is approved as submitted by the applicant.

the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No

as suggested by the applicant.

because the applicant failed to suggest a figure.

because this figure better characterizes the invention.

6

 None of the figures.

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US 99/25766

**Box III TEXT OF THE ABSTRACT (Continuation of item 5 of the first sheet)**

This invention provides methods and materials for making and using genetically engineered cells which are responsive to the presence of an FKBP/CAB ligand or a cyclophilin/CAB ligand. The invention relies upon the introduction into cells of recombinant DNAs encoding fusion proteins which are capable of forming a complex with each other in the presence of ligand. One of the fusion proteins contains a calcineurin A/calcineurin B domain (CAB) and at least one heterologous protein domain. The second fusion protein contains a domain derived from an FKBP protein which is capable of binding to an FKBP/CAB ligand and forming a complex with a CAB-containing protein. The second fusion protein may alternatively contain a cyclophilin domain which is capable of binding cyclosporin or other cyclophilin/CAB ligand and forming a complex with a CAB-containing protein. The second fusion protein also contains at least one heterologous domain.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 99/25766

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  

Although claims 34-35, 38-41 and 43-45 are directed to a method of treatment of the human/animal body (as far as they embrace methods carried out "in vivo"), the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: 47-48  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  

see FURTHER INFORMATION sheet PCT/ISA/210
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 47-48

Present claims 47-48 refers to ligands and antagonists of the disclosed fusion proteins without giving a true technical characterization. Moreover, only a very limited number of such specific compounds are defined in the application. In consequence, the scope of said claim is ambiguous and vague, and its subject matter is not sufficiently disclosed and supported (Articles 5 and 6 PCT). No search has been carried out for such claims whose wording is, in fact, a mere recitation of the result to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

International Application No

P 99/25766

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/62 C12N15/52 C12N9/16 C12N15/86 A01K67/027  
G01N33/566

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 18317 A (UNIV LELAND STANFORD JUNIOR ;HARVARD COLLEGE (US)) 18 August 1994 (1994-08-18) cited in the application * whole document, in particular page 75 to 77 * --- WO 96 12806 A (UNIV LELAND STANFORD JUNIOR) 2 May 1996 (1996-05-02)  *whole document, in particular page 5, line 28 to page 6, line 6 and page 24 to page 25 * --- -/-	1,2,5-7, 11-46, 49,50
X		1,2,5-7, 11-27, 34-44



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
29 June 2000	08.08.00

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Julia, P

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/25766

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 16172 A (ICOS CORP ;OREGON STATE (US)) 30 May 1996 (1996-05-30)  * whole document, in particular page 15 example 4, page 19 example 5 and page 23 table 1 * ----	1,2,5-7, 11,19, 20,23, 25,26, 34,36
Y	WO 97 06246 A (VERTEX PHARMA) 20 February 1997 (1997-02-20)  * whole document, in particular page 28 to page 31 and figure 2 * ----	1-5,11, 20,21, 23,25, 26,28, 30,32, 34,36,38
Y	EP 0 618 227 A (AMGEN INC) 5 October 1994 (1994-10-05)  the whole document ----	1-5,11, 20,21, 23,25, 26,28, 30,32, 34,36,38
A	M.T. KENNEDY ET AL., : "Contributions of Myristoylation to Calcineurin Structure/Function" J. BIOL. CHEM., vol. 271, no. 43, 25 October 1996 (1996-10-25), pages 26517-26521, XP002140377 US the whole document ----	1-5,11, 19-21, 23,25, 26,28, 30,34, 36,38
A	Q. WEI AND E.Y. LEE: "Expression and reconstitution of calcineurin A and B subunits" BIOCHEM. MOL. BIOL. INT., vol. 41, no. 1, January 1997 (1997-01), pages 169-177, XP000915910 the whole document ----	1-5,11, 19-21, 23-26, 28,30, 34,36,38

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US 99/25766

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9418317	A 18-08-1994	AU 690898 B AU 6240394 A AU 7880798 A CA 2155728 A CN 1119876 A CZ 9502061 A EP 0804561 A FI 953812 A HU 73101 A JP 8510896 T PL 310327 A US 6011018 A US 6054436 A US 6063625 A US 6046047 A US 6043082 A US 5834266 A US 5869337 A US 5871753 A US 5830462 A		07-05-1998 29-08-1994 08-10-1998 18-08-1994 03-04-1996 17-04-1996 05-11-1997 11-08-1995 28-06-1996 19-11-1996 11-12-1995 04-01-2000 25-04-2000 16-05-2000 04-04-2000 28-03-2000 10-11-1998 09-02-1999 16-02-1999 03-11-1998
WO 9612806	A 02-05-1996	US 5723436 A AU 4006695 A		03-03-1998 15-05-1996
WO 9616172	A 30-05-1996	US 5807693 A US 5744354 A US 5871945 A AU 712168 B AU 4513396 A BR 9506540 A CA 2181826 A CN 1148407 A CZ 9602136 A EP 0748379 A FI 962932 A HU 75826 A JP 9509849 T NO 963049 A PL 315627 A SK 95096 A US 5629163 A		15-09-1998 28-04-1998 16-02-1999 28-10-1999 17-06-1996 07-10-1997 30-05-1996 23-04-1997 14-05-1997 18-12-1996 20-09-1996 28-05-1997 07-10-1997 23-09-1996 25-11-1996 09-07-1997 13-05-1997
WO 9706246	A 20-02-1997	US 5978740 A AU 6766896 A EP 0846163 A JP 11511016 T		02-11-1999 05-03-1997 10-06-1998 28-09-1999
EP 0618227	A 05-10-1994	AU 6497294 A CA 2159499 A EP 0691989 A FI 954657 A JP 8503858 T NO 953882 A WO 9422916 A US 5705484 A ZA 9402206 A		24-10-1994 13-10-1994 17-01-1996 23-10-1995 30-04-1996 28-11-1995 13-10-1994 06-01-1998 31-10-1994

## PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

## (PCT Article 36 and Rule 70)

Applicant's or agent's file reference ARIAD 385A PCT	<b>FOR FURTHER ACTION</b>	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/US99/25766	International filing date (day/month/year) 05/11/1999	Priority date (day/month/year) 06/11/1998
International Patent Classification (IPC) or national classification and IPC C12N15/00		
<p>Applicant PRESIDENT AND FELLOWS OF HARVARD COLLEGE et al.</p> <p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 10 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p> <p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> <li>I <input checked="" type="checkbox"/> Basis of the report</li> <li>II <input checked="" type="checkbox"/> Priority</li> <li>III <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</li> <li>IV <input type="checkbox"/> Lack of unity of invention</li> <li>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li> <li>VI <input type="checkbox"/> Certain documents cited</li> <li>VII <input type="checkbox"/> Certain defects in the international application</li> <li>VIII <input checked="" type="checkbox"/> Certain observations on the international application</li> </ul>		

Date of submission of the demand 26/05/2000	Date of completion of this report 16.01.2001
Name and mailing address of the international preliminary examining authority: European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Julia, P Telephone No. +49 89 2399 8410



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US99/25766

**I. Basis of the report**

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17.)*):

**Description, pages:**

1-100                   as originally filed

**Claims, No.:**

1-50                   as originally filed

**Drawings, sheets:**

1/10-10/10           as originally filed

**Sequence listing part of the description, pages:**

1-9, filed with the letter of 14.02.2000

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- the language of publication of the international application (under Rule 48.3(b)).
- the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- contained in the international application in written form.
- filed together with the international application in computer readable form.
- furnished subsequently to this Authority in written form.
- furnished subsequently to this Authority in computer readable form.
- The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US99/25766

the description,      pages:  
 the claims,      Nos.:  
 the drawings,      sheets:

5.  This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):  
*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:  
**see separate sheet**

**II. Priority**

1.  This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:  
 copy of the earlier application whose priority has been claimed.  
 translation of the earlier application whose priority has been claimed.

2.  This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:  
**see separate sheet**

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:  
 the entire international application.  
 claims Nos. 47-48.

because:

the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US99/25766

- the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- no international search report has been established for the said claims Nos. 47-48.

2. A meaningful international preliminary examination report cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- the written form has not been furnished or does not comply with the standard.
- the computer readable form has not been furnished or does not comply with the standard.

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes:	Claims 3-4, 8-10
	No:	Claims 1-2, 5-7, 11-46, 49-50
Inventive step (IS)	Yes:	Claims
	No:	Claims 1-46, 49-50
Industrial applicability (IA)	Yes:	Claims 1-33, 36-37, 46, 49-50
	No:	Claims 34-35, 38-45 (see citations and explanations)

2. Citations and explanations  
**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US99/25766

**1. Additional remarks to item I :**

A "Sequence Listing" has been filed on 14.02.00 with the present application. This "Sequence Listing" comprises SEQ ID No.: 1 to SEQ ID No.: 31 (pages 1-9).

**2. Additional remarks to item II :**

The priority documents pertaining to the present application were not available at the time of establishing this international preliminary examination report (IPER). Hence, the current assessment is based on the assumption that all claims enjoy priority rights from the filing date of the priority document (06.11.98).

**3. Additional remarks to item III :**

The subject matter of claims 47-48 refers to ligands and antagonists of the disclosed fusion proteins without giving a true technical characterization. Moreover, only a very limited number of such specific compounds are defined in the application. In consequence, the scope of these claims is ambiguous and vague, and its subject matter is not sufficiently disclosed and supported (Articles 5 and 6 PCT). No search has been carried out for such claims whose wording is, in fact, a mere recitation of the result to be achieved. Claims, or parts thereof, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1 (e) PCT).

**4. Additional remarks to item V :**

The present application discloses a so-called recombinant minimal functional calcineurin (CN, EC 3.1.3.16) A and B domain (CAB domain) consisting of a portion of CN-A (residues 12-394, 12-370 or 340-394 of human CN-A) and a portion of CN-B (residues 3-170 of human CN-B), which can further be fused with an "heterologous" portion such as a DNA binding domain, a transcription regulatory domain, a cellular localizing domain or a signalling domain (derived from LexA, Gal4, p65, VP16, etc...). A fusion protein containing one or more of this recombinant (minimal) functional CAB domain is also explicitly claimed. These CAB domains are all required to be functional in the sense that they are all able to form a tripartite complex with an FKBP/CAB ligand and an FKBP domain (FKBP, FK506 binding protein). The application further claims the corresponding recombinant nucleic acids as well as a composition comprising these nucleic acids as a first recombinant nucleic acid and as a second recombinant nucleic acid one encoding a fusion protein comprising at least one FKBP domain and at least one additional domain "heterologous"

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/25766

thereto (same or different from the other) as well as their use in a system similar to the yeast two-hybrid system (namely CAB domain-transcription activation domain/FKBP domain-DNA binding domain or CAB domain-DNA binding domain/FKBP domain-transcription activation domain with complex in presence of a ligand (FK506) results in a detectable biological signal). Further embodiments refer to vectors, host cells, non-human animals, a method for multimerizing fusion proteins, a method for initiating a detectable biological signal, a kit, etc...

The following documents have been cited in the International Search Report (ISR) as being relevant for assessing the novelty and inventiveness of the claimed subject matter:

- i) WO-A-94/18317 (**D1**) discloses the (regulated/inducible) dimerization or oligomerization of intracellular proteins by suitable ligands, in particular (i) the intracellular aggregation of the cytoplasmic tail of the zeta-chain of the T-cell-receptor (TCR) and CD3 thereby leading to signalling and transcription of a reporter gene, (ii) the homodimerization of cytoplasmic tail of the Fas receptor thereby leading to cell-specific apoptosis and (iii) the heterodimerization (by "bumped-FK506") of a calcineurin subunit A/DNA-binding domain (Gla4) and a FKBP12/transcription-activation domain (VP16) thereby leading to the transcription of a reporter gene. In view of the ambiguous wording of claim 1 and the possible interpretations thereof (see paragraph (iii) below under "Additional remarks to item VIII"), the IPEA considers that the calcineurin subunit A can be seen as a functional CAB domain which comprises a "portion" of subunit A (such as the complete sequence minus one residue) and a "portion" of subunit B (namely "the" residue) and thus, the subject matter of claims 1-2, 5-7 and 11-46, 49-50 is considered to be anticipated by this document (Articles 33 (2) and (3) PCT).
- ii) WO-A-96/12806 (**D2**) discloses a (yeast) cell-based two hybrid protein-protein interaction assay for identifying a small molecule immunosuppressant compound, wherein one of two fusion hybrid proteins in the cell contains a calcineurin A subunit (CN-A) (with a GAL4 activation domain) and the other of the two fusion proteins contains an immunophilin (FK506-binding proteins, FKBP) (with a GAL4 DNA binding domain). The document discloses similar systems using calcineurin B subunit (CN-B) and different C-terminal deleted calcineurin A subunits. The document also refers to the effect of the presence, absence or "overexpression, or increased expression, of a B subunit of calcineurin" in the different systems studied. In agreement with the interpretation given for

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US99/25766

D1 above, D2 is considered to be novelty destroying for the subject matter of claims 1-2, 5-7 and 11-46, 49-50 (Articles 33 (2) , (3) PCT).

iii) WO-A-96/16172 (**D3**) demonstrates the interaction of calcineurin with the A-kinase anchor protein-79 (AKAP-79) and using a two-hybrid assay system (using as a "bait" AKAP-79/GAL4 DNA-binding domain and as a "target" GAL4 transcription activating domain) isolates and characterizes a clone (clone 11.1) encoding a mouse calcineurin subunit A. The document discloses several deletion mutants of the disclosed mouse CN-A. In agreement with the interpretation given for documents D1 and D2 above, D3 is novelty destroying for the subject matter of at least claims 1-2, 5-7, 11, 19-20, 23, 25- 26, 34 and 36 (Articles 33 (2) , (3) PCT).

None of these documents seems to anticipate the specific subject matter of claims 3-4 and 8-10, which is thus considered to fulfil the requirements of Article 33 (2) PCT. However, the IPEA does not consider such a subject matter as inventive (Article 33 (3) PCT) in view of the following documents and argumentation :

iv) WO-A-97/06246 (**D4**) discloses crystal molecules of complexes comprising CN-A, CN-B, FKBP and FK506 and the characterization therein of the domains involved in their interactions. In particular, the document refers to the successful use of a 42 kDa deleted calcineurin A subunit (residues 17-392 of the native 59 kDa CN-A) without the C-terminal autoinhibitory domain (4kDa) and the adjacent calmodulin binding domain (14 kDa), which is still active, binds to the CN-B and to FKBP/FK506 (page 28 to page 31). This particular deleted CN-A subunit is said to be advantageously produced through recombinant DNA techniques (page 28 lines 18-19). In this respect, the IPEA considers that the advantages of producing homodimeric or heterodimeric proteins by recombinant DNA techniques were well-known in the prior art and in particular the simultaneous production of both subunits in a single vector (simultaneous production of both subunits, easy and advantageous refolding, appropriate stoichiometry, etc...) as shown for instance for the PDGF protein in the document EP-A-0 618 227 (**D5**). The presence of an additional arbitrary domain, such as for instance a domain for obtaining an easier purification, detection, etc.. (tag, epitope, His) does not seem to involve any further inventive skill. Thus, the combined teachings of these documents makes the subject matter of claims 1-5, 11, 20-21, 23, 25-26, 28, 30, 32, 34, 36 and 38 obvious (Article 33 (3) PCT).

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/25766

In view of the successful use of this deleted CN-A subunit in the system of D4 (wherein the CN-B subunit is also present), the IPEA considers that the substitution of the recombinant CN-A subunit in any of the documents D1-D3 by the above recombinant (deleted) Cn-A/CN-B would not have required any specific inventive skill. Thus, the subject matter of claims 1-46 and 49-50 does not fulfil the requirements of Article 33 (3) PCT.

The IPEA further considers that as far as the subject matter of claims 1-4 does not clearly define the "CAB domain" and that it comprises any arbitrary "portion" of CN-A and CN-B (see paragraph (iii.b) below under "Additional remarks to item VIII"), the scope of these claims embraces the complete calcineurin with subunits A and B (CN-A/B) with arbitrarily deletions and modifications. These arbitrary calcineurin deletion mutants cannot be inventive over the complete calcineurin and thus, the combined teachings of any document disclosing the production of recombinant CN-A/B (such as J. Biol. Chem. 1996, Vol. 271(43), pages 26517-26521 (**D6**) or Biochem Mol. Biol. Int, 1997, Vol. 41(1), pages 169-177 (**D7**)) with the teachings of D5 (homo- and heterodimer advantageous production in a single or one vector) makes these claims obvious.

The attention of the Applicant is also drawn to the fact that the subject matter of claims 34-35 and 38-45 is directed to methods for treatment of the human or animal body (insofar the claimed subject matter comprises embraces a method *in vivo* too) and thus, it may be excluded from examination by Article 34(4)(a)(i) PCT in combination with Rule 67(iv) PCT too. Furthermore, for such a subject matter no unified criteria exist in PCT for the assessment whether it is industrially applicable or not. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject matter of claims to the use of a compound in medical treatment, but will allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

**4. Additional remarks to item VIII :**

The following objections are also raised under **Article 6 PCT** concerning the clarity of the claims :

i) according to Article 6 PCT, the claims shall be clear and concise. The requirement that

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/25766

the claims shall be concise refers to the claims in their entirety as well as to individual claims. The number of claims must be reasonable in relation to the nature of the invention claimed, and undue repetition of wording, for example between one claim and another, should be avoided by the use of dependent form (see PCT Gazette, 29.10.98, PCT International Preliminary Examination Guidelines, Section IV, III-5.1). The IPEA considers that the present set of claims contains a large number of claims (50) which further repetition of wording among them (see for instance claims 21-22, 23-24, 26-27, 28-29, 30-31, etc...).

ii) according to Article 6 PCT in combination with Rule 6.3 PCT the claims shall define the matter for which protection is sought in terms of technical features. The IPEA considers that a peptide, polypeptide, protein, oligonucleotide, gene, etc.. being chemical products must be clearly and unambiguously characterized by their amino acid and/or nucleic acid sequences, i.e. by reference to their specific SEQ ID No. The characterization of a product only by the desired function or by an arbitrary abbreviation (such as "CAB domain" in claim 1, AP domain in claim 8, KRAB domain in claim 9, etc...) without any real technical meaning does not fulfill the requirements of said Article 6 PCT in combination with Rule 6.3 PCT.

iii) in this respect and as far as the "CAB domain" is not clearly defined, the IPEA considers that the actual wording of claim 1 is ambiguous and it can be differently interpreted making the actual scope of the present set of claims ambiguous for the following reasons:

a) by using the wording "...**comprising** a portion of CN-A and CN-B ..." the claimed subject matter actually embraces a fusion protein of CN-A and CN-B which certainly will comprise a portion of both A and B (in fact, it will comprise the complete CN-A and CN-B). The same objection applies for the subject matter of claims 2 and 3 which by using the wording "...comprising..." do not overcome this problem as they do not clearly define these "portions".

b) on the other hand, the wording "a portion" includes short arbitrary fragments of CN-A and/or CN-B. However, claim 1 further requires that the "CAB domain forms a tripartite complex with an FKBP/CAB ligand and an FKBP domain" (functional restriction). Thus, as

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/25766

far as the formation of said complex is mainly dependent on the presence of CN-A, the IPEA considers that the minimal length of the "portion" of CN-A is defined by this functional requirement but not the length of the CN-B "portion" that could be as short as consisting of only one residue (and thus, a product such as a known recombinant functional CN-A comprises a CAB domain in a sense that it comprises a functional CN-A subunit and one residue (arbitrary) of CN-B).

c) moreover, the "CAB domain" as defined can comprise the complete calcineurin with subunits A and B (CN-A/B) with arbitrary, non-significant or non-relevant deletions, such as one, two, etc... residues of the CN-A N-terminal (which were already known to have no functional importance) or the C-terminal (obtaining known deletions in the autoinhibitory domain) and one, two, etc... residues of the CN-B subunit.

iv) the reference to a "composition" in claim 12 is not clear. Both recombinant nucleic acids together or presence of different components, etc... even more in view of claim 22 which seems to imply "a vector comprising the composition" (????). In this respect, claim 18 is also ambiguous by reference to a "target gene construct" (????).

v) the reference in claim 41 to "... permitting gene expression..." is ambiguous as far as neither claim 27 (host cell comprising nucleic acid composition of claim 12) nor claim 12 explicitly refer to any specific gene. A similar objection applies for the ambiguous reference to "DNA constructs" in claim 49 (contrary to claim 59 which clearly refers to the "target gene constructs" of claim 18).

vi) claims 34 and 35 as far as dependent claims 38-39 imply methods carried out "in vivo" seems that all claims 34-35 and 38-39 could be seen as "methods of treatment". The same objection applies to claims 40-41 and 43-45

viii) the attention of the Applicant is drawn to the fact that the "common or single inventive concept" among the different claimed products is considered to be the presence of the "CAB domain". If this is not inventive/novel, a non-unity objection could be raised for : (i) "CAB domain", (ii) fusion products with "CAB domain" and (iii) fusion products of "fused CAB domains" and "fused FKBP".

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

HAUSDORFF, Sharon F.  
ARIAD Pharmaceuticals, Inc.  
26 Landsdowne Street  
Cambridge, MA 02139-4234  
ETATS-UNIS D'AMERIQUE

PCT

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing  
(day/month/year)

16.01.2001

Applicant's or agent's file reference  
ARIAD 385A PCT

IMPORTANT NOTIFICATION

International application No.  
PCT/US99/25766

International filing date (day/month/year)  
05/11/1999

Priority date (day/month/year)  
06/11/1998

Applicant

PRESIDENT AND FELLOWS OF HARVARD COLLEGE et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

**4. REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/



European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized officer

Zoglauer, H

Tel. +49 89 2399-8051



# PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT (PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>ARIAD 385A PCT</b>	<b>FOR FURTHER ACTION</b>	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. <b>PCT/US99/25766</b>	International filing date ( <i>day/month/year</i> ) <b>05/11/1999</b>	Priority date ( <i>day/month/year</i> ) <b>06/11/1998</b>
International Patent Classification (IPC) or national classification and IPC <b>C12N15/00</b>		
<p><b>Applicant</b>  <b>PRESIDENT AND FELLOWS OF HARVARD COLLEGE et al.</b></p>		
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 10 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p>		
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> <li>I    <input checked="" type="checkbox"/> Basis of the report</li> <li>II   <input checked="" type="checkbox"/> Priority</li> <li>III   <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</li> <li>IV   <input type="checkbox"/> Lack of unity of invention</li> <li>V   <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li> <li>VI   <input type="checkbox"/> Certain documents cited</li> <li>VII   <input type="checkbox"/> Certain defects in the international application</li> <li>VIII   <input checked="" type="checkbox"/> Certain observations on the international application</li> </ul>		

Date of submission of the demand <b>26/05/2000</b>	Date of completion of this report <b>16.01.2001</b>
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer <b>Julia, P</b> Telephone No. +49 89 2399 8410



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International Application No. PCT/US99/25766

**I. Basis of the report**

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).)*;

**Description, pages:**

1-100                   as originally filed

**Claims, No.:**

1-50                   as originally filed

**Drawings, sheets:**

1/10-10/10           as originally filed

**Sequence listing part of the description, pages:**

1-9, filed with the letter of 14.02.2000

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- the language of publication of the international application (under Rule 48.3(b)).
- the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- contained in the international application in written form.
- filed together with the international application in computer readable form.
- furnished subsequently to this Authority in written form.
- furnished subsequently to this Authority in computer readable form.
- The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International Application No. PCT/US99/25766

the description,      pages:

the claims,      Nos.:

the drawings,      sheets:

5.  This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):  
*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:  
**see separate sheet**

**II. Priority**

1.  This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:

copy of the earlier application whose priority has been claimed.

translation of the earlier application whose priority has been claimed.

2.  This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.  
Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:  
**see separate sheet**

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

the entire international application.

claims Nos. 47-48.

because:

the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International Application No. PCT/US99/25766

- the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- no international search report has been established for the said claims Nos. 47-48.

2. A meaningful international preliminary examination report cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- the written form has not been furnished or does not comply with the standard.
- the computer readable form has not been furnished or does not comply with the standard.

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes:	Claims 3-4, 8-10
	No:	Claims 1-2, 5-7, 11-46, 49-50
Inventive step (IS)	Yes:	Claims
	No:	Claims 1-46, 49-50
Industrial applicability (IA)	Yes:	Claims 1-33, 36-37, 46, 49-50
	No:	Claims 34-35, 38-45 (see citations and explanations)

2. Citations and explanations  
**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**

**1. Additional remarks to item I :**

A "Sequence Listing" has been filed on 14.02.00 with the present application. This "Sequence Listing" comprises SEQ ID No.: 1 to SEQ ID No.: 31 (pages 1-9).

**2. Additional remarks to item II :**

The priority documents pertaining to the present application were not available at the time of establishing this international preliminary examination report (IPER). Hence, the current assessment is based on the assumption that all claims enjoy priority rights from the filing date of the priority document (06.11.98).

**3. Additional remarks to item III :**

The subject matter of claims 47-48 refers to ligands and antagonists of the disclosed fusion proteins without giving a true technical characterization. Moreover, only a very limited number of such specific compounds are defined in the application. In consequence, the scope of these claims is ambiguous and vague, and its subject matter is not sufficiently disclosed and supported (Articles 5 and 6 PCT). No search has been carried out for such claims whose wording is, in fact, a mere recitation of the result to be achieved. Claims, or parts thereof, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1 (e) PCT).

**4. Additional remarks to item V :**

The present application discloses a so-called recombinant minimal functional calcineurin (CN, EC 3.1.3.16) A and B domain (CAB domain) consisting of a portion of CN-A (residues 12-394, 12-370 or 340-394 of human CN-A) and a portion of CN-B (residues 3-170 of human CN-B), which can further be fused with an "heterologous" portion such as a DNA binding domain, a transcription regulatory domain, a cellular localizing domain or a signalling domain (derived from IlexA, Gal4, p65, VP16, etc...). A fusion protein containing one or more of this recombinant (minimal) functional CAB domain is also explicitly claimed. These CAB domains are all required to be functional in the sense that they are all able to form a tripartite complex with an FKBP/CAB ligand and an FKBP domain (FKBP, FK506 binding protein). The application further claims the corresponding recombinant nucleic acids as well as a composition comprising these nucleic acids as a first recombinant nucleic acid and as a second recombinant nucleic acid one encoding a fusion protein comprising at least one FKBP domain and at least one additional domain "heterologous"

thereto (same or different from the other) as well as their use in a system similar to the yeast two-hybrid system (namely CAB domain-transcription activation domain/FKBP domain-DNA binding domain or CAB domain-DNA binding domain/FKBP domain-transcription activation domain with complex in presence of a ligand (FK506) results in a detectable biological signal). Further embodiments refer to vectors, host cells, non-human animals, a method for multimerizing fusion proteins, a method for initiating a detectable biological signal, a kit, etc...

The following documents have been cited in the International Search Report (ISR) as being relevant for assessing the novelty and inventiveness of the claimed subject matter:

- i) WO-A-94/18317 (**D1**) discloses the (regulated/inducible) dimerization or oligomerization of intracellular proteins by suitable ligands, in particular (i) the intracellular aggregation of the cytoplasmic tail of the zeta-chain of the T-cell-receptor (TCR) and CD3 thereby leading to signalling and transcription of a reporter gene, (ii) the homodimerization of cytoplasmic tail of the Fas receptor thereby leading to cell-specific apoptosis and (iii) the heterodimerization (by "bumped-FK506") of a calcineurin subunit A/DNA-binding domain (Gla4) and a FKBP12/transcription-activation domain (VP16) thereby leading to the transcription of a reporter gene. In view of the ambiguous wording of claim 1 and the possible interpretations thereof (see paragraph (iii) below under "Additional remarks to item VIII"), the IPEA considers that the calcineurin subunit A can be seen as a functional CAB domain which comprises a "portion" of subunit A (such as the complete sequence minus one residue) and a "portion" of subunit B (namely "the" residue) and thus, the subject matter of claims 1-2, 5-7 and 11-46, 49-50 is considered to be anticipated by this document (Articles 33 (2) and (3) PCT).
- ii) WO-A-96/12806 (**D2**) discloses a (yeast) cell-based two hybrid protein-protein interaction assay for identifying a small molecule immunosuppressant compound, wherein one of two fusion hybrid proteins in the cell contains a calcineurin A subunit (CN-A) (with a GAL4 activation domain) and the other of the two fusion proteins contains an immunophilin (FK506-binding proteins, FKBP) (with a GAL4 DNA binding domain). The document discloses similar systems using calcineurin B subunit (CN-B) and different C-terminal deleted calcineurin A subunits. The document also refers to the effect of the presence, absence or "overexpression, or increased expression, of a B subunit of calcineurin" in the different systems studied. In agreement with the interpretation given for

D1 above, D2 is considered to be novelty destroying for the subject matter of claims 1-2, 5-7 and 11-46, 49-50 (Articles 33 (2) , (3) PCT).

iii) WO-A-96/16172 (**D3**) demonstrates the interaction of calcineurin with the A-kinase anchor protein-79 (AKAP-79) and using a two-hybrid assay system (using as a "bait" AKAP-79/GAL4 DNA-binding domain and as a "target" GAL4 transcription activating domain) isolates and characterizes a clone (clone 11.1) encoding a mouse calcineurin subunit A. The document discloses several deletion mutants of the disclosed mouse CN-A. In agreement with the interpretation given for documents D1 and D2 above, D3 is novelty destroying for the subject matter of at least claims 1-2, 5-7, 11, 19-20, 23, 25- 26, 34 and 36 (Articles 33 (2) , (3) PCT).

None of these documents seems to anticipate the specific subject matter of claims 3-4 and 8-10, which is thus considered to fulfil the requirements of Article 33 (2) PCT. However, the IPEA does not consider such a subject matter as inventive (Article 33 (3) PCT) in view of the following documents and argumentation :

iv) WO-A-97/06246 (**D4**) discloses crystal molecules of complexes comprising CN-A, CN-B, FKBP and FK506 and the characterization therein of the domains involved in their interactions. In particular, the document refers to the successful use of a 42 kDa deleted calcineurin A subunit (residues 17-392 of the native 59 kDa CN-A) without the C-terminal autoinhibitory domain (4kDa) and the adjacent calmodulin binding domain (14 kDa), which is still active, binds to the CN-B and to FKBP/FK506 (page 28 to page 31). This particular deleted CN-A subunit is said to be advantageously produced through recombinant DNA techniques (page 28 lines 18-19). In this respect, the IPEA considers that the advantages of producing homodimeric or heterodimeric proteins by recombinant DNA techniques were well-known in the prior art and in particular the simultaneous production of both subunits in a single vector (simultaneous production of both subunits, easy and advantageous refolding, appropriate stoichiometry, etc...) as shown for instance for the PDGF protein in the document EP-A-0 618 227 (**D5**). The presence of an additional arbitrary domain, such as for instance a domain for obtaining an easier purification, detection, etc.. (tag, epitope, His) does not seem to involve any further inventive skill. Thus, the combined teachings of these documents makes the subject matter of claims 1-5, 11, 20-21, 23, 25-26, 28, 30, 32, 34, 36 and 38 obvious (Article 33 (3) PCT).

In view of the successful use of this deleted CN-A subunit in the system of D4 (wherein the CN-B subunit is also present), the IPEA considers that the substitution of the recombinant CN-A subunit in any of the documents D1-D3 by the above recombinant (deleted) Cn-A/CN-B would not have required any specific inventive skill. Thus, the subject matter of claims 1-46 and 49-50 does not fulfil the requirements of Article 33 (3) PCT.

The IPEA further considers that as far as the subject matter of claims 1-4 does not clearly define the "CAB domain" and that it comprises any arbitrary "portion" of CN-A and CN-B (see paragraph (iii.b) below under "Additional remarks to item VIII"), the scope of these claims embraces the complete calcineurin with subunits A and B (CN-A/B) with arbitrarily deletions and modifications. These arbitrary calcineurin deletion mutants cannot be inventive over the complete calcineurin and thus, the combined teachings of any document disclosing the production of recombinant CN-A/B (such as J. Biol. Chem. 1996, Vol. 271(43), pages 26517-26521 (**D6**) or Biochem Mol. Biol. Int, 1997, Vol. 41(1), pages 169-177 (**D7**) with the teachings of D5 (homo- and heterodimer advantageous production in a single or one vector) makes these claims obvious.

The attention of the Applicant is also drawn to the fact that the subject matter of claims 34-35 and 38-45 is directed to methods for treatment of the human or animal body (insofar the claimed subject matter comprises embraces a method *in vivo* too) and thus, it may be excluded from examination by Article 34(4)(a)(i) PCT in combination with Rule 67(iv) PCT too. Furthermore, for such a subject matter no unified criteria exist in PCT for the assessment whether it is industrially applicable or not. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject matter of claims to the use of a compound in medical treatment, but will allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

**4. Additional remarks to item VIII :**

The following objections are also raised under **Article 6 PCT** concerning the clarity of the claims :

- i) according to Article 6 PCT, the claims shall be clear and concise. The requirement that

the claims shall be concise refers to the claims in their entirety as well as to individual claims. The number of claims must be reasonable in relation to the nature of the invention claimed, and undue repetition of wording, for example between one claim and another, should be avoided by the use of dependent form (see PCT Gazette, 29.10.98, PCT International Preliminary Examination Guidelines, Section IV, III-5.1). The IPEA considers that the present set of claims contains a large number of claims (50) which further repetition of wording among them (see for instance claims 21-22, 23-24, 26-27, 28-29, 30-31, etc...).

**ii)** according to Article 6 PCT in combination with Rule 6.3 PCT the claims shall define the matter for which protection is sought in terms of technical features. The IPEA considers that a peptide, polypeptide, protein, oligonucleotide, gene, etc.. being chemical products must be clearly and unambiguously characterized by their amino acid and/or nucleic acid sequences, i.e. by reference to their specific SEQ ID No. The characterization of a product only by the desired function or by an arbitrary abbreviation (such as "CAB domain" in claim 1, AP domain in claim 8, KRAB domain in claim 9, etc...) without any real technical meaning does not fulfill the requirements of said Article 6 PCT in combination with Rule 6.3 PCT.

**iii)** in this respect and as far as the "CAB domain" is not clearly defined, the IPEA considers that the actual wording of claim 1 is ambiguous and it can be differently interpreted making the actual scope of the present set of claims ambiguous for the following reasons:

**a)** by using the wording "...**comprising** a portion of CN-A and CN-B ..." the claimed subject matter actually embraces a fusion protein of CN-A and CN-B which certainly will comprise a portion of both A and B (in fact, it will comprise the complete CN-A and CN-B). The same objection applies for the subject matter of claims 2 and 3 which by using the wording "...comprising..." do not overcome this problem as they do not clearly define these "portions".

**b)** on the other hand, the wording "a portion" includes short arbitrary fragments of CN-A and/or CN-B. However, claim 1 further requires that the "CAB domain forms a tripartite complex with an FKBP/CAB ligand and an FKBP domain" (functional restriction). Thus, as

far as the formation of said complex is mainly dependent on the presence of CN-A, the IPEA considers that the minimal length of the "portion" of CN-A is defined by this functional requirement but not the length of the CN-B "portion" that could be as short as consisting of only one residue (and thus, a product such as a known recombinant functional CN-A comprises a CAB domain in a sense that it comprises a functional CN-A subunit and one residue (arbitrary) of CN-B).

c) moreover, the "CAB domain" as defined can comprise the complete calcineurin with subunits A and B (CN-A/B) with arbitrary, non-significant or non-relevant deletions, such as one, two, etc... residues of the CN-A N-terminal (which were already known to have no functional importance) or the C-terminal (obtaining known deletions in the autoinhibitory domain) and one, two, etc... residues of the CN-B subunit.

iv) the reference to a "composition" in claim 12 is not clear. Both recombinant nucleic acids together or presence of different components, etc... even more in view of claim 22 which seems to imply "a vector comprising the composition" (???). In this respect, claim 18 is also ambiguous by reference to a "target gene construct" (????).

v) the reference in claim 41 to "... permitting gene expression..." is ambiguous as far as neither claim 27 (host cell comprising nucleic acid composition of claim 12) nor claim 12 explicitly refer to any specific gene. A similar objection applies for the ambiguous reference to "DNA constructs" in claim 49 (contrary to claim 59 which clearly refers to the "target gene constructs" of claim 18).

vi) claims 34 and 35 as far as dependent claims 38-39 imply methods carried out "in vivo" seems that all claims 34-35 and 38-39 could be seen as "methods of treatment". The same objection applies to claims 40-41 and 43-45

viii) the attention of the Applicant is drawn to the fact that the "common or single inventive concept" among the different claimed products is considered to be the presence of the "CAB domain". If this is not inventive/novel, a non-unity objection could be raised for : (i) "CAB domain", (ii) fusion products with "CAB domain" and (iii) fusion products of "fused CAB domains" and "fused FKBP".

## PATENT COOPERATION TREATY

MAY 15

From the RECEIVING OFFICE

To:  
 SHARON F. HAUSDORFF  
 ARIAD PHARMACEUTICALS, INC.  
 26 LANDSDOWNE STREET  
 CAMBRIDGE, MA 02139 4234

**PCT****NOTIFICATION RELATING  
TO PRIORITY CLAIM**(PCT Rules 26bis.1 and 26bis.2 and  
Administrative Instructions, Sections 302 and 314)

		Date of mailing (day/month/year) <b>10 MAY 2000</b>
Applicant's or agent's file reference  385A PCT		<b>IMPORTANT NOTIFICATION</b>
International application No.  PCT/US99/25766	International filing date (day/month/year)	05 NOV 99
Applicant <b>PRESIDENT AND FELLOWS OF HARVARD COLLEGE</b>		

The applicant is hereby notified of the following in respect of the priority claim(s) made in the international application.

1.  **Correction of priority claim.** In accordance with the applicant's notice received on : 17 FEB 00  
the following priority claim has been corrected to read as follows:  
**60/107,473**
  - even though the indication of the number of the earlier application is missing.
  - even though the following indication in the priority claim is not the same as the corresponding indication appearing in the priority document:
2.  **Addition of priority claim.** In accordance with the applicant's notice received on : \_\_\_\_\_  
the following priority claim has been added:
  - even though the indication of the number of the earlier application is missing.
  - even though the following indication in the priority claim is not the same as the corresponding indication appearing in the priority document:
3.  **As a result of the correction and/or addition** of (a) priority claim(s) under items 1 and/or 2, the (earliest) priority date is:
4.  The priority claim (*see also item 5, below, if applicable*) is considered not to have been made because:
  - the applicant failed to respond to the invitation under Rule 26bis.2(a) (Form PCT/RO/110) within the prescribed time limit.
  - the applicant's notice was received after the expiration of the prescribed time limit under Rule 26bis.1(a).
  - the applicant's notice failed to correct the priority claim so as to comply with the requirements of Rule 4.10.

The applicant may, before the technical preparations for international publication have been completed and subject to the payment of a fee, request the International Bureau to publish, together with the international application, information concerning the priority claim. See Rule 26bis.2(c) and the *PCT Applicant's Guide*, Volume I, Annex B2(1B).
5.  In case where **multiple priorities** have been claimed, the above item(s) relate to the following priority claim(s):
6. A copy of this notification has been sent to the International Bureau and  
 to the International Searching Authority

Name and mailing address of the receiving Office  
 Assistant Commissioner for Patent  
 Box PCT  
 Washington, D.C. 20231 Attn: RO/US  
 Facsimile No. 703-305-3230

Authorized officer  
 Sigfried Hostad  
 Telephone No. 703-305-3680

## PCT TENT COOPERATION TREA

PCT

## NOTIFICATION RELATING TO PRIORITY CLAIM

(PCT Rules 26bis.1 and 26bis.2 and  
Administrative Instructions, Sections 402 and 409)IR 17  
From the INTERNATIONAL BUREAU

To:

HAUSDORFF, Sharon, F.  
 Ariad Pharmaceuticals, Inc.  
 26 Landsdowne Street  
 Cambridge, MA 02139-4234  
 ÉTATS-UNIS D'AMÉRIQUE

Date of mailing (day/month/year) 02 March 2000 (02.03.00)	
Applicant's or agent's file reference 385A PCT	<b>IMPORTANT NOTIFICATION</b>
International application No. PCT/US99/25766	International filing date (day/month/year) 05 November 1999 (05.11.99)
Applicant <b>PRESIDENT AND FELLOWS OF HARVARD COLLEGE et al</b>	

The applicant is hereby **notified** of the following in respect of the priority claim(s) made in the international application.

1.  **Correction of priority claim.** In accordance with the applicant's notice received on: 23 February 2000 (23.02.00),  
the following priority claim has been corrected to read as follows:

US 06 November 1998 (06.11.98) 60/107,473

even though the indication of the number of the earlier application is missing.  
 even though the following indication in the priority claim is not the same as the corresponding indication appearing  
in the priority document:

2.  **Addition of priority claim.** In accordance with the applicant's notice received on: ,  
the following priority claim has been added:

even though the indication of the number of the earlier application is missing.  
 even though the following indication in the priority claim is not the same as the corresponding indication appearing  
in the priority document:

3.  As a **result of the correction and/or addition** of (a) priority claim(s) under items 1 and/or 2, the (earliest) priority date is:

4.  **Priority claim considered not to have been made.**

The applicant failed to respond to the Invitation under Rule 26bis.2(a) (Form PCT/IB/316) within the prescribed time limit.  
 The applicant's notice was received after the expiration of the prescribed time limit under Rule 26bis.1(a).  
 The applicant's notice failed to correct the priority claim so as to comply with the requirements of Rule 4.10.

The applicant may, before the technical preparations for international publication have been completed and subject to the payment of a fee, request the International Bureau to publish, together with the international application, information concerning the priority claim. See Rule 26bis.2(c) and the PCT Applicant's Guide, Volume I, Annex B2(1B).

5.  In case where **multiple priorities** have been claimed, the above item(s) relate to the following priority claim(s):

6. A copy of this notification has been sent to the receiving Office and

to the International Searching Authority (where the international search report has not yet been issued).  
 the designated Offices (which have already been notified of the receipt of the record copy).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland  Facsimile No. (41-22) 740.14.35	Authorized officer  Dominique DELMAS  Telephone No. (41-22) 338.83.38
--	---

# PCT

## REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

International Application

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference  
(if desired) (12 character maximum)

385A PCT

### Box No. I TITLE OF THE INVENTION

FK506-BASED REGULATION OF BIOLOGICAL EVENTS

### Box No. II APPLICANT

Name and address:

PRESIDENT AND FELLOWS OF HARVARD COLLEGE  
124 Mt. Auburn Street  
Cambridge, MA 02138-5701  
United States of America

This person is also inventor.

Telephone No.

Facsimile No.

Teleprinter No.

State (i.e. country) of nationality:  
US

State (i.e. country) of residence:  
US

This person is applicant  all designated  all designated States except  the United States  the States indicated in  
for the purposes of : States the United States of America of America only the Supplemental Box

### Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address:

Paul A. CLEMONS  
23 Elm Street #109  
Somerville, MA 02143

This person is:

applicant only

applicant and inventor

inventor only (If this check-box  
is marked, do not fill in below.)

State (i.e. country) of nationality:  
US

State (i.e. country) of residence:  
US

This person is applicant  all designated  all designated States except  the United States  the States indicated in  
for the purposes of : States the United States of America of America only the Supplemental Box

Further applicants and (further) inventors are indicated on a continuation sheet.

### Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf  agent  common representative  
of the applicant(s) before the competent International Authorities as:

Name and address: (*Family name followed by given name; for legal entity, full  
official designation. The address must include postal code and  
name of country.*)

Telephone No.

617-494-0400

Facsimile No.

617-494-0208

Teleprinter No.

Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to  
indicate a special address to which correspondence should be sent.

Box No.  
III FURTHER  
APPLICANT(S)  
AND/OR  
(FURTHER)  
INVENTOR(S)

If none of the following sub-boxes is used, this sheet is not to be included in the request.

Name and address:  Brian G. GLADSTONE 50 Harbor Point Blvd. #208 Dorchester, MA 02125	This person is:  <input type="checkbox"/> applicant only <input checked="" type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)
State (i.e. country) of nationality: GB	State (i.e. country) of residence: US
This person is applicant <input type="checkbox"/> all designated <input type="checkbox"/> all designated States except <input checked="" type="checkbox"/> the United States <input type="checkbox"/> the States indicated in for the purposes of: States the United States of America of America only the Supplemental Box	
Name and address:  Abhinav SETH 300 Engle Street Tenafly, NJ 07670	This person is:  <input type="checkbox"/> applicant only <input checked="" type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)
State (i.e. country) of nationality: US	State (i.e. country) of residence: US
This person is applicant <input type="checkbox"/> all designated <input type="checkbox"/> all designated States except <input checked="" type="checkbox"/> the United States <input type="checkbox"/> the States indicated in for the purposes of: States the United States of America of America only the Supplemental Box	
Name and address:  Stuart L. SCHREIBER 434 Marlborough Street Boston, MA 02115	This person is:  <input type="checkbox"/> applicant only <input checked="" type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)
State (i.e. country) of nationality: US	State (i.e. country) of residence: US
This person is applicant <input type="checkbox"/> all designated <input type="checkbox"/> all designated States except <input checked="" type="checkbox"/> the United States <input type="checkbox"/> the States indicated in for the purposes of: States the United States of America of America only the Supplemental Box	
Name and address:	This person is:  <input type="checkbox"/> applicant only <input type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)
State (i.e. country) of nationality:	State (i.e. country) of residence:
This person is applicant <input type="checkbox"/> all designated <input type="checkbox"/> all designated States except <input type="checkbox"/> the United States <input type="checkbox"/> the States indicated in for the purposes of: States the United States of America of America only the Supplemental Box	

## Box No. V DESIGNATION OF STATES

The following designations are hereby made under rule 4.9(a) (mark the applicable check-boxes - at least one must be marked):

## Regional Patent

AP ARIPO Patent: KE Kenya, LS Lesotho, MW Malawi, SD Sudan, SZ Swaziland, UG Uganda, and any other State which is a Contracting State of the Harare Protocol and of the PCT

EA Eurasian Patent: AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT

EP European Patent: AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT

OA OAPI Patent: BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line).....

## National Patent (if other kind of protection or treatment desired, specify on dotted line)

<input type="checkbox"/> AL Albania .....	<input type="checkbox"/> LU Luxembourg .....
<input type="checkbox"/> AM Armenia .....	<input type="checkbox"/> LV Latvia .....
<input type="checkbox"/> AT Austria .....	<input type="checkbox"/> MD Republic of Moldova .....
<input checked="" type="checkbox"/> AU Australia .....	<input type="checkbox"/> MG Madagascar .....
<input type="checkbox"/> AZ Azerbaijan .....	<input type="checkbox"/> MK The former Yugoslav Republic of Macedonia .....
<input type="checkbox"/> BA Bosnia and Herzegovina .....	
<input type="checkbox"/> BB Barbados .....	<input type="checkbox"/> MN Mongolia .....
<input type="checkbox"/> BG Bulgaria .....	<input type="checkbox"/> MW Malawi .....
<input type="checkbox"/> BR Brazil .....	<input type="checkbox"/> MX Mexico .....
<input type="checkbox"/> BY Belarus .....	<input type="checkbox"/> NO Norway .....
<input checked="" type="checkbox"/> CA Canada .....	<input type="checkbox"/> NZ New Zealand .....
<input type="checkbox"/> CH and LI Switzerland and Liechtenstein .....	<input type="checkbox"/> PL Poland .....
<input type="checkbox"/> CN China .....	<input type="checkbox"/> PT Portugal .....
<input type="checkbox"/> CU Cuba .....	<input type="checkbox"/> RO Romania .....
<input type="checkbox"/> CZ Czech Republic .....	<input type="checkbox"/> RU Russian Federation .....
<input type="checkbox"/> DE Germany .....	<input type="checkbox"/> SD Sudan .....
<input type="checkbox"/> DK Denmark .....	<input type="checkbox"/> SE Sweden .....
<input type="checkbox"/> EE Estonia .....	<input type="checkbox"/> SG Singapore .....
<input type="checkbox"/> ES Spain .....	<input type="checkbox"/> SI Slovenia .....
<input type="checkbox"/> FI Finland .....	<input type="checkbox"/> SK Slovakia .....
<input type="checkbox"/> GB United Kingdom .....	<input type="checkbox"/> TJ Tajikistan .....
<input type="checkbox"/> GE Georgia .....	<input type="checkbox"/> TM Turkmenistan .....
<input type="checkbox"/> HU Hungary .....	<input type="checkbox"/> TR Turkey .....
<input type="checkbox"/> IL Israel .....	<input type="checkbox"/> TT Trinidad and Tobago .....
<input type="checkbox"/> IS Iceland .....	<input type="checkbox"/> UA Ukraine .....
<input checked="" type="checkbox"/> JP Japan .....	<input type="checkbox"/> UG Uganda .....
<input type="checkbox"/> KE Kenya .....	<input checked="" type="checkbox"/> US United States of America .....
<input type="checkbox"/> KG Kyrgyzstan .....	
<input type="checkbox"/> KP Democratic People's Republic of Korea .....	
<input type="checkbox"/> KR Republic of Korea .....	<input type="checkbox"/> UZ Uzbekistan .....
<input type="checkbox"/> KZ Kazakstan .....	<input type="checkbox"/> VN Viet Nam .....
<input type="checkbox"/> LC Saint Lucia .....	
<input type="checkbox"/> LK Sri Lanka .....	
<input type="checkbox"/> LR Liberia .....	
<input type="checkbox"/> LS Lesotho .....	
<input type="checkbox"/> LT Lithuania .....	

Check-boxes reserved for designating States (for the purposes of a national patent) which have become party to the PCT after issuance of this sheet:

YU Yugoslavia .....

.....

.....

.....

In addition to the designations made above, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except the designation(s) of \_\_\_\_\_.  
The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation of a designation consist of the filing of a notice specifying that designation and the payment of the

## Box No. VI PRIORITY CLAIM

Further priority claims are indicated in the supplemental box [ ]

The priority of the following earlier application(s) is hereby claimed:

Country (in which, or for which, the application was filed)	Filing Date (day/month/year)	Application No.	Office of filing (only for regional or international applications)
item (1) US	6 November 1998 (06.11.98)	60/107,743	
item (2)			
item (3)			

Mark the following check-box if the certified copy of the earlier application is to be issued by the Office for which the purposes of the present international application is the receiving Office (a fee may be required):

[X] The receiving Office is hereby requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) identified above as item(s): (1)

## Box No. VII INTERNATIONAL SEARCHING AUTHORITY

Choice of International Searching Authority (ISA) (If two or more International Searching Authorities are competent to carry out the international search, indicate the authority chosen; the two letter code may be used)

ISA/ EP

Earlier Search Fill in where a search (international, international-type or other) by the International Searching Authority has already been carried out or requested and the Authority is now requested to base the international search, to the extent possible, on the results of that earlier search. Identify such search or requested either by reference to the relevant application (of the translation thereof) or by reference to the search request:

Country (or regional Office):

Date (day/month/year):

Number:

## Box No. VIII CHECK LIST

This international application contains the following number of sheets:

1 request	:	4 sheets
2 description	:	100 sheets
3 claims	:	5 sheets
4 abstract	:	1 sheets
5 drawings	:	10 sheets
Total	:	120 sheets

This application is accompanied by the item(s) marked below:

1. [X] separate signed power of attorney	5. [X] fee calculation sheet
2. [ ] copy of general power of attorney	6. [ ] separate indications concerning deposited microorganisms
3. [ ] statement explaining lack of signature	7. [ ] nucleotide and/or amino acid sequence listing (diskette)
4. [ ] priority document(s) identified in Box No. VI as item(s):	8. [X] other (specify): Transmittal letter and Return post card

Figure No. 6 of the drawings (if any) should accompany the abstract when it is published.

## Box No. IX SIGNATURE OF APPLICANT OR AGENT

ARIAD GENE THERAPEUTICS, INC.

---

 Sharon F. Hausdorff, Senior Patent Agent

For receiving Office use only

1. Date of actual receipt of the purported international application:	2. Drawings:  [ ] received [ ] not received:	
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:		
4. Date of timely receipt of the required corrections under PCT Article 11(2):		
5. International Searching Authority specified by the applicant:	ISA /	6. [ ] Transmittal of search copy delayed until search fee is paid

For International Bureau use only

Date of receipt of the record copy by the International Bureau:

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : <b>C12N 15/62, 15/52, 9/16, 15/86, A01K 67/027, G01N 33/566</b>	A3	(11) International Publication Number: <b>WO 00/28011</b> (43) International Publication Date: <b>18 May 2000 (18.05.00)</b>
(21) International Application Number: <b>PCT/US99/25766</b>		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(22) International Filing Date: <b>5 November 1999 (05.11.99)</b>		
(30) Priority Data: <b>60/107,473 6 November 1998 (06.11.98) US</b>		<b>Published</b> <i>With international search report.</i>
(71) Applicant (for all designated States except US): PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 124 Mount Auburn Street, Cambridge, MA 02138-5701 (US).		(88) Date of publication of the international search report: <b>23 November 2000 (23.11.00)</b>
(72) Inventors; and		
(75) Inventors/Applicants (for US only): CLEMONS, Paul, A. [US/US]; 23 Elm Street #109, Somerville, 02143 (US). GLADSTONE, Brian, G. [GB/US]; 50 Harbor Point Boulevard #208, Dorchester, MA 02125 (US). SETH, Abhinav [US/US]; 300 Engle Street, Tenafly, NJ 07670 (US). SCHREIBER, Stuart, L. [US/US]; 434 Marlborough Street, Boston, MA 02115 (US).		
(74) Agent: HAUSDORFF, Sharon, F.; Ariad Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, MA 02139-4234 (US).		

(54) Title: FK506-BASED REGULATION OF BIOLOGICAL EVENTS

(57) Abstract

This invention provides methods and materials for making and using genetically engineered cells which are responsive to the presence of an FKBP/CAB ligand or a cyclophilin/CAB ligand. The invention relies upon the introduction into cells of recombinant DNAs encoding fusion proteins which are capable of forming a complex with each other in the presence of ligand. One of the fusion proteins contains a calcineurin A/calcineurin B domain (CAB) and at least one heterologous protein domain. The second fusion protein contains a domain derived from an FKBP protein which is capable of binding to an FKBP/CAB ligand and forming a complex with a CAB-containing protein. The second fusion protein may alternatively contain a cyclophilin domain which is capable of binding cyclosporin or other cyclophilin/CAB ligand and forming a complex with a CAB-containing protein. The second fusion protein also contains at least one heterologous domain.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

Interr. Ref Application No

PCT/US 99/25766

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 7 C12N15/62 C12N15/52 C12N9/16 C12N15/86 A01K67/027  
G01N33/566

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 18317 A (UNIV LELAND STANFORD JUNIOR ; HARVARD COLLEGE (US)) 18 August 1994 (1994-08-18) cited in the application * whole document, in particular page 75 to 77 * --- WO 96 12806 A (UNIV LELAND STANFORD JUNIOR) 2 May 1996 (1996-05-02) *whole document, in particular page 5, line 28 to page 6, line 6 and page 24 to page 25 * --- -/-	1, 2, 5-7, 11-46, 49, 50
X		1, 2, 5-7, 11-27, 34-44

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

29 June 2000

Date of mailing of the international search report

08.08.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Julia, P

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/25766

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 16172 A (ICOS CORP ;OREGON STATE (US)) 30 May 1996 (1996-05-30)  * whole document, in particular page 15 example 4, page 19 example 5 and page 23 table 1 * ---	1,2,5-7, 11,19, 20,23, 25,26, 34,36
Y	WO 97 06246 A (VERTEX PHARMA) 20 February 1997 (1997-02-20)  * whole document, in particular page 28 to page 31 and figure 2 * ---	1-5,11, 20,21, 23,25, 26,28, 30,32, 34,36,38
Y	EP 0 618 227 A (AMGEN INC) 5 October 1994 (1994-10-05)  the whole document ---	1-5,11, 20,21, 23,25, 26,28, 30,32, 34,36,38
A	M.T. KENNEDY ET AL., : "Contributions of Myristylation to Calcineurin Structure/Function" J. BIOL. CHEM., vol. 271, no. 43, 25 October 1996 (1996-10-25), pages 26517-26521, XP002140377 US the whole document ---	1-5,11, 19-21, 23,25, 26,28, 30,34, 36,38
A	Q. WEI AND E.Y. LEE: "Expression and reconstitution of calcineurin A and B subunits" BIOCHEM. MOL. BIOL. INT., vol. 41, no. 1, January 1997 (1997-01), pages 169-177, XP000915910 the whole document -----	1-5,11, 19-21, 23-26, 28,30, 34,36,38

## INTERNATIONAL SEARCH REPORT

In. International application No.  
PCT/US 99/25766

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  

Although claims 34-35, 38-41 and 43-45 are directed to a method of treatment of the human/animal body (as far as they embrace methods carried out "in vivo"), the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: 47-48  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  

see FURTHER INFORMATION sheet PCT/ISA/210
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 47-48

Present claims 47-48 refers to ligands and antagonists of the disclosed fusion proteins without giving a true technical characterization. Moreover, only a very limited number of such specific compounds are defined in the application. In consequence, the scope of said claim is ambiguous and vague, and its subject matter is not sufficiently disclosed and supported (Articles 5 and 6 PCT). No search has been carried out for such claims whose wording is, in fact, a mere recitation of the result to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l. Application No.

PCT/US 99/25766

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9418317	A 18-08-1994	AU 690898	B	07-05-1998
		AU 6240394	A	29-08-1994
		AU 7880798	A	08-10-1998
		CA 2155728	A	18-08-1994
		CN 1119876	A	03-04-1996
		CZ 9502061	A	17-04-1996
		EP 0804561	A	05-11-1997
		FI 953812	A	11-08-1995
		HU 73101	A	28-06-1996
		JP 8510896	T	19-11-1996
		PL 310327	A	11-12-1995
		US 6011018	A	04-01-2000
		US 6054436	A	25-04-2000
		US 6063625	A	16-05-2000
		US 6046047	A	04-04-2000
		US 6043082	A	28-03-2000
		US 5834266	A	10-11-1998
		US 5869337	A	09-02-1999
		US 5871753	A	16-02-1999
		US 5830462	A	03-11-1998
-----				
WO 9612806	A 02-05-1996	US 5723436	A	03-03-1998
		AU 4006695	A	15-05-1996
-----				
WO 9616172	A 30-05-1996	US 5807693	A	15-09-1998
		US 5744354	A	28-04-1998
		US 5871945	A	16-02-1999
		AU 712168	B	28-10-1999
		AU 4513396	A	17-06-1996
		BR 9506540	A	07-10-1997
		CA 2181826	A	30-05-1996
		CN 1148407	A	23-04-1997
		CZ 9602136	A	14-05-1997
		EP 0748379	A	18-12-1996
		FI 962932	A	20-09-1996
		HU 75826	A	28-05-1997
		JP 9509849	T	07-10-1997
		NO 963049	A	23-09-1996
		PL 315627	A	25-11-1996
		SK 95096	A	09-07-1997
		US 5629163	A	13-05-1997
-----				
WO 9706246	A 20-02-1997	US 5978740	A	02-11-1999
		AU 6766896	A	05-03-1997
		EP 0846163	A	10-06-1998
		JP 11511016	T	28-09-1999
-----				
EP 0618227	A 05-10-1994	AU 6497294	A	24-10-1994
		CA 2159499	A	13-10-1994
		EP 0691989	A	17-01-1996
		FI 954657	A	23-10-1995
		JP 8503858	T	30-04-1996
		NO 953882	A	28-11-1995
		WO 9422916	A	13-10-1994
		US 5705484	A	06-01-1998
		ZA 9402206	A	31-10-1994




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> :	A2	(11) International Publication Number:	<b>WO 00/28011</b>
C12N 15/00		(43) International Publication Date:	18 May 2000 (18.05.00)
(21) International Application Number:	PCT/US99/25766		
(22) International Filing Date:	5 November 1999 (05.11.99)		
(30) Priority Data:	60/107,473	6 November 1998 (06.11.98)	US
(71) Applicant (for all designated States except US):	PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 124 Mount Auburn Street, Cambridge, MA 02138-5701 (US).		
(72) Inventors; and			
(75) Inventors/Applicants (for US only):	CLEMONS, Paul, A. [US/US]; 23 Elm Street #109, Somerville, 02143 (US). GLADSTONE, Brian, G. [GB/US]; 50 Harbor Point Boulevard #208, Dorchester, MA 02125 (US). SETH, Abhinav [US/US]; 300 Engle Street, Tenafly, NJ 07670 (US). SCHREIBER, Stuart, L. [US/US]; 434 Marlborough Street, Boston, MA 02115 (US).		
(74) Agent:	HAUSDORFF, Sharon, F.; Ariad Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, MA 02139-4234 (US).		

(54) Title: FK506-BASED REGULATION OF BIOLOGICAL EVENTS

## (57) Abstract

Materials and methods are disclosed for regulation of biological events such as target gene transcription and growth, proliferation or differentiation of engineered cells.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## FK506-Based Regulation Of Biological Events

This work was supported in part by grant number GM-52067 from the National  
5 Institute of General Medical Sciences. Accordingly, the US government has certain  
rights in this invention.

### Background of the Invention

FK506 is a natural product which binds to an FK506-binding protein, FKBP,  
10 with high affinity to form an FK506:FKBP complex. Reported Kd values for that  
interaction are as low as 400 pM. The FK506:FKBP complex binds with high affinity  
to the protein phosphatase calcineurin to form a tripartite,  
[FKBP:FK506]:[calcineurin], complex. Calcineurin is a heterodimer of a catalytic  
subunit (calcineurin A) and a regulatory subunit (calcineurin B.) In this tripartite  
15 complex FK506 acts as a dimerizer or adapter to join FKBP to calcineurin.

Numerous naturally occurring FK506 binding proteins (FKBPs) are known. See  
e.g. Kay, 1996, Biochem. J. 314:361-385 (review). FKBPs have been used for  
their ligand-binding properties in biological switches based on ligand-mediated  
multimerization of immunophilin-based recombinant proteins as disclosed e.g. in  
20 Spencer et al, 1993, Science 262:1019-1024 and in WO 94/18317.

Cyclosporin A is another macrocyclic natural product of interest. It binds to  
the protein cyclophilin to form a complex which also binds to calcineurin to form an  
immunosuppressive complex. Cyclosporin thus also acts as a dimerizer. While the  
potent immunosuppressive activity of FK506 and cyclosporin would limit their utility  
25 as a dimerizer, especially in animals, this invention harnesses their dimerizing  
potential (and that of related compounds) while avoiding their profound, inherent  
limitations.

### Summary of the Invention

30 This invention concerns new configurations for biological switches and  
provides new methods and materials for regulating biological events, particularly in  
animal cells. Those biological events include, for example, gene transcription,  
activation of an intracellular signal transduction pathway (leading, for example, to  
gene expression, cell proliferation or apoptotic cell death), gene knock-out, blockade of  
35 expression of a gene, and inhibition of the function of a gene product. The invention  
relies upon two types of fusion proteins which when complexed through mutual

binding to a common ligand, are capable of actuating, directly or indirectly, the desired event.

This invention encompasses recombinant DNA constructs encoding those fusion proteins; DNA vectors containing one or more of those constructs; the fusion proteins encoded by the foregoing constructs; cells, especially animal cells, transduced with (i.e., containing and capable of expressing) one or more of the DNA constructs described herein; small molecules (bivalent or multivalent multimerizing agents) which bind to and are capable of inducing multimerization of the fusion protein molecules; and methods for preparing and using the foregoing.

More specifically, this invention provides methods and materials for making and using genetically engineered cells which are responsive to the presence of an FKBP/CAB ligand or a cyclophilin/CAB ligand. The invention relies upon the introduction into cells of recombinant DNAs encoding a set of fusion proteins which are capable of forming a complex with each other in the presence of ligand. Contacting such genetically engineered cells with a ligand results in complex formation between the fusion proteins and initiation of a biological response. One of the fusion proteins contains one or more copies of a calcineurin A/calcineurin B domain (CAB) and at least one heterologous protein domain. The second fusion protein contains one or more copies of a domain derived from an FKBP protein which is capable of binding to an FKBP/CAB ligand and forming a complex with a CAB-containing protein. The second fusion protein may alternatively contain one or more copies of a cyclophilin domain which is capable of binding cyclosporin or other cyclophilin/CAB ligand and forming a complex with a CAB-containing protein. The second fusion protein also contains at least one heterologous domain which may be the same or different from a heterologous domain of the first fusion protein. CAB and FKBP domains for use in fusion proteins of this invention may be selected from naturally occurring proteins and may be variously modified, as is discussed in detail below. While CAB, FKBP and heterologous domains derived from various species may be used, human peptide sequences or variants thereof are preferred for human gene therapy applications.

Operationally, the CAB and FKBP domains serve as receptor (or "ligand-binding") domains and direct the complex formation between the fusion proteins under the mediation of ligand molecules. The nature of the biological response triggered by ligand-mediated complexes is determined by the heterologous domains of the fusion proteins. The heterologous domains are therefore also referred to as "action" domains.

Various heterologous protein domains may be used in these fusion proteins, including, among others, DNA binding domains, transcription regulatory domains and

cellular signaling domains. In one aspect of the invention, the two fusion proteins (one of which contains at least one CAB domain, the other contains at least one FKBP or cyclophilin domain) each contain at least one different heterologous domain, i.e., a heterologous domain not contained in the other fusion protein. For example, in certain 5 embodiments, one of the fusion proteins contains at least one DNA binding domain and the other fusion protein contains at least one transcription activation domain. Ligand-mediated association of the fusion proteins represents the formation of a transcription factor complex and leads to initiation of transcription of a target gene linked to a DNA sequence recognized by (i.e., capable of binding with) a DNA- 10 binding domain on one of the fusion proteins. In other embodiments, one of the fusion proteins contains at least one domain capable of directing the fusion protein to a particular cellular location such as the cell membrane, nucleus, etc. Localization domains which target the cell membrane include domains such as a myristylation site or a transmembrane region of a receptor protein or other membrane-spanning protein. 15 The other fusion protein contains a signalling domain capable, upon membrane localization and/or clustering, of activating a cellular signal transduction pathway. Examples of signalling domains include an intracellular domain of a growth factor or cytokine receptor, an apoptosis triggering domain such as the intracellular domain of FAS or TNF-R1, and domains derived from other intracellular signalling proteins such 20 as SOS, Raf, lck, ZAP-70, caspases, etc. A number of illustrative signalling proteins are disclosed in WO 94/18317 (see e.g. pages 23 - 26). In still other embodiments, each of the fusion proteins contains at least one CAB domain and at least one FKBP domain and/or a cyclophilin domain, as well as one or more heterologous domains. Such fusion proteins are capable of homodimerization in the presence of ligand. In 25 general, domains containing peptide sequence endogenous to the host cell are preferred. Thus, for human gene therapy applications, domains of human origin are of particular interest.

Recombinant DNA molecules encoding the fusion proteins are also provided, as are vectors capable of directing their expression, particularly in eukaryotic cells, of 30 which yeast and animal cells are of particular interest. In view of the constituent components of the fusion proteins, the recombinant DNA molecules which encode them are capable of selectively hybridizing (a) to a DNA molecule encoding a given fusion protein's ligand-binding domain (CAB domain, FKBP domain or cyclophilin domain) or a protein containing such a domain and (b) to a DNA molecule encoding 35 the heterologous domain or a protein from which the heterologous protein domain was

derived. DNAs are also encompassed which would be capable of so hybridizing but for the degeneracy of the genetic code.

Using DNA sequences encoding the fusion proteins of this invention and vectors capable of directing their expression in eukaryotic cells, one may genetically engineer cells for a number of important uses. To do so, one first provides an expression vector or DNA construct for directing the expression in a eukaryotic (preferably animal) cell of the desired fusion protein and then introduces the recombinant DNA into the cells in a manner permitting DNA uptake and expression of the introduced DNA in at least a portion of the cells. One may use any of the various methods and materials for introducing DNA into cells for heterologous gene expression, a variety of which are well known and/or commercially available.

One object of this invention is thus to provide an animal cell containing recombinant DNAs encoding two fusion proteins as described herein. One of the fusion proteins is capable of binding to ligand and contains at least one FKBP or cyclophilin domain and at least one domain that is heterologous thereto. The second fusion protein contains at least one CAB domain and at least one domain heterologous thereto and is capable of forming a tripartite complex with the first fusion protein and one or more molecules of ligand. In some embodiments one or more of the heterologous domains present on one of the fusion proteins are also present on the other fusion protein, i.e., the two fusion proteins have one or more common heterologous domains. In other embodiments, each fusion protein contains one or more different heterologous domains.

A specific object of this invention is to provide animal cells engineered such that contacting the cells with ligand leads to transcription of a target gene. Such cells contain, in addition to recombinant DNAs encoding the two fusion proteins, a target gene construct which comprises a target gene operably linked to a DNA sequence which is responsive to the presence of a complex of the fusion proteins with the ligand. In certain embodiments the cells are responsive to contact with a ligand which binds to the FKBP fusion protein and CAB fusion protein with a detectable preference over binding to endogenous FKBP or CAB-containing proteins of the host cell. Similarly, ligands which bind cyclophilin-containing fusion proteins with greater affinity than their binding to endogenous cyclophilin may be desirable.

Another specific object of this invention is to provide animal cells engineered such that contacting the cells with the ligand stimulates cell growth, differentiation or proliferation. In such cells, at least one of the heterologous domains on at least one of the fusion proteins is a domain such as the intracellular domain of a receptor for a

hormone which mediates cell growth, differentiation or proliferation. Cell growth, differentiation and/or proliferation follow clustering of the receptor intracellular signalling domains. Such clustering occurs in nature following hormone binding, and in engineered cells of this invention following contact with ligand.

5 Cells of human origin are preferred for human gene therapy applications, although cell types of various origins (human or other species) may be used, and may, if desired, be encapsulated within a biocompatible material for use in human subjects.

Another object of the invention is to provide materials and methods for producing the foregoing engineered cells. This object is met by providing recombinant 10 DNAs encoding the fusion proteins, together with any ancillary recombinant DNAs such as a target gene construct, and introducing the recombinant DNAs into the host cells under conditions permitting DNA uptake by cells. Such transduction may be effected *ex vivo*, using host cells maintained in culture. Cells that are engineered in culture may subsequently be introduced into a host organism, e.g. in *ex vivo* gene 15 therapy applications. Doing so thus constitutes a method for providing a host organism, preferably a human or non-human mammal, which is responsive (as described herein) to the presence of ligand. Alternatively transduction may be effected *in vivo*, using host cells present in a human or non-human host organism. In 20 such cases, the DNA molecules are introduced directly into the host organism under conditions permitting uptake of the DNA by one or more of the host organism's cells. This approach thus constitutes an alternative method for providing a host organism, preferably a human or non-human mammal, which is responsive (as described herein) 25 to the presence of ligand. Various materials and methods for the introduction of DNA into cells in culture or in whole organisms are known in the art and may be adapted for use in practicing this invention.

Other objects are achieved using the engineered cells described herein. For instance, a method is provided for multimerizing the fusion proteins of this invention by contacting cells engineered as described herein with an effective amount of ligand, permitting the ligand to form a complex with the fusion proteins. In embodiments in 30 which multimerization of the fusion proteins triggers transcription of a target gene, this constitutes a method for activating the expression of the target gene. In embodiments in which the fusion proteins contain one or more signalling domains, this constitutes a method for activating a cellular signal transduction pathway. These methods may be carried out in cell culture or in whole organisms, including human patients. In the 35 former case, the ligand is added to the culture medium. In the latter case, the ligand (which may be in the form of a pharmaceutical or veterinary composition) is

administered to the whole organism, e.g., orally, parenterally, etc. Preferably, the dose or ligand administered to an animal is below the dosage level that would cause undue immunosuppression in the recipient.

A further object of this invention is to provide kits for use in the genetic engineering of cells or human or non-human animals as described herein. One such kit contains recombinant DNA constructs encoding a pair of fusion proteins of this invention. The recombinant DNA constructs will generally be in the form of eukaryotic expression vectors suitable for introduction into animal cells and capable of directing the expression of the fusion proteins therein. The kit may also contain a sample of ligand capable of forming a complex with the encoded fusion proteins. The kit may further contain a multimerization antagonist such as rapamycin or some other compound capable of binding to one of the fusion proteins but incapable of forming a complex with both. In certain embodiments, the recombinant DNA constructs encoding the fusion proteins will contain a cloning site in place of DNA encoding one or more of the heterologous domains, thus permitting the practitioner to introduce DNA encoding a heterologous domain of choice. In some embodiments the kit may also contain a target gene construct containing a target gene or cloning site linked to a DNA sequence responsive to the presence of the complexed fusion proteins, as described in more detail elsewhere.

20

#### Brief Description of the Figures

Figure 1: Constructs used in the CAB dimerization system.

25 Figure 2: Reaction scheme for synthesis of E/Z C40-phenyl-FK506.

Figure 3: Styrene analogs to be used in cross-metathesis reaction with FK506.

30 Figure 4: Effect of varying the number of CAB domains on secreted alkaline phosphatase activity.

Figure 5: Secreted alkaline phosphatase activity induced by full length CABs and mini CABs.

35 Figure 6: Schematic depictions of three-construct systems involving the CAB dimerization domain. A Recruitment of a CAB fusion protein to either FKBP in the

context of a nuclear localization signal (NLS) or cyclophilin A (CypA) in the context of a nuclear export signal (NES). B. Recruitment of kinases fused to either the CAB domain or the FRB domain to FKBP localized to the plasma membrane by virtue of a CaaX isoprenylation signal.

5

Figure 7: Effect of C40 derivatization on calcineurin-dependent reporter gene activity. Results represent the average of at least three independent experiments per derivative. Abbreviations: Nap, naphthyl; Ph, phenyl; PhOPh, phenoylphenyl; TMS, trimethylsilyl; FPh, fluorophenyl; Iph, iodophenyl.

10

Figure 8: Effect of high-level fCAB expression on NFAT-SEAP reporter gene activity. SEAP assays were carried out as described above except that aliquots of transfected cells were grown up separately for analysis by Western blotting. A. Western blot using antibodies (3F10, Gibco) directed against the HA epitope tag., and showing the expression of fCAB protein as a function of the concentration of transfected DNA. B. SEAP assay results showing the high constitutive reporter activity in the presence of overexpressed fCAB. Data shown is for 4000ng of transfected fCAB DNA.

15

Figure 9: Tuning of phosphatase assay as a function of fCAB construct DNA concentration. SEAP assays were carried out as described above using the indicated amount of fCAB construct DNA. Data represent the average of two independent experiments.

20

Figure 10: Development of FK506-mediated transcription assay using CAB-p65 fusion proteins. SEAP assays were carried out as described using the optimized concentrations of each DNA species and the indicated dose of FK506 or FK506 derivative. A. SEAP assay results showing the activation of transcription by FK506 and two derivatives. Data represent the average of three independent experiments. B. SEAP assay results showing the behavior of the dose response with many closely-spaced doses over a narrow concentration range. Data represent the results of three independent experiments.

25

30

35

## Detailed Description of the Invention

### Definitions

The definitions of terms as they are used herein will be helpful for a full  
5 understanding of the present disclosure.

"Activate" as applied to the expression or transcription of a gene denotes a directly or indirectly observable increase in the production of a gene product, e.g., an RNA or polypeptide encoded by the gene.

"Capable of selectively hybridizing" as that phrase is used herein means that  
10 two DNA molecules are susceptible to hybridization with one another, despite the presence of other DNA molecules, under hybridization conditions which can be chosen or readily determined empirically by the practitioner of ordinary skill in this art. Such treatments include conditions of high stringency such as washing extensively with buffers containing 0.2 to 6 x SSC, and/or containing 0.1% to 1% SDS, at temperatures  
15 ranging from room temperature to 65-75°C. See for example F.M. Ausubel et al., Eds, Short Protocols in Molecular Biology, Units 6.3 and 6.4 (John Wiley and Sons, New York, 3d Edition, 1995).

"Cells", "host cells" or "recombinant host cells" refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain  
20 modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

"Cell line" refers to a population of cells capable of continuous or prolonged growth and division in vitro. Often, cell lines are clonal populations derived from a single progenitor cell. It is further known in the art that spontaneous or induced changes can occur in karyotype during storage or transfer of such clonal populations. Therefore, cells derived from the cell line referred to may not be precisely identical to the ancestral cells or cultures, and the cell line referred to includes such variants.

A "cloning site", also sometimes referred to as a "multiple cloning site" or a "polylinker" is a region within a vector which contains multiple sites for restriction enzyme cleavage, thus rendering the vector suitable for cloning of exogenous genes.

A "coding sequence" or a sequence which "encodes" a particular polypeptide or RNA, is a nucleic acid sequence which is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide in vitro or in vivo when placed under the control of an appropriate expression control sequence. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a

translation stop codon at the 3' (carboxy) terminus. A coding sequence can include, but is not limited to, cDNA from prokaryotic or eukaryotic mRNA, genomic DNA sequences from prokaryotic or eukaryotic DNA, and even synthetic DNA sequences. A transcription termination sequence will usually be located 3' to the coding sequence.

5        “Composite”, “fusion”, and “recombinant” denote a material such as a nucleic acid, nucleic acid sequence or polypeptide which contains at least two constituent portions which are mutually heterologous in the sense that they are not otherwise found directly (covalently) linked in nature, e.g. are not found in the same continuous polypeptide or gene in nature, at least not in the same order or orientation  
10      or with the same spacing present in the composite, fusion or recombinant product. Such materials contain components derived from at least two different proteins or genes or from at least two non-adjacent portions of the same protein or gene. In general, “composite” refers to portions of different proteins or nucleic acids which are joined together to form a single functional unit, while “fusion” generally refers to two  
15      or more functional units which are linked together. “Recombinant” is generally used in the context of nucleic acids or nucleic acid sequences.

20        The term “conjoint”, with respect to administration of two or more viruses, refers to the simultaneous, sequential or separate dosing of the individual virus provided that some overlap occurs in the simultaneous presence of the viruses in one or more cells of the animal.

A “construct”, e.g., a “nucleic acid construct” or “DNA construct” refers to a nucleic acid or nucleic acid sequence.

25        “Derived from” denotes a peptide or nucleotide sequence selected from within a given sequence. A peptide or nucleotide sequence derived from a named sequence may further contain a small number of modifications relative to the parent sequence, in most cases representing deletion, replacement or insertion of less than about 15%, preferably less than about 10%, and in many cases less than about 5%, of amino acid residues or bases present in the parent sequence. In the case of DNAs, one DNA molecule is also considered to be derived from another if the two are capable of  
30      selectively hybridizing to one another. Polypeptides or polypeptide sequences are also considered to be derived from a reference polypeptide or polypeptide sequence if any DNAs encoding the two polypeptides or sequences are capable of selectively hybridizing to one another. Typically, a derived peptide sequence will differ from a parent sequence by the replacement of up to 5 amino acids, in many cases up to 3  
35      amino acids, and very often by 0 or 1 amino acids. A derived nucleic acid sequence will differ from a parent sequence by the replacement of up to 15 bases, in many cases

up to 9 bases, and very often by 0 - 3 bases. In some cases the amino acid(s) or base(s) is/are added or deleted rather than replaced.

"Dimerization", "oligomerization" and "multimerization" are used interchangeably herein and refer to the association or clustering of two or more protein molecules, mediated by the binding of a drug to at least one of the proteins. In preferred embodiments, the multimerization is mediated by the binding of two or more such protein molecules to a common divalent or multivalent drug. The formation of a complex comprising two or more protein molecules, each of which containing one or more FKBP domains, together with one or more molecules of an FKBP ligand which is at least divalent (e.g. FK1012 or AP1510) is an example of such association or clustering. In cases where at least one of the proteins contains more than one drug binding domain, e.g., where at least one of the proteins contains three FKBP domains, the presence of a divalent drug leads to the clustering of more than two protein molecules. Embodiments in which the drug is more than divalent (e.g. trivalent) in its ability to bind to proteins bearing drug binding domains also can result in clustering of more than two protein molecules. The formation of a tripartite complex comprising a protein containing at least one CAB domain, a protein containing at least one FKBP domain and a ligand molecule is another example of such protein clustering. In certain embodiments of this invention, fusion proteins contain multiple CAB and/or FKBP domains. Complexes of such proteins may contain more than one molecule of ligand or other dimerizing agent and more than one copy of one or more of the constituent proteins. Again, such multimeric complexes are still referred to herein as tripartite complexes to indicate the presence of the three types of constituent molecules, even if one or more are represented by multiple copies. The formation of complexes containing at least one divalent drug and at least two protein molecules, each of which contains at least one drug binding domain, may be referred to as "oligomerization" or "multimerization", or simply as "dimerization", "clustering" or "association".

"Dimerizer" denotes a compound which brings together two or more proteins in a multimeric complex.

"Divalent", as that term is applied to ligands in this document, denotes a ligand which is capable of complexing with at least two protein molecules which contain ligand binding domains, to form a three (or greater number)-component complex.

"Domain" refers to a portion of a protein or polypeptide. In the art, the term "domain" may refer to a portion of a protein having a discrete secondary structure. However, as will be apparent from the context used herein, the term "domain" as used

in this document does not necessarily connote a given secondary structure. Rather, a peptide sequence is referred to herein as a "domain" simply to denote a polypeptide sequence from a defined source, or having or conferring an intended or observed activity. Domains can be derived from naturally occurring proteins or may comprise  
5 non-naturally-occurring sequence.

"DNA recognition sequence" means a DNA sequence which is capable of binding to one or more DNA-binding domains, e.g., of a transcription factor or an engineered polypeptide.

"Endogenous" refers to molecules which are naturally occurring in a cell, i.e.  
10 prior to the genetic engineering or infection of the cell.

"Exogenous" refers to molecules which are not naturally present in the cell, and which have been, e.g., introduced by transfection or transduction of the cell (or the parent cell thereof).

FKBPs (FK506 binding proteins) are the cytosolic receptors for macrolides such as FK506, FK520 and rapamycin and are highly conserved across species lines. For the purpose of this disclosure, FKBPs are proteins or protein domains which are capable of binding to an FKB/CAB ligand and further forming a tripartite complex with calcineurin or a CAB-containing protein. An FKB domain may also be referred to as a "FK506 binding domain". Information concerning the nucleotide sequences,  
15

cloning, and other aspects of various FKB species is already known in the art, permitting the synthesis or cloning of DNA encoding the desired FKB peptide sequence, e.g., using well known methods and PCR primers based on published sequences. See e.g. Staendart et al, 1990, Nature 346, 671-674 (human FKB12); Kay,  
20 1996, Biochem. J. 314, 361-385 (review). Homologous FKB proteins in other

mammalian species, in yeast, and in other organisms are also known in the art and may be used in the fusion proteins disclosed herein. See e.g. Kay, 1996, Biochem. J.  
25 314, 361-385 (review). The size of FKB domains for use in this invention are usually 90-100 amino acids, although this varies, depending on which FKB protein is employed. An FKB domain of a fusion protein of this invention will be capable of  
30

binding to an FKB/CAB ligand and participating in a tripartite complex with calcineurin or a CAB-containing protein (as may be determined by any means, direct or indirect, for detecting such binding). The peptide sequence of an FKB domain of an FKB fusion protein of this invention comprises (a) a naturally occurring FKB peptide sequence, preferably derived from the human FKB12 protein (exemplified below) or a peptide sequence derived from another human FKB, from a murine or other mammalian FKB, or from some other animal, yeast or fungal FKB; (b) a  
35

variant of a naturally occurring FKBP sequence in which up to about ten (preferably 1-5, more preferably 1-3, and in some embodiments just one) amino acids of the naturally-occurring peptide sequence have been deleted, inserted, or replaced with substitute amino acids; or (c) a peptide sequence encoded by a DNA sequence

5 capable of selectively hybridizing to a DNA molecule encoding a naturally occurring FKBP or by a DNA sequence which would be capable, but for the degeneracy of the genetic code, of selectively hybridizing to a DNA molecule encoding a naturally occurring FKBP.

An "FKBP/CAB ligand" is a compound, e.g. FK506 or an analog, homolog, derivative or mimetic of any of the foregoing, which binds to an FKBP protein to form a complex which binds to calcineurin or a CAB protein. Similarly, a "cyclophilin/CAB ligand" is a compound, e.g. cyclosporin or an analog, homolog, derivative or mimetic of any of the foregoing, which binds to a cyclophilin protein to form a complex which binds to calcineurin or a CAB protein.

10 "Gene" refers to a nucleic acid molecule or sequence comprising an open reading frame and including at least one exon and (optionally) an intron sequence. The term "intron" refers to a DNA sequence present in a given gene which is not translated into protein and is generally found between exons.

15 "Genetically engineered cells" denotes cells which have been modified by the introduction of recombinant or heterologous nucleic acids (e.g. one or more DNA constructs or their RNA counterparts) and further includes the progeny of such cells which retain part or all of such genetic modification.

20 "Heterologous" as it relates to nucleic acid sequences such as coding sequences and control sequences, denotes sequences that are not normally joined together, and/or are not normally associated with a particular cell. Thus, a "heterologous" region of a nucleic acid construct is a segment of nucleic acid within or attached to another nucleic acid molecule that is not found in association with the other molecule in nature. For example, a heterologous region of a construct could include a coding sequence flanked by sequences not found in association with the coding sequence in nature. Another example of a heterologous coding sequence is a construct where the coding sequence itself is not found in nature (e.g., synthetic sequences having codons different from the native gene). Similarly, in the case of a cell transduced with a nucleic acid construct which is not normally present in the cell, the cell and the construct would be considered mutually heterologous for purposes of this invention.

25 Allelic variation or naturally occurring mutational events do not give rise to heterologous DNA, as used herein.

"Interact" as used herein is meant to include detectable interactions between molecules, such as can be detected using, for example, a yeast or mammalian two hybrid assay or by immunoprecipitation. The term interact is also meant to include "binding" interactions between molecules. Interactions may be, for example, protein-protein, protein-nucleic acid, protein-small molecule or small molecule-nucleic acid in nature.

"Ligand" refers to any molecule which is capable of interacting with a corresponding protein or protein domain. A ligand can be naturally occurring, or the ligand can be partially or wholly synthetic. The term "modified ligand" refers to a ligand which has been modified such that it does not significantly interact with the naturally occurring receptor of the ligand in its non modified form. As used herein, ligand refers to an FKBP/CAB ligand.

"Minimal promoter" refers to the minimal expression control sequence that is necessary for initiating transcription of a selected DNA sequence to which it is operably linked.

The terms "promoter" and "expression control sequence" further encompass "tissue specific" promoters and expression control sequences, i.e., promoters and expression control sequences which effect expression of the selected DNA sequence preferentially in specific cells (e.g., cells of a specific tissue). Gene expression occurs preferentially in a specific cell if expression in this cell type is significantly higher than expression in other cell types. The terms "promoter" and "expression control sequence" also encompass so-called "leaky" promoters and "expression control sequences", which regulate expression of a selected DNA primarily in one tissue, but cause expression in other tissues as well. These terms also encompass non-tissue specific promoters and expression control sequences which are active in most cell types. Furthermore, a promoter or expression control sequence can be constitutive i.e. one which is active basally or inducible, i.e., a promoter or expression control sequence which is active primarily in response to a stimulus. A stimulus can be, e.g., a molecule, such as a hormone, a cytokine, a heavy metal, phorbol esters, cyclic AMP (cAMP), or retinoic acid.

"Nucleic acid" refers to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA). The term should also be understood to include, as equivalents, derivatives, variants and analogs of either RNA or DNA made from nucleotide analogs, and, as applicable to the embodiment being described, single (sense or antisense) and double-stranded polynucleotides. For simplicity, the term DNA is often used herein to refer to any nucleic acid.

A "nucleic acid binding domain" refers to a polypeptide which interacts, or binds, with a higher affinity to a nucleic acid having a specific nucleotide sequence relative to a nucleic acid having a nucleotide sequence which is essentially unrelated to the specific nucleotide sequence. In a preferred embodiment, a nucleic acid binding domain is a "DNA binding domain".

"Operably linked" refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function. Thus, an expression control sequence operably linked to a coding sequence permits expression of the coding sequence. The control sequence need not be contiguous with the coding sequence, so long as it functions to direct the expression thereof. Thus, for example, intervening untranslated yet transcribed sequences can be present between a promoter sequence and the coding sequence and the promoter sequence can still be considered "operably linked" to the coding sequence.

"Protein", "polypeptide" and "peptide" are used interchangeably herein when referring to a gene product, e.g., as may be encoded by a coding sequence.

A "recombinant virus" is a complete virus particle in which the packaged nucleic acid contains a heterologous portion.

"Subunit", when referring to the subunit of an activation domain, refers to a portion of the transcription activation domain.

A "target gene" is a nucleic acid of interest, the expression of which is modulated according to the methods of the invention. The target gene can be endogenous or exogenous and can integrate into a cell's genome, or remain episomal. The target gene can encode a protein or be a non coding nucleic acid, e.g., a nucleic acid which is transcribed into an antisense RNA or a ribozyme.

A "therapeutically effective dose" of ligand denotes a treatment- or prophylaxis-effective dose, e.g., a dose which yields detectable target gene transcription or cell growth, proliferation, differentiation, death, etc. in the genetically engineered cell, or a dose which is predicted to be treatment- or prophylaxis-effective by extrapolation from data obtained in animal or cell culture models. A therapeutically effective dose is usually preferred for the treatment of a human or non-human mammal.

"Transcription control element" denotes a regulatory DNA sequence, such as initiation signals, enhancers, and promoters, which induce or control transcription of protein coding sequences with which they are operably linked. The term "enhancer" is intended to include regulatory elements capable of increasing, stimulating, or enhancing transcription from a promoter. Such transcription regulatory components

can be present upstream of a coding region, or in certain cases (e.g. enhancers), in other locations as well, such as in introns, exons, coding regions, and 3' flanking sequences.

"Transcription factor" refers to any protein or modified form thereof that is involved in the initiation of transcription but which is not itself a part of the polymerase. Transcription factors are proteins or modified forms thereof, which interact preferentially with specific nucleic acid sequences, i.e., regulatory elements. Some transcription factors are active when they are in the form of a monomer. Alternatively, other transcription factors are active in the form of oligomers consisting of two or more identical proteins or different proteins (heterodimer). The factors have different actions during the transcription initiation: they may interact with other factors, with the RNA polymerase, with the entire complex, with activators, or with DNA. Transcription factors usually contain one or more transcription regulatory domains.

"Transcription regulatory domain" refers to any domain which regulates transcription, and includes both activation and repression domains. The term "transcription activation domain" denotes a domain in a transcription factor which positively regulates (increases) the rate of gene transcription. The term "transcription repression domain" denotes a domain in a transcription factor which negatively regulates (inhibits or decreases) the rate of gene transcription.

"Transfection" means the introduction of a naked nucleic acid molecule into a recipient cell. "Infection" refers to the process wherein a virus enters the cell in a manner whereby the genetic material of the virus can be expressed in the cell. A "productive infection" refers to the process wherein a virus enters the cell, is replicated, and then released from the cell (sometimes referred to as a "lytic" infection).

"Transduction" encompasses the introduction of nucleic acid into cells by any means.

"Transgene" refers to a nucleic acid sequence which has been introduced into a cell. Daughter cells deriving from a cell in which a transgene has been introduced are also said to contain the transgene (unless it has been deleted). A transgene can encode, e.g., a polypeptide, partly or entirely heterologous to the animal or cell into which it is introduced, or comprises or is derived from an endogenous gene of the animal or cell into which it is introduced, but which is designed to be inserted, or is inserted, into the recipient's genome in such a way as to alter that genome. (e.g., it is inserted at a location which differs from that of the natural gene). Alternatively, a transgene can also be present in an episome. A transgene can include one or more expression control sequences and any other nucleic acid, (e.g. intron), that may be necessary or desirable for optimal expression of a selected coding sequence.

"Transient transfection" refers to cases where exogenous DNA does not integrate into the genome of a transfected cell, e.g., where episomal DNA is transcribed into mRNA and translated into protein. A cell has been "stably transfected" with a nucleic acid construct when the nucleic acid construct has been integrated into the genome of that cell.

By "virus" is meant a complete virus, such as a wild-type (wt) virus particle comprising a nucleic acid genome associated with a capsid protein coat, or a recombinant virus particle as described above. For example, an adenovirus is a complete virus particle, comprising an Ad nucleic acid genome associated with an Ad capsid protein coat.

"Wild-type" means naturally occurring in a normal cell.



15

This invention involves methods and materials for multimerizing fusion proteins in genetically engineered cells using a novel dimerization-based biological switch. The design and implementation of various dimerization-based biological switches has been reported, inter alia, in Spencer et al and in various international patent applications cited herein. Other accounts of successful application of this general approach have also been reported. Fusion proteins containing a domain from human FRAP fused to an effector domain have been disclosed in Rivera et al, 1996, Nature Medicine 2, 1028-1032 and in WO 96/41865 (Clackson et al) and WO 95/33052 (Berlin et al). As noted previously, the fusion proteins are designed such that association of the effector domains, through ligand-mediated "dimerization" or "multimerization" of the fusion proteins which contain them, triggers a desired biological event such as transcription of a desired gene, cell death, cell proliferation, etc. For example, clustering of fusion proteins containing an action domain derived from the intracellular portion of the T cell receptor CD3 zeta domain triggers transcription of a gene under the transcription control of the IL-2 promoter or promoter elements derived therefrom. In other embodiments, the action domain comprises a domain derived from the intracellular portion of a protein such as FAS or the TNF-alpha receptor (TNFalpha-R1), which are capable, upon oligomerization, of triggering apoptosis of the cell. In still other embodiments, the action domains comprise a DNA-binding domain such as GAL4 or ZFHD1 and a transcription activation domain such as VP16 or p65, paired such that oligomerization of the fusion

proteins represents assembly of a transcription factor complex which triggers transcription of a gene linked to a DNA sequence recognized by (capable of specific binding interaction with) the DNA binding domain.

Fusion proteins containing one or more ligand-binding domains and one or  
5 more action domains, e.g. for activation of transcription of a target gene, triggering cell  
death or other signal transduction pathway, cellular localization, cell proliferation etc.,  
are disclosed in WO 94/18317, PCT/US94/08008, Spencer et al, *supra* and Blau et  
al. (PNAS 1997 94:3076). The design and use of such fusion proteins for ligand-  
mediated gene-knock out and for ligand-mediated blockade of gene expression or  
10 inhibition of gene product function are disclosed in PCT/US95/10591. Novel DNA  
binding domains and DNA sequences to which they bind which are useful in  
embodiments involving regulated transcription of a target gene are disclosed, e.g., in  
Pomeranz et al, 1995, Science 267:93-96. Those references provide substantial  
15 information, guidance and examples relating to the design, construction and use of  
DNA constructs encoding analogous fusion proteins, target gene constructs, and other  
aspects which may also be useful to the practitioner of the subject invention.

By appropriate choice of fusion proteins, this invention permits one to activate  
the transcription of a desired gene; actuate cell growth, proliferation, differentiation or  
apoptosis, or trigger other biological events in engineered cells in an FK506-dependent  
20 manner analogous to the systems described in the patent documents and other  
references cited above. The engineered cells, preferably animal cells, may be growing or  
maintained in culture or may be present within whole organisms, as in the case of  
human gene therapy, transgenic animals, and other such applications. An FKBP/CAB  
ligand is administered to the cell culture or to the organism containing the engineered  
25 cells, as the case may be, in an amount effective to multimerize the FKBP fusion  
proteins and CAB fusion proteins (as may be observed indirectly by monitoring target  
gene transcription, apoptosis or other biological process so triggered). In the case of  
administration to whole organisms, the ligand may be administered in a composition  
containing the ligand and one or more acceptable veterinary or pharmaceutical  
30 diluents and/or excipients.

A compound which binds to one of the fusion proteins but does not form  
tripartite complexes with both fusion proteins may be used as a multimerization  
antagonist. As such it may be administered to the engineered cells, or to organisms  
containing them (preferably in a composition as described above in the case of  
35 administration to whole animals), in an amount effective for blocking or reversing the  
effect of the ligand, i.e. for preventing, inhibiting or disrupting multimerization of the

fusion proteins. For instance, rapamycin, a rapalog, or any of the many synthetic FKBP ligands which do not form tripartite complexes with FKBP and CAB may be used as an antagonist.

One important aspect of this invention provides materials and methods for 5 ligand-dependent, direct activation of transcription of a desired gene. In one such embodiment, a set of two or more different fusion proteins, and corresponding DNA constructs capable of directing their expression, is provided. One such fusion protein contains as its action domain(s) one or more transcription activation domains. The other fusion protein contains as its action domain(s) one or more DNA-binding 10 domains. The selected ligand is capable of binding to both fusion proteins to form a dimeric or multimeric complex thus containing at least one DNA binding domain and at least one transcription activation domain. Formation of such complexes leads to activation of transcription of a target gene linked to, and under the transcription control of, a DNA sequence to which the DNA-binding domain is capable of binding, 15 as can be observed by monitoring directly or indirectly the presence or concentration of the target gene product.

Preferably the DNA binding domain, and a fusion protein containing it, binds 20 to its recognized DNA sequence with sufficient selectivity so that binding to the selected DNA sequence can be observed (directly or indirectly) despite the presence of other, often numerous other, DNA sequences. Preferably, binding of the fusion protein comprising the DNA-binding domain to the selected DNA sequence is at least two, 25 more preferably three and even more preferably more than four orders of magnitude greater than binding to any one alternative DNA sequence, as measured by in vitro binding studies or by measuring relative rates or levels of transcription of genes associated with the selected DNA sequence as compared with any alternative DNA sequences.

Cells which have been genetically engineered to contain such a set of 30 constructs, together with any desired accessory constructs, may be used in applications involving ligand-mediated, regulated actuation of the desired biological event, be it regulated transcription of a desired gene, regulated triggering of a signal transduction pathway such as the triggering of apoptosis, or another event. Cells engineered for regulatable expression of a target gene, for instance, can be used for regulated production of a desired protein (or other gene product) encoded by the target gene. Such cells may be grown in culture by conventional means. Addition of 35 ligand to the culture medium containing the cells leads to expression of the target gene by the cells and production of the protein encoded by that gene. Expression of the

gene and production of the protein can be turned off by withholding further ligand from the medium, by removing residual ligand from the medium, or by adding to the medium a multimerization antagonist reagent.

Engineered cells of this invention can also be produced and/or used in vivo, to 5 modify whole organisms, preferably animals, especially humans, e.g. such that the cells produce a desired protein or other result within the animal containing them. Such uses include gene therapy applications.

Embodiments involving regulatable actuation of apoptosis provide engineered 10 cells susceptible to FK506-inducible cell death. Such engineered cells can be eliminated from a cell culture or host organism after they have served their intended purposes (e.g. production of a desired protein or other product), if they have or develop 15 unwanted properties, or if they are no longer useful, safe or desired. Elimination is effected by adding ligand to the medium or administering it to the host organism. In such cases, the action domains of the fusion proteins are protein domains such as the intracellular domains of FAS or TNF-R1, downstream components of their signaling pathways or other protein domains which upon oligomerization trigger apoptosis.

Said differently, this invention provides a method for achieving any of those 20 objectives, e.g. activation of transcription of a target gene (typically a heterologous gene for a therapeutic protein), cell growth or proliferation, cell death or some other selected biological event, in an animal, preferably a human patient, in need thereof and 25 containing engineered cells of this invention. That method involves administering to the animal a pharmaceutical composition containing the ligand by a route of administration and in an amount effective to cause multimerization of the fusion proteins in at least a portion of the engineered cells. Multimerization may be detected indirectly by detecting the occurrence of target gene expression, cell growth, proliferation or death, or other objective for which the fusion proteins were designed and the cells genetically engineered.

This invention further encompasses a pharmaceutical composition comprising 30 a multimerization antagonist of this invention in admixture with a pharmaceutically acceptable carrier and optionally with one or more pharmaceutically acceptable excipients for inhibiting or otherwise reducing, in whole or part, the extent of multimerization of fusion proteins in engineered cells of this invention in a subject, and thus for de-activating the transcription of a target gene, for example, or turning off another biological result of this invention. Thus, the use of the multimerizing ligands 35 and of the multimerization antagonist reagents to prepare pharmaceutical

compositions and achieve their pharmacologic results is encompassed by this invention.

Also disclosed is a method for providing a host organism, preferably an animal, typically a non-human mammal or a human subject, responsive to a ligand of this invention. The method involves introducing into the organism cells which have been engineered in accordance with this invention, i.e. containing one or more nucleic acid constructs encoding the fusion proteins, and so forth. The engineered cells may be encapsulated using any of a variety of materials and methods before being introduced into the host organism. Alternatively, one can introduce the nucleic acid constructs of this invention into a host organism, e.g. a mammal, under conditions permitting incorporation thereof into one or more cells of the host mammal, e.g. using viral vectors, introduction of DNA by injection or via catheter, etc.

Also provided are kits for producing cells responsive to a ligand of this invention. One such kit contains one or more nucleic acid constructs encoding and capable of directing the expression of fusion proteins which, upon ligand-mediated oligomerization, trigger the desired biological response. The kit may contain a quantity of a ligand capable of multimerizing the fusion protein molecules encoded by the construct(s) of the kit, and may contain in addition a quantity of a multimerization antagonist. The kit may further contain a nucleic acid construct encoding a target gene (or cloning site) linked to a cognate DNA sequence which is recognized by the dimerized fusion proteins permitting transcription of a gene linked to that cognate DNA sequence in the presence of multimerized fusion protein molecules. The constructs may be associated with one or more selection markers for convenient selection of transfected cells, as well as other conventional vector elements useful for replication in prokaryotes, for expression in eukaryotes, and the like. The selection markers may be the same or different for each different construct, permitting the selection of cells which contain each such construct(s).

The accessory construct for introducing into cells a target gene in association with a cognate DNA sequence may contain a cloning site in place of a target gene. A kit containing such a construct permits the engineering of cells for regulatable expression of a gene to be provided by the practitioner.

Other kits of this invention may contain one or two (or more) nucleic acid constructs for fusion proteins in which one or more contain a cloning site in place of the transcription activator or DNA binding protein, permitting the user to insert whichever such domain s/he wishes. Such a kit may optionally include other elements

as described above, e.g. a nucleic acid construct for a target gene with or without a cognate DNA sequence for a pre-selected DNA binding domain.

Any of the kits may also contain positive control cells which were stably transformed with constructs of this invention such that they express a reporter gene (for CAT, beta-galactosidase or any conveniently detectable gene product) in response to exposure of the cells to the ligand. Reagents for detecting and/or quantifying the expression of the reporter gene may also be provided.

For further information and guidance on the design, construction and use of such systems or components thereof which may be adapted for use in practising the subject invention, reference to the following publications is suggested: Spencer et al, 1993, *supra*; Rivera et al, 1996, *supra*; Spencer et al, 1996, *Current Biology* 6, 839-847; Luo et al, 1996, *Nature*, 383, 181-185; Ho et al, 1996, *Nature* 382, 822-826; Belshaw et al, 1996, *Proc. Natl. Acad. Sci. USA* 93, 4604-4607; Spencer, 1996, *TIG* 12(5), 181-187; Spencer et al, 1995, *Proc., Natl. Acad. Sci. USA* 92, 9805-9809; Holsinger et al, 1995, *Proc. Natl. Acad. Sci. USA* 92, 9810-9814; Prusky et al, 1994, *Chemistry & Biology* 1(3), 163-172; and published international patent applications WO 94/18317, WO 95/02684, WO 95/33052, WO 96/20951 and WO 96/41865.

## 20 FKBP domains and fusion proteins

The FKBP fusion protein comprises at least one FKBP domain containing all or part of the peptide sequence of an FKBP domain and at least one heterologous action domain. This fusion protein must be capable of binding to ligand, preferably with a Kd value below about 100 nM, more preferably below about 10 nM and even more preferably below about 1 nM, as measured by direct binding measurement (e.g. fluorescence quenching), competition binding measurement (e.g. versus FK506), inhibition of FKBP enzyme activity (rotamase), or other assay methodology. Typically the fusion protein will contain one or more protein domains comprising peptide sequence selected from that of a naturally occurring FKBP protein such as human FKBP12, e.g. as described in International Patent Application PCT/US94/01617. That peptide sequence may be modified to adjust the binding specificity, usually with replacement, insertion or deletion of 10 or fewer, preferably 5 or fewer, in some cases 1-3, and often 1, amino acid residue. Such modifications are elected in certain embodiments to yield one or both of the following binding profiles: (a) binding of a ligand to the modified FKBP domain, or fusion protein containing it, preferably at least one, and more preferably at least two, and even more preferably three or four or

more, orders of magnitude better (by any measure) than to FKBP12 or the FKBP endogenous to the host cells to be engineered; and (b) binding of the FKBP:ligand complex to the CAB fusion protein, preferably at least one, and more preferably at least two, and even more preferably at least three, orders of magnitude better (by any measure) than to the calcineurin endogenous to the host cell to be engineered.

The FKBP fusion protein also contains at least one heterologous action domain, i.e., a protein domain containing non-FKBP peptide sequence. The action domain may be a DNA-binding domain, transcription activation domain, transcription repression domain, cellular localization domain, intracellular signal transduction domain, etc., e.g. as described elsewhere herein or in PCT/US94/01617 or the other cited references. Generally speaking, the action domain is capable of directing the fusion protein to a selected cellular location or of initiating a biological effect upon association or aggregation with another action domain, for instance, upon multimerization of proteins containing the same or different action domains.

A recombinant nucleic acid encoding such a fusion protein will be capable of selectively hybridizing to a DNA encoding the parent FKBP protein, e.g. human FKBP12, or would be capable of such hybridization but for the degeneracy of the genetic code. Since these fusion proteins contain an action domain derived from another protein, e.g. Gal4, ZFHD1, p65, VP16, FAS, CD3 zeta chain, etc., the recombinant DNA encoding the fusion protein will also be capable of selectively hybridizing to a DNA encoding that other protein, or would be capable of such hybridization but for the degeneracy of the genetic code.

FKBP fusion proteins of this invention, as well as CAB fusion proteins discussed in further detail below, may contain one or more copies of one or more different ligand binding domains and one or more copies of one or more action domains. The ligand binding domain(s) (i.e., FKBP and CAB domains) may be N-terminal, C-terminal, or interspersed with respect to the action domain(s). Embodiments involving multiple copies of a ligand binding domain usually have 2, 3 or 4 such copies. For example, an FKBP fusion protein may contain 2, 3 or 4 FKBP domains. The various domains of the FKBP fusion proteins (and of the CAB fusion proteins discussed below) are optionally separated by linking peptide regions which may be derived from one of the adjacent domains or may be heterologous.

Illustrative examples of FKBP fusion proteins useful in the practice of this invention include the FKBP fusion proteins disclosed in PCT/US94/01617 (Stanford & Harvard), PCT/US94/08008 (Stanford & Harvard), Spencer et al (supra), PCT/US95/10591 (ARIAD), PCT/US95/06722 (Mitotix, Inc.) and other references

cited herein; the FKBP fusion proteins disclosed in the examples which follow; variants of any of the foregoing FKBP fusion proteins which contain up to 10 (preferably 1-5) amino acid insertions, deletions or substitutions in one or more of the FKBP domains and which are still capable of binding to a ligand; variants of any of the foregoing FKBP fusion proteins which contain one or more copies of an FKBP domain which is encoded by a DNA sequence capable of selectively hybridizing to a DNA sequence encoding a naturally occurring FKBP domain and which are still capable of binding to a ligand; variants of any of the foregoing in which one or more heterologous action domains are deleted, replaced or supplemented with a different heterologous action domain; variants of any of the foregoing FKBP fusion proteins which are capable of binding to an FKBP/CAB ligand and which contain an FKBP domain derived from a non-human source; and variants of any of the foregoing FKBP fusion proteins which contain one or more amino acid residues corresponding to Tyr26, Phe36, Asp37, Arg42, Phe46, Phe48, Glu54, Val55, or Phe99 of human FKBP12 in which one or more of those amino acid residues is replaced by a different amino acid, the variant being capable of binding to a ligand.

For instance, in a number of cases the FKBP fusion proteins comprise multiple copies of an FKBP domain containing amino acids 1-107 of human FKBP12, separated by the 2-amino acid linker Thr-Arg encoded by ACTAGA, the ligation product of DNAs digested respectively with the restriction endonucleases SpeI and XbaI. The following table provides illustrative subsets of mutant FKBP domains based on the foregoing FKBP12 sequence:

#### Illustrative Mutant FKBP<sub>s</sub>

25

F36A	Y26V	F46A	W59A
F36V	Y26S	F48H	H87W
F36M	D37A	F48L	H87R
F36S	I90A	F48A	F36V/F99A
F99A	I91A	E54A	F36V/F99G
F99G	F46H	E54K	F36M/F99A
Y26A	F46L	V55A	F36M/F99G

note: Entries identify the native amino acid by single letter code and sequence position, followed by the replacement amino acid in the mutant. Thus, F36V designates a human FKBP12 sequence in which phenylalanine at position 36 is replaced by valine. F36V/F99A indicates a double mutation in which phenylalanine at positions 36 and 99 are replaced by valine and alanine, respectively.

#### Cyclophilin domains and fusion proteins

Cyclophilin fusion proteins may contain all or part of murine cyclophilin C (e.g. residues 36-212; Friedman et al., Cell 664(1991)799-806) or human cyclophilin C (Genbank Accession number S71018; Schneider et al., Biochemistry 33 (27), 8218-8224 (1994)). These fusion proteins contain a heterologous action domain and form complexes with a cyclophilin/CAB ligand, such as cyclosporin, as described above for FKBP fusion proteins. Cyclophilin domains may also be modified to adjust the binding specificity, usually with replacement, insertion or deletion of 10 or fewer, preferably 5 or fewer, in some cases 1-3, and often 1, amino acid residue, again as described in detail above for FKBP domains. In general, any description of FKBP domains and fusion proteins and their use in this invention is applicable to cyclophilin domains as well. Cyclophilin domains and their use in chimeric proteins are described in US 5,830,462, in particular example 4c, the full contents of which are incorporated herein by reference.

#### CAB domains and fusion proteins

The structure of FKBP-FK506 complexed to calcineurin phosphatase (Griffith et al., Cell, 82:507-522, 1995) has been reported. Calcineurin A (residues 12-394) was shown to be effective as a dimerization domain using a three hybrid system in yeast using three FKBPs fused to Gal4 and residues 12-394 of murine calcineurin A fused C-terminally to the Gal4 activation domain (Ho, 1996 Nature. 382:822-826). Addition of FK506 activated transcription of a reporter gene in these cells. This system is not optimal, however, because it requires a complex to form between endogenous calcineurin B and the calcineurin A fusion protein. In addition, the calcineurin fusion protein might interfere with the calcineurin signaling pathway.

The present invention provides a "minimal" calcineurin domain, termed a CAB, which is a smaller, more manipulatable domain that can be used in a general way to control dimerization of proteins for the purposes of regulating biological processes. A CAB domain of this invention must be able to form a complex with

FKBP in the presence of an FKBP/CAB ligand. In other embodiments, the CAB domain can form a tripartite complex with a cyclophilin domain and cyclosporin. Thus, one of the most compelling potential features of the CAB as a dimerization domain is its ability to dock with two different partners under the control of two different ligands. With this system, a single dimerization domain (i.e. the CAB) can interact with two other protein partners simultaneously or competitively, depending on the particular drug added. The same is also true for FKBP which is now capable of being recruited to either FRAP in the presence of rapamycin or a rapalog or to CAB in the presence of an FKBP/CAB ligand.

Since the CAB should bind both the FK506:FKBP complex and the cyclosporin:cyclophilin complex, one can engineer cells or animals in which a fusion of the CAB to a heterologous action domain is present in the same cell as two other fusion proteins, one containing FKBP and one containing cyclophilin. Addition of FK506 to these cells results in the formation of an FKBP/FK506/CAB complex, while addition of cyclosporin to the same cell would result in a cyclophilin/cyclosporin/CAB complex. An example of this situation is illustrated in Figure 6A.

Furthermore, since FKBP is required to mediate the interactions between both FK506 or rapamycin and their cellular targets, one can engineer cells or animals in which a fusion of the CAB to a heterologous action domain is present in the same cell as a fusion protein containing an FRB domain. FRB domains are described in detail in WO 95/33052 and in WO 96/41865. In this embodiment, addition of FK506 to the cell induces the formation of an FKBP/FK506/CAB complex, while addition of rapamycin should result in the formation of an FKBP/rapamycin/FRB complex. This allows for complex order of addition experiments in cell culture or for more complex control over signal transduction processes that require localization or protein association for function. An example of this situation is illustrated in Figure 6B.

CAB domains of this invention are composite ligand binding domains, comprising a portion of calcineurin A and a portion of calcineurin B, such that the resulting composite ligand binding domain contains the surface of calcineurin phosphatase that contacts the FKBP-FK506 complex. The region of calcineurin that has been truncated contains the autoregulatory and calmodulin domains, which are not involved in FKBP binding. The portion of calcineurin A used in the examples includes residues 12 to 394 or residues 12 to 370 of human calcineurin A in the full length CABS, however, equivalent regions of the calcineurin gene from other species could also be used. For example, one may desire to use the sequence of the mouse or

rat genes for the construction of transgenic animals. The N or C terminus of the calcineurin A portion could also be shortened or extended, if desired. The 12-394 CABs contain an active phosphatase domain, while the 12-370 CABs have an H151A mutation in calcineurin A that abolishes the phosphatase activity.

5       The calcineurin B portion of the CABs described in the examples contains residues 2 or 3 to 170 of human calcineurin B. The N-terminal methionine (residue 1) or methionine and glycine (residue 1 and residue 2) can be removed to prevent processing or myristoylation of calcineurin B at its N-terminus and to remove an alternative start site for translation. The calcineurin B portion of the composite  
10 domain may also be shortened, if desired. Literature references and Genbank accession numbers for various calcineurin genes are given in the table below:

	Calcineurin A		Calcineurin B	
Species	Genbank #	Reference	Genbank #	Reference
Human	M29550	Guerini and Klee, PNAS USA 86, 9183-9187 (1989).	M30773	Guerini et al., DNA 8(9), 675-682 (1989).
Rat	D90035	Ito et al., BBRC 163(3), 1492-1497 (1989).	D14568	Chang et al., BBA 1217(2), 174-180 (1994).
Bovine	U33868	Griffith et al., Cell, 82:507-522, (1995)	X71666	Nargang et al., DNA seq 4(5), 313-318 (1994).
Mouse	M81483	Guerini and Klee, PNAS USA 86, 9183-9187 (1989).	S43864	Ueki et al., BBRC 187(1), 537-543 (1992)

15       The distance between residue 370 of calcineurin A and the N-terminus of calcineurin B is 17.5 Angstroms, as determined from the crystal structure. Thus, when the CAB domain is constructed in such a way that the calcineurin A portion is N-

terminal to the calcineurin B portion, only a small linker region is necessary to connect the two. In fact, since the structure indicates that calcineurin A maintains a rigid structure only as far as residue 370, the C-terminus of calcineurin A can be linked directly to the N-terminus of calcineurin B, thereby using residues 370-394 of calcineurin A as the linker region. Hence, a preferred embodiment of the invention comprises a CAB domain composed of residues 12-394 of calcineurin A fused N-terminally to residues 3-170 of calcineurin B.

The CAB fusion protein comprises at least one CAB domain and at least one heterologous action domain, i.e., a protein domain containing non-CAB peptide sequence. The action domain may be a DNA-binding domain, transcription activation domain, transcription repression domain, cellular localization domain, intracellular signal transduction domain, etc., e.g. as described elsewhere herein or in PCT/US94/01617 or the other cited references. Generally speaking, the action domain is capable of directing the fusion protein to a selected cellular location or of initiating a biological effect upon association or aggregation with another action domain, for instance, upon multimerization of proteins containing the same or different action domains. As described in the examples, both CAB-VP16 fusion proteins and CAB-GAL4 fusion proteins are functional in SEAP reporter assays. As in the case of FKBP fusion proteins, the CAB domains should be able to hybridize with either calcineurin A or calcineurin B or portions thereof, or would be able to but for the degeneracy of the genetic code.

A shorter version of the CAB domain, termed the mini CAB, comprises residues 340-394 of calcineurin A fused N-terminally to residues 3-170 of calcineurin B. This construct eliminates the phosphatase domain of calcineurin and provides a less bulky protein for use in the dimerization system. Example 8 shows that the mini CAB can work as well as the full length CABs in reporter assays. As described above for FKBP<sub>s</sub>, CAB fusion proteins of this invention may contain one or more copies of the ligand binding domain and one or more copies of one or more action domains. The CAB domain may be N-terminal, C-terminal, or interspersed with respect to the action domain(s). Embodiments involving multiple copies of a ligand binding domain usually have 2, 3 or 4 such copies. For example, a CAB fusion protein may contain 2, 3, or 4 CAB domains, although currently, the preferred embodiment for regulated transcription contains 2 CAB domains.

### Mixed fusion proteins

A third type of fusion protein comprises one or more FKBP domains, one or more heterologous action domains, and one or more CAB domains as described for the CAB fusion proteins.

5 Mixed fusion protein molecules are capable of forming homodimeric or homomultimeric protein complexes in the presence of an FKBP/CAB ligand to which they bind. Embodiments involving mixed fusion proteins have the advantage of requiring the introduction into cells of a single recombinant nucleic acid construct in place of two recombinant nucleic acid constructs otherwise required to direct the  
10 expression of both an FKBP fusion protein and a CAB fusion protein.

A recombinant DNA encoding a mixed fusion protein will be capable of selectively hybridizing to a DNA encoding an FKBP protein, a DNA encoding calcineurin A or B, and a heterologous DNA sequence encoding the protein from which one or more effector domains is derived (e.g. Gal4, VP16, Fas, CD3 zeta chain, etc.),  
15 or would be capable of such hybridization but for the degeneracy of the genetic code.

### Heterologous domains

As mentioned above, the heterologous action domains of the fusion proteins are protein domains which, upon mutual association of the fusion proteins bearing them, are capable of triggering (or inhibiting) events such as DNA-binding and/or transcription of a target gene; actuating cell growth, differentiation, proliferation or apoptosis; directing proteins to a particular cellular location; or actuating other biological events.

Embodiments involving regulatable gene transcription involve the use of target  
25 gene constructs which comprise a target gene (which encodes a polypeptide, antisense RNA, ribozyme, etc. of interest) under the transcription control of a DNA element responsive to the association or multimerization of the heterologous domains of the 1st and 2d fusion proteins.

In embodiments of the invention involving direct activation of transcription, the  
30 heterologous domains of the 1st and 2nd fusion proteins comprise a DNA binding domain such as Gal4 or a fusion DNA binding domain such as ZFHD1, and a transcription activation domain such as those derived from VP16 or p65, respectively. The multimerization of a fusion protein containing such a transcription activation domain to a fusion protein containing a DNA binding domain targets the transcription factor to the expression control sequence to which the DNA binding domain binds, and thus activates the transcription of a target gene linked to that expression control

sequence. Foregoing the transcription activation domain or substituting a repressor domain (see PCT/US94/01617) in place of a transcription activation domain provides an analogous fusion protein useful for inhibiting transcription of a target gene. Composite DNA binding domains and DNA sequences to which they bind are disclosed in Pomerantz et al, 1995, *supra*, the contents of which are incorporated herein by reference. Such composite DNA binding domains may be used as DNA binding domains in the practice of this invention, together with a target gene construct containing the cognate DNA sequences to which the composite DBD binds.

In embodiments involving indirect activation of transcription, the heterologous domains of the fusion proteins are action domains of signaling proteins which upon aggregation or multimerization trigger the activation of transcription under the control of a responsive promoter. For example, the signaling domain may be the intracellular domain of the zeta subunit of the T cell receptor, which, upon aggregation, triggers transcription of a gene linked to the IL-2 promoter or a derivative thereof (e.g. iterated NF-AT binding sites). Alternatively, the signaling domain may be a cell surface receptor such as the erythropoietin receptor, which can initiate cell proliferation upon multimerization.

In another aspect of the invention, the heterologous domains are protein domains which upon mutual association are capable of triggering cell death. Examples of such domains are the intracellular domains of the Fas antigen or of the TNF R1. Fusion proteins containing a Fas domain can be designed and prepared by analogy to the disclosure of PCT/US94/01617.

#### Engineered receptor domains

As noted previously, the FKBP and CAB domains may contain peptide sequence selected from the peptide sequences of naturally occurring FKBP and CAB domains. Naturally occurring sequences include those of human FKBP12 and portions of human calcineurin A or calcineurin B. Alternatively, the peptide sequences may be derived from such naturally occurring peptide sequences but contain generally up to 10, and preferably 1-5, mutations in one or both such peptide sequences. As disclosed in greater detail elsewhere herein, such mutations can confer a number of important features. For instance, an FKBP domain may be modified such that it is capable of binding an improved ligand preferentially, i.e. at least one, preferably two, and even more preferably three or four or more orders of magnitude more effectively, with respect to ligand binding by the unmodified FKBP domain. A CAB domain may be modified such that it is capable of binding a (modified or unmodified) FKBP:ligand

complex preferentially, i.e. at least one, preferably two, and even more preferably three orders of magnitude more effectively, with respect to the unmodified CAB domain. FKBP and CAB domains may be modified such that they are capable of forming a tripartite complex with an improved ligand, preferentially, i.e. at least one, 5 preferably two, and even more preferably three orders of magnitude more effectively, with respect to unmodified FKBP and CAB domains.

Methods for identifying FKBP mutations that confer enhanced ability to bind derivatives of FK506 containing various substituents ("bumps") were disclosed in US 5,830,462. In this approach, molecular modelling is used to identify candidate amino acid substitutions in the FKBP domain that would accommodate the ligand 10 substituent(s), and site-directed mutagenesis may then be used to engineer the protein mutations so identified. The mutants are expressed by standard methods and their binding affinity for the ligands measured, for example by inhibition of rotamase activity, or by competition for binding with a molecule such as FK506, if the mutant 15 retains appropriate activity/affinity.

A similar strategy can be used to identify bump-hole pairs for the CAB domain. An exemplary FKBP/CAB ligand is C40-phenyl-FK506. This compound appears to be at least 30-fold less immunosuppressive than FK506 as measured by its dose-dependent suppression of PMA/ionomycin-induced activation of an NFAT- 20 SEAP reporter in transient transfection experiments.

Without being bound by a particular theory, the inability of C40-phenyl-FK506 to inhibit NFAT-SEAP activity can be understood as a failure of the FKBP12/C40-phenyl-FK506 complex to bind endogenous calcineurin. The inhibition of NFAT-SEAP activity by FK506 is known to require binding of the FKBP12/FK506 complex to calcineurin, which results in a loss of calcineurin phosphatase activity (J. Liu, et al. Cell, 1991; 66: 807-815. J. Liu et al., Biochemistry, 1992; 31: 3896-3901). Indeed, the crystal structure of FKBP12/FK506 with the calcineurin heterodimer reveals that the terminal C39-C40 olefin of FK506 protrudes into the protein-protein interface between calcineurin A and calcineurin B (J.P. Griffith, et al Cell, 1995; 82(3): 507-522.) 25 Grafting a model of the phenyl group of C40-phenyl-FK506 onto this structure allows the identification of several residues of calcineurin (W352, S353, and F356 from calcineurin A; L116, M119, and V120 from calcineurin B) whose side chains might be responsible for the steric interference which abrogates binding. Each of the residues in question is part of the CAB minimal binding domain structure. Thus, these residues 30 may be mutated randomly or rationally to obtain a "holed" CAB which 35

accommodates bumped FK506. These mutations may be inserted randomly or in a directed fashion, as described above for FKBP.

An alternative to iterative engineering and testing of single or multiple mutants is to co-randomize structurally-identified residues that are or would be in contact with 5 or near one or more ligand or FK506 substituents. A collection of polypeptides containing FKBP or CAB domains randomized at the identified positions (such as are noted in the foregoing paragraph) is prepared e.g. using conventional synthetic or genetic methods. Such a collection represents a set of receptor domains containing replacement amino acids at one or more of such positions. The collection is screened 10 and variants are selected which possess the desired ligand binding properties. In general, randomizing several residues simultaneously is expected to yield compensating mutants of higher affinity and specificity for a given bumped ligand as it maximizes the likelihood of beneficial cooperative interactions between sidechains. Techniques for preparing libraries randomized at discrete positions are known and 15 include primer-directed mutagenesis using degenerate oligonucleotides, PCR with degenerate oligonucleotides, and cassette mutagenesis with degenerate oligonucleotides (see for example Lowman, H.B. and Wells, J.A. Methods: Comp. Methods Enzymol. 1991. 3, 205-216; Dennis, M.S. and Lazarus, R.A. 1994. J. Biol. Chem. 269, 22129-22136; and references therein).

We further contemplate that in many cases, randomization of only the few 20 residues in or near direct contact with a given position in FK506 may not completely explore all the possible variations in FKBP or CAB conformation that could optimally accommodate a ligand substituent (bump). Thus the construction is also envisaged of unbiased libraries containing random substitutions that are not based on structural 25 considerations, to identify subtle mutations or combinations thereof that confer preferential binding to bumped ligands. Several suitable mutagenesis schemes have been described, including alanine-scanning mutagenesis (Cunningham and Wells (1989) Science 244, 1081-1085), PCR misincorporation mutagenesis (see eg. Cadwell and Joyce, 1992, PCR Meth. Applic. 2, 28-33), and 'DNA shuffling' (Stemmer, 1994, 30 Nature 370, 389-391 and Crameri et al, 1996, Nature Medicine 2, 100-103). These techniques produce libraries of random mutants, or sets of single mutants, that are then searched by screening or selection approaches.

In many cases, an effective strategy to identify the best mutants for preferential 35 binding of a given bump is a combination of structure-based and unbiased approaches. See Clackson and Wells, 1994, Trends Biotechnology 12, 173-184 (review). For example we contemplate the construction of libraries in which key

contact residues are randomized by PCR with degenerate oligonucleotides, but with amplification performed using error-promoting conditions to introduce further mutations at random sites. A further example is the combination of component DNA fragments from structure-based and unbiased random libraries using DNA shuffling.

5 Screening of libraries for desirable mutations may be performed by use of a yeast 2-hybrid system (Fields and Song (1989) *Nature* 340, 245-246). For example, a CAB-VP16 fusion may be introduced into one vector, and a library of randomized FKBP sequences cloned into a separate GAL4 fusion vector. Yeast co-transformants are treated with ligand, and those harboring complementary FKBP mutants are  
10 identified by for example beta-galactosidase or luciferase production (a screen), or survival on plates lacking an essential nutrient (a selection), as appropriate for the vectors used. The requirement for bumped FK506 to bridge the FKBP-CAB interaction is a useful screen to eliminate false positives.

A further strategy for isolating modified ligand-binding domains from libraries  
15 of FKBP (or cyclophilin or CAB) mutants utilizes a genetic selection for functional dimer formation described by Hu et. al. (Hu, J.C., et al. 1990. *Science*. 250:1400-1403; for review see Hu, J.C. 1995. *Structure*. 3:431-433). This strategy utilizes the fact that the bacteriophage lambda repressor cI binds to DNA as a homodimer and that binding of such homodimers to operator DNA prevents transcription of phage genes  
20 involved in the lytic pathway of the phage life cycle. Thus, bacterial cells expressing functional lambda repressor are immune to lysis by superinfecting phage lambda. Repressor protein comprises an amino terminal DNA binding domain (amino acids 1-  
25 92), joined by a 40 amino acid flexible linker to a carboxy terminal dimerization domain. The isolated N-terminal domain binds to DNA with low affinity due to inefficient dimer formation. High affinity DNA binding can be restored with heterologous dimerization domains such as the GCN4 "leucine zipper". Hu et al have described a system in which phage immunity is used as a genetic selection to isolate GCN4 leucine zipper mutants capable of mediating lambda repressor dimer formation from a large population of sequences (Hu et. al., 1990).

30 For example, to use the lambda repressor system to identify FRAP mutants complementary to bumped ligands, lambda repressor-FRAP libraries bearing mutant FRAP sequences are transformed into E. coli cells expressing wildtype lambda repressor-FKBP protein. Plasmids expressing FRAP mutants are isolated from those colonies that survive lysis on bacterial plates containing high titres of lambda phage  
35 and "bumped" FK506 compounds. Alternatively, to isolate FKBP mutants, the above strategy is repeated with lambda repressor-FKBP libraries bearing mutant FKBP

sequences transformed into *E. coli* cells expressing wildtype lambda repressor-FRAP protein.

A further alternative is to clone the randomized FKBP sequences into a vector for phage display, allowing *in vitro* selection of the variants that bind best to the ligand. Affinity selection *in vitro* may be performed in a number of ways. For example, 5 ligand is mixed with the library phage pool in solution in the presence of CAB tagged with an affinity handle (for example a hexa-histidine tag, or GST), and the resultant complexes are captured on the appropriate affinity matrix to enrich for phage displaying FKBP harboring complementary mutations. Techniques for phage display 10 have been described, and other *in vitro* selection systems can also be contemplated (for example display on lambda phage, display on plasmids, display on baculovirus). Furthermore, selection and screening strategies can also be used to improve other properties of benefit in the application of this invention, such as enhanced stability *in vivo*. For a review see Clackson, T. & Wells, J.A. 1994. Trends 15 Biotechnol. 12, 173-184.

Additionally, in optimizing the receptor domains of this invention, it should be appreciated that immunogenicity of a polypeptide sequence is thought to require the binding of peptides by MHC proteins and the recognition of the presented peptides as foreign by endogenous T-cell receptors. It may be preferable, at least in human gene 20 therapy applications, to tailor a given foreign peptide sequence, including junction peptide sequences, to minimize the probability of its being immunologically presented in humans. For example, peptide binding to human MHC class I molecules has strict requirements for certain residues at key 'anchor' positions in the bound peptide: eg. HLA-A2 requires leucine, methionine or isoleucine at position 2 and leucine or valine 25 at the C-terminus (for review see Stern and Wiley (1994) Structure 2, 145-251). Thus in engineering proteins in the practice of this invention, this periodicity of these residues is preferably avoided, especially in human gene therapy applications. The foregoing applies to all protein engineering aspects of the invention, including without limitation the engineering of point mutations into receptor domains, and to the choice 30 or design of boundaries between the various protein domains.

### Ligands

Modified FKBP ligands for use with engineered FKBP domains have been extensively described in the scientific literature and in published patent applications, 35 including WO 94/18317 and US 5,830,462. A number of modified FKBP/CAB ligands have been identified and synthesized, including C40-phenyl-FK506, C40-p-

phenoxyphenyl-FK506, C40-p-biphenyl-FK506, C40-beta-naphthyl-FK506, C40-m-fluorophenyl-FK506, C40-p-iodophenyl-FK506, and "C41"-trimethylsilyl-FK506. The synthesis of FKBP/CAB ligands is described in Example 9.

Each of these compounds is made using the appropriate styrene derivative,  
5 except for "C41"-trimethylsilyl-FK506 which uses allyltrimethylsilane, coupled to  
FK506's terminal olefin using the Grubbs catalyst to facilitate the olefin metathesis  
chemistry. As shown in figure 3, any styrene derivative may be added at the C40  
position of FK506 using the methods described in Example 9. By such means one may  
prepare a wide variety of aryl- and heteroaryl-substituted C40 FK506 derivatives  
10 which can be used in the practice of this invention.

Modified cyclosporin A derivatives have also been prepared and are described  
in detail in US 5,830,462, especially example 22, and in WO 98/08956, example 1,  
the full contents of which are incorporated herein by reference.

15 **Other components, design features and applications**

The fusion proteins may contain as a heterologous domain a cellular  
localization domain such as a membrane retention domain. See e.g.  
PCT/US94/01617, especially pages 26-27. Briefly, a membrane retention domain can  
be isolated from any convenient membrane-bound protein, whether endogenous to the  
20 host cell or not. The membrane retention domain may be a transmembrane retention  
domain, i.e., an amino acid sequence which extends across the membrane as in the  
case of cell surface proteins, including many receptors. The transmembrane peptide  
sequence may be extended to span part or all of an extracellular and/or intracellular  
domain as well. Alternatively, the membrane retention domain may be a lipid  
25 membrane retention domain such as a myristylation or palmitoylation site which  
permits association with the lipids of the cell surface membrane. Lipid membrane  
retention domains will usually be added at the 5' end of the coding sequence for N-  
terminal binding to the membrane and, proximal to the 3' end for C-terminal binding.  
Peptide sequences involving post-translational processing to provide for lipid  
30 membrane binding are described by Carr, et al., PNAS USA (1988) 79, 6128; Aitken,  
et al., FEBS Lett. (1982) 150, 314; Henderson, et al., PNAS USA (1983) 80, 319;  
Schulz, et al., Virology (1984), 123, 2131; Dellman, et al., Nature (1985) 314, 374; and  
reviewed in Ann. Rev. of Biochem. (1988) 57, 69. An amino acid sequence of interest  
includes the sequence M-G-S-S-K-S-K-P-K-D-P-S-Q-R. Various DNA sequences can  
35 be used to encode such sequences in the various fusion proteins of this invention.  
Other localization domains include organelle-targeting domains and sequences such as

-K-D-E-L and -H-D-E-L which target proteins bearing them to the endoplasmic reticulum, as well as nuclear localization sequences which are particularly useful for fusion proteins designed for (direct) transcription regulation. Various cellular localization sequences and signals are well known in the art.

5 Other fusion proteins may contain a bundling domain as a heterologous domain. These domains, such as the lac repressor tetramerization domain constitutively oligomerize proteins containing such domains. Bundling domains may be used to deliver additional copies of activation domains or DNA binding domains to a given promoter.

10 Further details which may be used in the practice of the subject invention relating to the design, assembly and use of constructs encoding fusion proteins containing various action domains including cytoplasmic signal initiation domains such as the CD3 zeta chain, nuclear transcription factor domains including among others VP16 and GAL4, domains capable of triggering apoptosis including the Fas 15 cytoplasmic domain and others are disclosed in PCT/US94/01617 and PCT/US95/10591. The latter international application further discloses additional features particularly applicable to the creation of genetically engineered animals which may be used as disease models in biopharmaceutical research. Those features include the use of tissue specific regulatory elements in the constructs for expression of the 20 fusion proteins and the application of regulated transcription to the expression of Cre recombinase as the target gene leading to the elimination of a gene of interest flanked by loxP sequences. Alternatively, fip and its cognate recognition sequences may be used instead of Cre and lox. Those features may be adapted to the subject invention.

In various cases, especially in embodiments involving whole animals containing 25 cells engineered in accordance with this invention, it will often be preferred, and in some cases required, that the various domains of the fusion proteins be derived from proteins of the same species as the host cell. Thus, for genetic engineering of human cells, it is often preferred that the heterologous domains (as well as the FKBP and CAB domains) be of human origin, rather than of bacterial, yeast or other non-human 30 source.

We also note that epitope tags may also be incorporated into fusion proteins of this invention to permit convenient detection.

#### Tissue-specific or cell-type specific expression

35 It will be preferred in certain embodiments, that the fusion proteins be expressed in a cell-specific or tissue-specific manner. Such specificity of expression

may be achieved by operably linking one or more of the DNA sequences encoding the fusion protein(s) to a cell-type specific transcription regulatory sequence (e.g. promoter/enhancer). Numerous cell-type specific transcription regulatory sequences are known. Others may be obtained from genes which are expressed in a cell-specific manner. See e.g. PCT/US95/10591, especially pp. 36-37.

For example, constructs for expressing the fusion proteins may contain regulatory sequences derived from known genes for specific expression in selected tissues.

Representative examples are tabulated below:

10

Tissue	Gene	Reference
lens	g2-crystallin	Breitman, M.L., Clapoff, S., Rossant, J., Tsui, L.C., Golde, L.M., Maxwell, I.H., Bernstein, A. (1987) Genetic Ablation: targeted expression of a toxin gene causes microphthalmia in transgenic mice. <i>Science</i> 238: 1563-1565
	aA-crystallin	Landel, C.P., Zhao, J., Bok, D., Evans, G.A. (1988) Lens-specific expression of a recombinant ricin induces developmental defects in the eyes of transgenic mice. <i>Genes Dev.</i> 2: 1168-1178
		Kaur, S., Key, B., Stock, J., McNeish, J.D., Akeson, R., Potter, S.S. (1989) Targeted ablation of alpha-crystallin-synthesizing cells produces lens-deficient eyes in transgenic mice. <i>Development</i> 105: 613-619
pituitary - somatrophic cells	Growth hormone	Behringer, R.R., Mathews, L.S., Palmiter, R.D., Brinster, R.L. (1988) Dwarf mice produced by genetic ablation of growth hormone-expressing cells. <i>Genes Dev.</i> 2: 453-461

pancreas	Insulin-Elastase - acinar cell specific	Ornitz, D.M., Palmiter, R.D., Hammer, R.E., Brinster, R.L., Swift, G.H., MacDonald, R.J. (1985) Specific expression of an elastase-human growth fusion in pancreatic acinar cells of transgenic mice. <i>Nature</i> 31: 600-603  Palmiter, R.D., Behringer, R.R., Quaife, C.J., Maxwell, F., Maxwell, I.H., Brinster, R.L. (1987) Cell lineage ablation in transgenic mice by cell-specific expression of a toxin gene. <i>Cell</i> 50: 435-443
T cells	Ick promoter	Chaffin, K.E., Beals, C.R., Wilkie, T.M., Forbush, K.A., Simon, M.I., Perlmutter, R.M. (1990) <i>EMBO Journal</i> 9: 3821-3829
B cells	Immunoglobulin kappa light chain	Borelli, E., Heyman, R., Hsi, M., Evans, R.M. (1988) Targeting of an inducible toxic phenotype in animal cells. <i>Proc. Natl. Acad. Sci. USA</i> 85: 7572-7576  Heyman, R.A., Borrelli, E., Lesley, J., Anderson, D., Richmond, D.D., Baird, S.M., Hyman, R., Evans, R.M. (1989) Thymidine kinase obliteration: creation of transgenic mice with controlled immunodeficiencies. <i>Proc. Natl. Acad. Sci. USA</i> 86: 2698-2702
Schwann cells	P <sub>0</sub> promoter	Messing, A., Behringer, R.R., Hammang, J.P., Palmiter, RD, Brinster, RL, Lemke, G. P <sub>0</sub> promoter directs expression of reporter and toxin genes to Schwann cells of transgenic mice. <i>Neuron</i> 8: 507-520 1992
	Myelin basic protein	Miskimins, R., Knapp, L., Dewey, MJ, Zhang, X. Cell and tissue-specific expression of a heterologous gene under control of the myelin basic protein gene promoter in transgenic mice. <i>Brain Res Dev Brain Res</i> 1992 Vol 65: 217-21

spermatids	protamine	Breitman, M.L., Rombola, H., Maxwell, I.H., Klintworth, G.K., Bernstein, A. (1990) Genetic ablation in transgenic mice with attenuated diphtheria toxin A gene. Mol. Cell. Biol. 10: 474-479
lung	Lung surfactant gene	Ornitz, D.M., Palmiter, R.D., Hammer, R.E., Brinster, R.L., Swift, G.H., MacDonald, R.J. (1985) Specific expression of an elastase-human growth fusion in pancreatic acinar cells of transgenic mice. Nature 31: 600-603
adipocyte P2		Ross, S.R, Braves, RA, Spiegelman, BM Targeted expression of a toxin gene to adipose tissue: transgenic mice resistant to obesity Genes and Dev 7: 1318-24 1993
muscle	myosin light chain	Lee, KJ, Ross, RS, Rockman, HA, Harris, AN, O'Brien, TX, van-Bilsen, M., Shubeta, HE, Kandolf, R., Brem, G., Prices et alJ. Biol. Chem. 1992 Aug 5, 267: 15875-85
	Alpha actin	Muscat, GE., Perry, S. , Prentice, H. Kedes, L. The human skeletal alpha-actin gene is regulated by a muscle-specific enhancer that binds three nuclear factors. Gene Expression 2, 111-26, 1992
neurons	neurofilament proteins	Reeben, M. Halmekyto, M. Alhonen, L. Sinervirta, R. Saarma, M. Janne,J. Tissue-specific expression of rat light neurofilament promoter-driven reporter gene in transgenic mice. BBRC 1993: 192: 465-70
liver	tyrosine aminotransferase, albumin, apolipoproteins	

### Target genes

As used herein, the term "target gene" refers to a gene, whose transcription is stimulated according to the method of the invention. In one preferred embodiment, the gene is integrated in the chromosomal DNA of a cell. Alternatively, the gene is episomal. A cell comprising a target gene is referred to herein as a "target cell".

In a preferred embodiment of the invention, the target gene is an endogenous gene. As used herein, the term "endogenous gene" refers to a gene which is naturally present in a cell, in its natural environment, i.e., not a gene which has been introduced into the cell by genetic engineering. The endogenous gene can be any gene having a promoter that is recognized by at least one transcription factor. In a preferred embodiment, the promoter or any regulatory element thereof, of the endogenous gene ("endogenous promoter" and "endogenous regulatory element", respectively), is recognized by a known, preferably cloned, DNA binding protein, whether it is a transcription activator or repressor. Alternatively, if no DNA binding protein is known to interact with a target promoter, it is possible to clone such a factor using techniques well known in the art without undue experimentation, such as screening of expression libraries with at least a portion of the target promoter. Furthermore, the affinity of binding of a DNA binding domain to a target sequence can be improved according to methods known in the art. Such methods comprise, e.g., introducing mutations into the DNA binding domain and screening for mutants having increased DNA binding affinity.

In another embodiment of the invention, the target gene is an endogenous gene, which contains an exogenous target sequence. The exogenous target sequence can be inserted into the endogenous promoter or substitute at least a portion of the endogenous promoter. In preferred embodiments, the exogenous promoter or regulatory element introduced into the endogenous target promoter is recognized by a DNA binding protein, capable of binding with high affinity and specificity to a target sequence. In a preferred embodiment, the DNA binding protein is human. However, the DNA binding protein can be from any other species. For example, the DNA binding protein can be from the yeast GAL4 protein.

In yet another embodiment, the target gene is an exogenous gene. In a preferred embodiment, the exogenous gene is integrated into the chromosomal DNA of a cell. The exogenous gene can be inserted into the chromosomal DNA, or the exogenous gene can substitute for at least a portion of an endogenous gene. The target gene can be present in a single copy or in multiple copies. In view of the experimental results described herein, it is not necessary that the target gene be present in more than one

copy. However, if even higher levels of protein encoded by the target gene is desired, multiple copies of the gene can be used.

In one embodiment, the target gene construct enables transcription of a target gene to be regulated by a transcription factor in accordance with this invention. 5 comprises a DNA molecule which includes a synthetic transcription unit typically consisting of: (1) one copy or multiple copies of a DNA sequence recognized with high-affinity by the DNA binding domain of a fusion protein which includes a transcription activator, or of a protein which recruits the transcription activator; (2) a promoter sequence consisting minimally of a TATA box and initiator sequence but 10 optionally including other transcription factor binding sites; (3) a coding sequence for a desired gene product, including sequences that promote the initiation and termination of translation, if appropriate; (4) an optional sequence consisting of a splice donor, splice acceptor, and intervening intron DNA; and (5) a sequence directing cleavage and polyadenylation of the resulting RNA transcript.

15 A wide variety of genes can be employed as the target gene, including genes that encode a therapeutic protein, antisense sequence or ribozyme of interest. The target gene can be any sequence of interest which provides a desired phenotype. It can encode a surface membrane protein, a secreted protein, a cytoplasmic protein, or there can be a plurality of target genes encoding different products. The target gene may be 20 an antisense sequence which can modulate a particular pathway by inhibiting a transcription regulation protein or turn on a particular pathway by inhibiting the translation of an inhibitor of the pathway. The target gene can encode a ribozyme which may modulate a particular pathway by interfering, at the RNA level, with the expression of a relevant transcription regulator or with the expression of an inhibitor 25 of a particular pathway. The proteins which are expressed, singly or in combination, can involve homing, cytotoxicity, proliferation, immune response, inflammatory response, clotting or dissolving of clots, hormonal regulation, etc. The proteins expressed may be naturally-occurring proteins, mutants of naturally-occurring proteins, unique sequences, or combinations thereof.

30 Various secreted products include hormones, such as insulin, human growth hormone, glucagon, pituitary releasing factor, ACTH, melanotropin, relaxin, etc.; growth factors, such as EGF, IGF-1, TGF- $\alpha$  or - $\beta$ , PDGF, G-CSF, M-CSF, GM-CSF, FGF, erythropoietin, thrombopoietin, megakaryocytic stimulating and growth factors, etc.; interleukins, such as IL-1 to -13; TNF- $\alpha$  and - $\beta$ , etc.; and enzymes and other 35 factors, such as tissue plasminogen activator, members of the complement cascade, perforins, superoxide dismutase, coagulation factors, antithrombin-III, Factor VIIIC,

Factor VIIIvW, Factor IX, a-antitrypsin, protein C, protein S, endorphins, dynorphin, bone morphogenetic protein, etc.

The gene can encode a naturally-occurring surface membrane protein or a protein made so by introduction of an appropriate signal peptide and transmembrane sequence. Various such proteins include homing receptors, e.g. L-selectin (Mel-14), blood-related proteins, particularly having a kringle structure, e.g. Factor VIIIc, Factor VIIIvW, hematopoietic cell markers, e.g. CD3, CD4, CD8, B-cell receptor, TCR subunits  $\alpha$ ,  $\beta$ ,  $\gamma$ ,  $\delta$ , CD10, CD19, CD28, CD33, CD38, CD41, etc., receptors, such as the interleukin receptors IL-2R, IL-4R, etc., channel proteins for influx or efflux of ions, e.g. Ca<sup>+2</sup>, K<sup>+</sup>, Na<sup>+</sup>, Cl<sup>-</sup> and the like; CFTR, tyrosine activation motif, zap-70, etc.

Proteins may be modified for transport to a vesicle for exocytosis. By adding the sequence from a protein which is directed to vesicles, where the sequence is modified proximal to one or the other terminus, or situated in an analogous position to the protein source, the modified protein will be directed to the Golgi apparatus for packaging in a vesicle. This process in conjunction with the presence of the fusion proteins for exocytosis allows for rapid transfer of the proteins to the extracellular medium and a relatively high localized concentration.

Also, intracellular proteins can be of interest, such as proteins in metabolic pathways, regulatory proteins, steroid receptors, transcription factors, etc., depending upon the nature of the host cell. Some of the proteins indicated above can also serve as intracellular proteins.

By way of further illustration, in T-cells, one may wish to introduce genes encoding one or both chains of a T-cell receptor. For B-cells, one could provide the heavy and light chains for an immunoglobulin for secretion. For cutaneous cells, e.g. keratinocytes, particularly stem cell keratinocytes, one could provide for protection against infection, by secreting  $\gamma$ -,  $\alpha$ - or  $\beta$ -interferon, antichemotactic factors, proteases specific for bacterial cell wall proteins, etc.

In addition to providing for expression of a gene having therapeutic value, there will be many situations where one may wish to direct a cell to a particular site. The site can include anatomical sites, such as lymph nodes, mucosal tissue, skin, synovium, lung or other internal organs or functional sites, such as clots, injured sites, sites of surgical manipulation, inflammation, infection, etc. By providing for expression of surface membrane proteins which will direct the host cell to the particular site by providing for binding at the host target site to a naturally-occurring epitope, localized concentrations of a secreted product can be achieved. Proteins of interest include homing receptors, e.g. L-selectin, GMP140, CLAM-1, etc., or

addressins, e.g. ELAM-1, PNAd, LNAd, etc., clot binding proteins, or cell surface proteins that respond to localized gradients of chemotactic factors. There are numerous situations where one would wish to direct cells to a particular site, where release of a therapeutic product could be of great value.

5 For use in gene therapy, the target gene can encode any gene product that is beneficial to a subject. The gene product can be a secreted protein, a membranous protein, or a cytoplasmic protein. Preferred secreted proteins include growth factors, differentiation factors, cytokines, interleukins, tPA, and erythropoietin. Preferred membranous proteins include receptors, e.g., growth factor or cytokine receptors or  
10 proteins mediating apoptosis, e.g., Fas receptor. Other candidate therapeutic genes are disclosed in PCT/US93/01617.

15 In yet another embodiment, a "gene activation" construct which, by homologous recombination with a genomic DNA, alters the transcription regulatory sequences of an endogenous gene, can be used to introduce recognition elements for a DNA binding activity of one of the subject engineered proteins. A variety of different formats for the gene activation constructs are available. See, for example, the  
Transkaryotic Therapies, Inc PCT publications WO93/09222, WO95/31560,  
WO96/29411, WO95/31560 and WO94/12650.

## 20 Design and assembly of the DNA constructs

Constructs may be designed in accordance with the principles, illustrative examples and materials and methods disclosed in the patent documents and scientific literature cited herein, each of which is incorporated herein by reference, with modifications and further exemplification as described herein. Components of the  
25 constructs can be prepared in conventional ways, where the coding sequences and regulatory regions may be isolated, as appropriate, ligated, cloned in an appropriate cloning host, analyzed by restriction or sequencing, or other convenient means. Particularly, using PCR, individual fragments including all or portions of a functional unit may be isolated, where one or more mutations may be introduced using "primer  
30 repair", ligation, in vitro mutagenesis, etc. as appropriate. In the case of DNA constructs encoding fusion proteins, DNA sequences encoding individual domains and sub-domains are joined such that they constitute a single open reading frame encoding a fusion protein capable of being translated in cells or cell lysates into a single polypeptide harboring all component domains. The DNA construct encoding the  
35 fusion protein may then be placed into a vector that directs the expression of the protein in the appropriate cell type(s). For biochemical analysis of the encoded fusion

protein, it may be desirable to construct plasmids that direct the expression of the protein in bacteria or in reticulocyte-lysate systems. For use in the production of proteins in mammalian cells, the protein-encoding sequence is introduced into an expression vector that directs expression in these cells. Expression vectors suitable for such uses are well known in the art. Various sorts of such vectors are commercially available.

Constructs encoding the fusion proteins and target genes of this invention can be introduced into the cells as one or more DNA molecules or constructs, in many cases in association with one or more markers to allow for selection of host cells which contain the construct(s). The construct(s) once completed and demonstrated to have the appropriate sequences may then be introduced into a host cell by any convenient means. The constructs may be incorporated into vectors capable of episomal replication (e.g. BPV or EBV vectors) or into vectors designed for integration into the host cells' chromosomes. The constructs may be integrated and packaged into non-replicating, defective viral genomes like Adenovirus, Adeno-associated virus (AAV), or Herpes simplex virus (HSV) or others, including retroviral vectors, for infection or transduction into cells. Viral delivery systems are discussed in greater detail below. Alternatively, the construct may be introduced by protoplast fusion, electro-poration, biolistics, calcium phosphate transfection, lipofection, microinjection of DNA or the like. The host cells will in some cases be grown and expanded in culture before introduction of the construct(s), followed by the appropriate treatment for introduction of the construct(s) and integration of the construct(s). The cells will then be expanded and screened by virtue of a marker present in the constructs. Various markers which may be used successfully include hprt, neomycin resistance, thymidine kinase, hygromycin resistance, etc., and various cell-surface markers such as Tac, CD8, CD3, Thy1 and the NGF receptor.

In some instances, one may have a target site for homologous recombination, where it is desired that a construct be integrated at a particular locus. For example, one can delete and/or replace an endogenous gene (at the same locus or elsewhere) with a recombinant target construct of this invention. For homologous recombination, one may generally use either  $\Omega$  or O-vectors. See, for example, Thomas and Capecchi, Cell (1987) 51, 503-512; Mansour, et al., Nature (1988) 336, 348-352; and Joyner, et al., Nature (1989) 338, 153-156.

The constructs may be introduced as a single DNA molecule encoding all of the genes, or different DNA molecules having one or more genes. The constructs may be introduced simultaneously or consecutively, each with the same or different markers.

Vectors containing useful elements such as bacterial or yeast origins of replication, selectable and/or amplifiable markers, promoter/enhancer elements for expression in prokaryotes or eukaryotes, and mammalian expression control elements, etc. which may be used to prepare stocks of construct DNAs and for carrying out transfections are well known in the art, and many are commercially available.

#### Delivery of Nucleic Acid: Ex vivo and in vivo

Any means for the introduction of heterologous nucleic acids into host cells, especially eukaryotic cells, and in particular animal cells, preferably human or non-human mammalian cells, may be adapted to the practice of this invention. For the purpose of this discussion, the various nucleic acid constructs described herein may together be referred to as the transgene. Ex vivo approaches for delivery of DNA include calcium phosphate precipitation, electroporation, lipofection and infection via viral vectors. Two general in vivo gene therapy approaches include (a) the delivery of "naked", lipid-complexed or liposome-formulated or otherwise formulated DNA and (b) the delivery of the heterologous nucleic acids via viral vectors. In the former approach, prior to formulation of DNA, e.g. with lipid, a plasmid containing a transgene bearing the desired DNA constructs may first be experimentally optimized for expression (e.g., inclusion of an intron in the 5' untranslated region and elimination of unnecessary sequences (Felgner, et al., Ann NY Acad Sci 126-139, 1995). Formulation of DNA, e.g. with various lipid or liposome materials, may then be effected using known methods and materials and delivered to the recipient mammal.

While various viral vectors may be used in the practice of this invention, retroviral, AAV, and adenovirus-based approaches are of particular interest. See, for example, Dubensky et al. (1984) Proc. Natl. Acad. Sci. USA 81, 7529-7533; Kaneda et al., (1989) Science 243,375-378; Hiebert et al. (1989) Proc. Natl. Acad. Sci. USA 86, 3594-3598; Hatzoglu et al. (1990) J. Biol. Chem. 265, 17285-17293 and Ferry, et al. (1991) Proc. Natl. Acad. Sci. USA 88, 8377-8381. When using viral vectors, the recombinant nucleic acids may be delivered in a single virus, or may be divided into two or more viruses. For example, the fusion protein constructs could be delivered by one virus, while the target gene could be on a second virus. The target gene virus may further comprise an additional transcription regulatory domain construct. The following additional guidance on the choice and use of viral vectors may be helpful to the practitioner.

**Viral Vectors:****Adenoviral vectors**

A viral gene delivery system useful in the present invention utilizes adenovirus-derived vectors. Knowledge of the genetic organization of adenovirus, a 36 kB, linear and double-stranded DNA virus, allows substitution of a large piece of adenoviral DNA with foreign sequences up to 8 kB. In contrast to retrovirus, the infection of adenoviral DNA into host cells does not result in chromosomal integration because adenoviral DNA can replicate in an episomal manner without potential genotoxicity. Also, adenoviruses are structurally stable, and no genome rearrangement has been detected after extensive amplification. Adenovirus can infect virtually all epithelial cells regardless of their cell cycle stage. So far, adenoviral infection appears to be linked only to mild disease such as acute respiratory disease in the human.

Adenovirus is particularly suitable for use as a gene transfer vector because of its mid-sized genome, ease of manipulation, high titer, wide target-cell range, and high infectivity. Both ends of the viral genome contain 100-200 base pair (bp) inverted terminal repeats (ITR), at the 3' and 5' terminal regions of the adenovirus genome which are cis elements necessary for viral DNA replication and packaging. See, e.g., Gingeras et al. (1982) J. Biol. Chem. 257:13475-13491. The early (E) and late (L) regions of the genome contain different transcription units that are divided by the onset of viral DNA replication. The E1 region (E1A and E1B) encodes proteins responsible for the regulation of transcription of the viral genome and a few cellular genes. The expression of the E2 region (E2A and E2B) results in the synthesis of the proteins for viral DNA replication. These proteins are involved in DNA replication, late gene expression, and host cell shut off (Renan (1990) Radiotherap. Oncol. 19:197). The products of the late genes, including the majority of the viral capsid proteins, are expressed only after significant processing of a single primary transcript issued by the major late promoter (MLP). The MLP (located at 16.8 m.u.) is particularly efficient during the late phase of infection, and all the mRNAs issued from this promoter possess a 5' tripartite leader (TL) sequence which makes them preferred mRNAs for translation.

The genome of an adenovirus can be manipulated such that it encodes a gene product of interest, but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle (see, for example, Berkner et al., (1988) BioTechniques 6:616; Rosenfeld et al., (1991) Science 252:431-434; and Rosenfeld et al., (1992) Cell 68:143-155). Suitable adenoviruses derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus (e.g., Ad2, Ad3, Ad7 etc.) are well known to those skilled

in the art. Recombinant adenoviruses can be advantageous in certain circumstances in that they are not capable of infecting nondividing cells and can be used to infect a wide variety of cell types, including airway epithelium (Rosenfeld et al., (1992) cited *supra*), endothelial cells (Lemarchand et al., (1992) PNAS USA 89:6482-6486),  
5 hepatocytes (Herz and Gerard, (1993) PNAS USA 90:2812-2816) and muscle cells (Quantin et al., (1992) PNAS USA 89:2581-2584).

Adenoviruses have also been used in vaccine development (Grunhaus and Horwitz (1992) Siminar in Virology 3:237; Graham and Prevec (1992) Biotechnology 20:363). Experiments in administering recombinant adenovirus to different tissues  
10 include trachea instillation (Rosenfeld et al. (1991) ; Rosenfeld et al. (1992) Cell 68:143), muscle injection (Ragot et al. (1993) Nature 361:647), peripheral intravenous injection (Herz and Gerard (1993) Proc. Natl. Acad. Sci. U.S.A. 90:2812), and stereotactic inoculation into the brain (Le Gal La Salle et al. (1993) Science 254:988).

Furthermore, the virus particle is relatively stable and amenable to purification  
15 and concentration, and as above, can be modified so as to affect the spectrum of infectivity. Additionally, adenovirus is easy to grow and manipulate and exhibits broad host range *in vitro* and *in vivo*. This group of viruses can be obtained in high titers, e.g.,  $10^9$  -  $10^{11}$  plaque-forming unit (PFU)/ml, and they are highly infective. The life cycle of adenovirus does not require integration into the host cell genome. The  
20 foreign genes delivered by adenovirus are episomal, and therefore, have low genotoxicity to host cells. No side effects have been reported in studies of vaccination with wild-type adenovirus (Couch et al., 1963; Top et al., 1971), demonstrating their safety and therapeutic potential as *in vivo* gene transfer vectors. Moreover, the carrying capacity of the adenoviral genome for foreign DNA is large (up to 8  
25 kilobases) relative to other gene delivery vectors (Berkner et al., *supra*; Haj-Ahmad and Graham (1986) J. Virol. 57:267).

The invention provides recombinant adenoviruses, pAdΔ, which have been deleted of adenovirus cis-elements necessary for replication and virion encapsidation and which contains a target gene and/or one or more genes encoding fusion proteins of  
30 the invention. Productive viral infection with pAdD requires a helper adenovirus, which alone or with a packaging cell line, supplies sufficient gene sequences necessary for a productive viral infection. Preferred helper viruses are altered in one or more native gene sequences which direct efficient packaging, to thereby produce a helper virus whose packaging function or ability to replicate is "crippled" or disabled. Such  
35 recombinant adenoviruses are further described in published PCT application No. PCT/US95/14017 having publication No. WO 96/13597 by Wilson et al.

Most replication-defective adenoviruses currently in use and favored by the present invention are deleted for all or parts of the viral E1 and E3 genes but may retain as much as 80% of the adenoviral genetic material (see, e.g., Jones et al., (1979) Cell 16:683; Berkner et al., *supra*; and Graham et al., in Methods in Molecular Biology, 5 E.J. Murray, Ed. (Humana, Clifton, NJ, 1991) vol. 7. pp. 109-127). Accordingly, a preferred adenovirus of the invention is an adenovirus in which the E1 and E3 genes have been deleted or mutated, and in which the E1 gene has been replaced with a gene encoding a fusion protein and/or reporter gene of the invention. An E1/E3 deleted adenovirus allows for an insert of up to 8 kb. A preferred viral backbone is dl327 10 which is deleted in E1a, E1b, and E3. Deletion within adenovirus genes other than E1 and E3 region genes may also be useful to further reduce viral genome size, allowing thereby the insertion of larger genes of interest. In addition, since replication and viral protein expression in these viruses is reduced or eliminated *in vivo*, the immune response of the infected host to the virus and viral protein is also reduced. By 15 decreasing the host immune response, the persistence of expression of the inserted gene is increased. Such vectors are further described in published PCT application No. PCT/US94/06338 having publication No. WO 94/28938 by Wilson and Engelhardt.

Other than the requirement that the adenovirus be replication defective, or at 20 least conditionally defective, the nature of the adenovirus is not believed to be crucial to the successful practice of the invention. The adenovirus may be of any of the 42 different known serotypes or subgroups A-F. Adenovirus type 5 of subgroup C is the preferred starting material in order to obtain the conditional replication-defective adenovirus for use in the method of the present invention. This is because Adenovirus 25 type 5 is a human adenovirus about which a great deal of biochemical and genetic information is known, and it has historically been used for most constructions employing adenovirus. As stated above, the typical virus according to the present invention is replication defective and will not have an adenovirus E1 region. Thus, it will be most convenient to introduce the nucleic acid of interest at the position from 30 which the E1 coding sequences have been removed. However, the position of insertion of the nucleic acid of interest in a region within the adenovirus sequences is not critical to the present invention. For example, the nucleic acid of interest may also be inserted in lieu of the deleted E3 region in E3 replacement viruses as described previously by Karlsson et. al. (1986) or in the E4 region where a helper cell line or 35 helper virus complements the E4 defect.

Various adenoviruses have been shown to be of use in the transfer of genes to mammals, including humans. Replication-deficient adenovirus has been used to express marker proteins and CFTR in the pulmonary epithelium. Because of their ability to efficiently infect dividing cells, their tropism for the lung, and the relative ease of generation of high titer stocks, adenoviruses have been the subject of much research in the last few years, and various viruses have been used to deliver genes to the lungs of human subjects (Zabner et al., Cell 75:207-216, 1993; Crystal, et al., Nat Genet. 8:42-51, 1994; Boucher, et al., Hum Gene Ther 5:615-639, 1994). The first generation E1a deleted adenovirus has been improved upon with a second generation that includes a temperature-sensitive E2a viral protein, designed to express less viral protein and thereby make the virally infected cell less of a target for the immune system (Goldman et al., Human Gene Therapy 6:839-851, 1995). More recently, a viral vector deleted of all viral open reading frames has been reported (Fisher et al., Virology 217:11-22, 1996). Moreover, it has been shown that expression of viral IL-10 inhibits the immune response to adenoviral antigen (Qin et al., Human Gene Therapy 8:1365-1374, 1997).

Adenoviruses can also be cell type specific, i.e., infect only restricted types of cells and/or express a transgene only in restricted types of cells. For example, the viruses comprise a gene under the transcription control of a transcription initiation region specifically regulated by target host cells, as described e.g., in U.S. Patent No. 5,698,443, by Henderson and Schuur, issued December 16, 1997. Thus, replication competent adenoviruses can be restricted to certain cells by, e.g., inserting a cell specific response element to regulate a synthesis of a protein necessary for replication, e.g., E1A or E1B.

Techniques for introducing viruses into a variety of cells including hepatocytes, pancreatic and biliary epithelial cells, endothelial cells and described in the following published PCT applications: PCT/US96/03041 (WO 96/26286) by Wilson et al. (hepatocytes); PCT/US91/09700 (WO 92/12242) by Mulligan and Wilson (hepatocytes); and PCT/US89/00422 (WO 89/07136) by Wilson and Mulligan (hepatocytes); PCT/US94/05187 (WO 94/26915) by J.M. Wilson (pancreatic cells); and PCT/US91/08127 (WO 92/07573) by Rafield et al. and PCT/US88/04383 (WO 89/05345) by Wilson and Mulligan (endothelial cells).

DNA sequences of a number of adenovirus types are available from Genbank. For example, human adenovirus type 5 has GenBank Accession No.M73260. The adenovirus DNA sequences may be obtained from any of the 42 human adenovirus types currently identified. Various adenovirus strains are available from the American

Type Culture Collection, Rockville, Maryland, or by request from a number of commercial and academic sources. A transgene as described herein may be incorporated into any adenovirus and delivery protocol, by the same methods (restriction digest, linker ligation or filling in of ends, and ligation) used to insert the  
5 CFTR or other genes into the vectors.

In another embodiment, the invention provides a virus, e.g., adenovirus, which is a recombinant replication defective virus comprising the DNA of, or corresponding to, at least a portion of the genome of said virus, capable of infecting a mammalian cell, and a first expression sequence comprising a gene of interest operably linked to an  
10 expression control sequence, flanked on each side by the cis-acting terminal repeat sequence of a transposon, said expression sequence flanked by the DNA of the virus. The recombinant virus is capable of infecting a mammalian cell and capable of expressing the gene of interest and transferring it to the chromatin of said cell in vivo or in vitro in the presence of a transposase. The virus can further comprise a gene  
15 encoding a suitable trans-acting transposase operably linked to an expression control sequence. Such a recombinant virus is capable of infecting a mammalian cell and capable of expressing the selected gene and transferring it to the chromatin of the infected cell in vivo or in vitro, when in the presence of a transposase. These viruses are further described in published PCT application No. WO 97/15679 by Kelley and  
20 Wilson.

The viruses of the invention can be administered to a host animal in such a manner that a potential immune reaction to the viruses is reduced. This can be achieved, e.g., by administering together with the virus a selected immune modulator, which substantially reduces the occurrence of neutralizing antibody responses directed  
25 against the virus encoded antigens and/or cytolytic T cell elimination of the viral protein containing cell. The immune modulator can be administered simultaneously or prior to administration of the viruses. The immune modulator can be, e.g., selected from the group consisting of a cytokine, an agent capable of depleting or inhibiting CD4+ T cells, and anti-T cell antibody, an agent capable of blocking the interaction  
30 between CD40 ligand on a T cell and CD40 on a B cell, an agent capable of blocking the interaction between the CD28 or CTLA4 ligand on a T cell and B7 on a B cell, and cyclophosphamide. This technique is further described in published PCT application No. WO 96/26285 by Wilson et al.

A preferred helper cell line is 293 (ATCC Accession No. CRL1573). This  
35 helper cell line, also termed a "packaging cell line" was developed by Frank Graham (Graham et al. (1987) J. Gen. Virol. 36:59-72 and Graham (1977) J.General Virology

68:937-940) and provides E1A and E1B in trans. However, helper cell lines may also be derived from human cells such as human embryonic kidney cells, muscle cells, hematopoietic cells or other human embryonic mesenchymal or epithelial cells. Alternatively, the helper cells may be derived from the cells of other mammalian species that are permissive for human adenovirus. Such cells include, e.g., Vero cells or other monkey embryonic mesenchymal or epithelial cells.

Adenovirus producer cell lines can include one or more of the adenoviral genes E1, E2a, and E4 DNA sequence, for packaging adenovirus in which one or more of these genes have been mutated or deleted are described, e.g., in WO 96/18418 by Kadan et al.; WO 95/346671 by Kovacs et al.; WO94/28152 by Imler et al.; WO 95/02697 by Perrocaudet et al., WO96/14061 by Wang et al.

#### AAV

Yet another viral system useful for delivery of the subject fusion genes is the adeno-associated virus (AAV). Adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle. (For a review, see Muzychka et al., Curr. Topics in Micro. and Immunol. (1992) 158:97-129).

AAV has not been associated with the cause of any disease. AAV is not a transforming or oncogenic virus. AAV integration into chromosomes of human cell lines does not cause any significant alteration in the growth properties or morphological characteristics of the cells. These properties of AAV also recommend it as a potentially useful human gene therapy vector.

AAV is also one of the few viruses that may integrate its DNA into non-dividing cells, e.g., pulmonary epithelial cells, and exhibits a high frequency of stable integration (see for example Flotte et al., (1992) Am. J. Respir. Cell. Mol. Biol. 7:349-356; Samulski et al., (1989) J. Virol. 63:3822-3828; and McLaughlin et al., (1989) J. Virol. 62:1963-1973). Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate. Space for exogenous DNA is limited to about 4.5 kb. An AAV vector such as that described in Tratschin et al., (1985) Mol. Cell. Biol. 5:3251-3260 can be used to introduce DNA into cells. A variety of nucleic acids have been introduced into different cell types using AAV vectors (see for example Hermonat et al., (1984) PNAS USA 81:6466-6470; Tratschin et al., (1985) Mol. Cell. Biol. 4:2072-2081; Wondisford et al., (1988) Mol. Endocrinol. 2:32-39; Tratschin et al., (1984) J. Virol. 51:611-619; and Flotte et al., (1993) J. Biol. Chem. 268:3781-3790).

The AAV-based expression vector to be used typically includes the 145 nucleotide AAV inverted terminal repeats (ITRs) flanking a restriction site that can be used for subcloning of the transgene, either directly using the restriction site available, or by excision of the transgene with restriction enzymes followed by blunting of the ends, ligation of appropriate DNA linkers, restriction digestion, and ligation into the site between the ITRs. By "adeno-associated virus inverted terminal repeats" or "AAV ITRs" is meant the palindromic regions which comprise the terminal repeats at the 3' and 5' ends of the AAV genome. The AAV ITR regions provide sequences for packaging the AAV provirus (i.e., the AAV genome) into the AAV viral capsid. The ITR regions also form secondary structures which act as self-primers for AAV replication. Samulski et al. (J. Virol. 63:3822, 1989), for example, describes AAV ITR sequences and structures. The nucleotide sequences of AAV ITR regions are known. See, e.g., Kotin, R. M. (1994) Human Gene Therapy 5:793-801; Berns, K. I. "Parvoviridae and their Replication" in Fundamental Virology, 2nd Edition, (B. N. Fields and D. M. Knipe, eds.) for the AAV-2 sequence. As used herein, an "AAV ITR" need not have the wild-type nucleotide sequence depicted, but may be altered, e.g., by the insertion, deletion or substitution of nucleotides. Additionally, the AAV ITR may be derived from any of several AAV serotypes, including without limitation, AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAVX7, etc. Furthermore, 5' and 3' ITRs which flank a selected nucleotide sequence in an AAV vector need not necessarily be identical or derived from the same AAV serotype or isolate, so long as they function as intended, i.e., to allow for excision and rescue of the sequence of interest from a host cell genome or vector, and to allow integration of the heterologous sequence into the recipient cell genome when the rep gene is present in the cell (either on the same or on a different vector).

The capacity of AAV vectors is about 4.4 kb. The following proteins have been expressed using various AAV-based vectors, and a variety of promoter/enhancers: neomycin phosphotransferase, chloramphenicol acetyl transferase, Fanconi's anemia gene, cystic fibrosis transmembrane conductance regulator, and granulocyte macrophage colony-stimulating factor (Kotin, R.M., Human Gene Therapy 5:793-801, 1994, Table I). A transgene incorporating the various DNA constructs of this invention can similarly be included in an AAV-based vector. As an alternative to inclusion of a constitutive promoter such as CMV to drive expression of the recombinant DNA encoding the fusion protein(s), e.g. fusion proteins comprising an activation domain or DNA-binding domain, an AAV promoter can be used (ITR itself or AAV p5 (Flotte, et al. J. Biol.Chem. 268:3781-3790, 1993)).

Such a vector can be packaged into AAV virions by reported methods. For example, a human cell line such as 293 can be co-transfected with the AAV-based expression vector and another plasmid containing open reading frames encoding AAV rep and cap (which are obligatory for replication and packaging of the recombinant viral construct) under the control of endogenous AAV promoters or a heterologous promoter. In the absence of helper virus, the rep proteins Rep68 and Rep78 prevent accumulation of the replicative form, but upon superinfection with adenovirus or herpes virus, these proteins permit replication from the ITRs (present only in the construct containing the transgene) and expression of the viral capsid proteins. This system results in packaging of the transgene DNA into AAV virions (Carter, B.J., Current Opinion in Biotechnology 3:533-539, 1992; Kotin, R.M, Human Gene Therapy 5:793-801, 1994)). Typically, three days after transfection, recombinant AAV is harvested from the cells along with adenoviurs and the contaminating adenovirus is then inactivated by heat treatment.

Methods to improve the titer of AAV can also be used to express the transgene in an AAV virion. Such strategies include, but are not limited to: stable expression of the ITR-flanked transgene in a cell line followed by transfection with a second plasmid to direct viral packaging; use of a cell line that expresses AAV proteins inducibly, such as temperature-sensitive inducible expression or pharmacologically inducible expression. Alternatively, a cell can be infected with a first AAV including a 5' ITR, a 3' ITR flanking a heterologous gene, and a second AAV vector which includes an inducible origin of replication, e.g., SV40 origin of replication, which is capable of being induced by an agent, such as the SV40 T antigen and which includes DNA sequences encoding the AAV rep and cap proteins. Upon induction by an agent, the second AAV vector may replicate to a high copy number, and thereby increased numbers of infectious AAV particles may be generated (see, e.g., U.S. Patent No. 5,693,531 by Chiorini et al., issued December 2, 1997). In yet another method for producing large amounts of recombinant AAV, a fusion plasmid is used which incorporate the Epstein Barr Nuclear Antigen (EBNA) gene , the latent origin of replication of Epstein Barr virus (oriP) and an AAV genome. These plasmids are maintained as a multicopy extra-chromosomal elements in cells, such as in 293 cells. Upon addition of wild-type helper functions, these cells will produce high amounts of recombinant AAV (U.S. Patent 5,691,176 by Lebkowski et al., issued Nov. 25, 1997). In another system, an AAV packaging plasmid is provided that allows expression of the rep gene, wherein the p5 promoter, which normally controls rep expression, is replaced with a heterologous promoter (U.S. Patent 5,658,776, by Flotte et al., issued Aug. 19, 1997).

Additionally, one may increase the efficiency of AAV transduction by treating the cells with an agent that facilitates the conversion of the single stranded form to the double stranded form, as described in Wilson et al., WO96/39530.

AAV stocks can be produced as described in Hermonat and Muzyczka (1984) 5 PNAS 81:6466, modified by using the pAAV/Ad described by Samulski et al. (1989) J. Virol. 63:3822. Concentration and purification of the virus can be achieved by reported methods such as banding in cesium chloride gradients, as was used for the initial report of AAV expression in vivo (Flotte, et al. J.Biol. Chem. 268:3781-3790, 1993) or chromatographic purification, as described in O'Riordan et al., 10 WO97/08298.

Methods for *in vitro* packaging AAV vectors are also available and have the advantage that there is no size limitation of the DNA packaged into the particles (see, U.S. Patent No. 5,688,676, by Zhou et al., issued Nov. 18, 1997). This procedure involves the preparation of cell free packaging extracts.

For additional detailed guidance on AAV technology which may be useful in the practice of the subject invention, including methods and materials for the incorporation of a transgene, the propagation and purification of the recombinant AAV containing the transgene, and its use in transfecting cells and mammals, see e.g. Carter et al, US Patent No. 4,797,368 (10 Jan 1989); Muzyczka et al, US Patent No. 5,139,941 (18 Aug 1992); Lebkowski et al, US Patent No. 5,173,414 (22 Dec 1992); Srivastava, US Patent No. 5,252,479 (12 Oct 1993); Lebkowski et al, US Patent No. 5,354,678 (11 Oct 1994); Shenk et al, US Patent No. 5,436,146(25 July 1995); Chatterjee et al, US Patent No. 5,454,935 (12 Dec 1995), Carter et al WO 93/24641 (published 9 Dec 1993), and Natsoulis, U.S. Patent No. 5,622,856 (April 22, 1997).  
Further information regarding AAVs and the adenovirus or herpes helper functions required can be found in the following articles.Berns and Bohensky (1987), "Adeno-Associated Viruses: An Update", Advanced in Virus Research, Academic Press, 33:243-306. The genome of AAV is described in Laughlin et al. (1983) "Cloning of infectious adeno-associated virus genomes in bacterial plasmids", Gene, 23: 65-73.  
Expression of AAV is described in Beaton et al. (1989) "Expression from the Adeno-associated virus p5 and p19 promoters is negatively regulated in trans by the rep protein", J. Virol., 63:4450-4454. Construction of rAAV is described in a number of publications: Tratschin et al. (1984) "Adeno-associated virus vector for high frequency integration, expression and rescue of genes in mammalian cells", Mol. Cell. Biol., 4:2072-2081; Hermonat and Muzyczka (1984) "Use of adeno-associated virus as a mammalian DNA cloning vector: Transduction of neomycin resistance into

mammalian tissue culture cells", Proc. Natl. Acad. Sci. USA, 81:6466-6470; McLaughlin et al. (1988) "Adeno-associated virus general transduction vectors: Analysis of Proviral Structures", J. Virol., 62:1963-1973; and Samulski et al. (1989) "Helper-free stocks of recombinant adeno-associated viruses: normal integration does  
5 not require viral gene expression", J. Virol., 63:3822-3828. Cell lines that can be infected by rAAV are those described in Lebkowski et al. (1988) "Adeno-associated virus: a vector system for efficient introduction and integration of DNA into a variety of mammalian cell types", Mol. Cell. Biol., 8:3988-3996. "Producer" or "packaging" cell lines used in manufacturing recombinant retroviruses are described in Dougherty et al.  
10 (1989) J. Virol., 63:3209-3212; and Markowitz et al. (1988) J. Virol., 62:1120-1124.

### Hybrid Adenovirus-AAV

Hybrid Adenovirus-AAV is represented by an adenovirus capsid containing a nucleic acid comprising a portion of an adenovirus, and 5' and 3' ITR sequences from an AAV which flank a selected transgene under the control of a promoter. See e.g. Wilson et al, International Patent Application Publication No. WO 96/13598. This hybrid virus is characterized by high titer transgene delivery to a host cell and the ability to stably integrate the transgene into the host cell chromosome in the presence of the rep gene. This virus is capable of infecting virtually all cell types (conferred by 15 its adenovirus sequences) and stable long term transgene integration into the host cell genome (conferred by its AAV sequences).

The adenovirus nucleic acid sequences employed in the this vector can range from a minimum sequence amount, which requires the use of a helper virus to produce the hybrid virus particle, to only selected deletions of adenovirus genes, which deleted 25 gene products can be supplied in the hybrid viral process by a packaging cell. For example, a hybrid virus can comprise the 5' and 3' inverted terminal repeat (ITR) sequences of an adenovirus (which function as origins of replication). The left terminal sequence (5') sequence of the Ad5 genome that can be used spans bp 1 to about 360 of the conventional adenovirus genome (also referred to as map units 0-1) and includes 30 the 5' ITR and the packaging/enhancer domain. The 3' adenovirus sequences of the hybrid virus include the right terminal 3' ITR sequence which is about 580 nucleotides (about bp 35,353- end of the adenovirus, referred to as about map units 98.4-100).

The AAV sequences useful in the hybrid vector are viral sequences from which the rep and cap polypeptide encoding sequences are deleted and are usually the cis 35 acting 5' and 3' ITR sequences. Thus, the AAV ITR sequences are flanked by the selected adenovirus sequences and the AAV ITR sequences themselves flank a selected

transgene. The preparation of the hybrid vector is further described in detail in published PCT application entitled "Hybrid Adenovirus-AAV Virus and Method of Use Thereof", WO 96/13598 by Wilson et al.

For additional detailed guidance on adenovirus and hybrid adenovirus-AAV technology which may be useful in the practice of the subject invention, including methods and materials for the incorporation of a transgene, the propagation and purification of recombinant virus containing the transgene, and its use in transfecting cells and mammals, see also Wilson et al, WO 94/28938, WO 96/13597 and WO 96/26285, and references cited therein.

10

### Retroviruses

The retroviruses are a group of single-stranded RNA viruses characterized by an ability to convert their RNA to double-stranded DNA in infected cells by a process of reverse-transcription (Coffin (1990) *Retroviridae and their Replication*" In Fields, Knipe ed. *Virology*. New York: Raven Press). The resulting DNA then stably integrates into cellular chromosomes as a provirus and directs synthesis of viral proteins. The integration results in the retention of the viral gene sequences in the recipient cell and its descendants. The retroviral genome contains three genes, gag, pol, and env that code for capsid proteins, polymerase enzyme, and envelope components, respectively. A sequence found upstream from the gag gene, termed psi, functions as a signal for packaging of the genome into virions. Two long terminal repeat (LTR) sequences are present at the 5' and 3' ends of the viral genome. These contain strong promoter and enhancer sequences and are also required for integration in the host cell genome (Coffin (1990), *supra*).

In order to construct a retroviral vector, a nucleic acid of interest is inserted into the viral genome in the place of certain viral sequences to produce a virus that is replication-defective. In order to produce virions, a packaging cell line containing the gag, pol, and env genes but without the LTR and psi components is constructed (Mann et al. (1983) *Cell* 33:153). When a recombinant plasmid containing a human cDNA, together with the retroviral LTR and psi sequences is introduced into this cell line (by calcium phosphate precipitation for example), the psi sequence allows the RNA transcript of the recombinant plasmid to be packaged into viruses, which are then secreted into the culture media (Nicolas and Rubenstein (1988) "Retroviral Vectors", In: Rodriguez and Denhardt ed. *Vectors: A Survey of Molecular Cloning Vectors and their Uses*. Stoneham:Butterworth; Temin, (1986) "Retrovirus Vectors for Gene Transfer: Efficient Integration into and Expression of Exogenous DNA in Vertebrate

Cell Genome", In: Kucherlapati ed. Gene Transfer. New York: Plenum Press; Mann et al., 1983, *supra*). The media containing the recombinant retroviruses is then collected, optionally concentrated, and used for gene transfer. Retroviruses are able to infect a broad variety of cell types. However, integration and stable expression require the division of host cells (Paskind et al. (1975) Virology 67:242).

A major prerequisite for the use of retroviruses is to ensure the safety of their use, particularly with regard to the possibility of the spread of wild-type virus in the cell population. The development of specialized cell lines (termed "packaging cells") which produce only replication-defective retroviruses has increased the utility of retroviruses for gene therapy, and defective retroviruses are well characterized for use in gene transfer for gene therapy purposes (for a review see Miller, A.D. (1990) Blood 76:271). Thus, recombinant retrovirus can be constructed in which part of the retroviral coding sequence (gag, pol, env) has been replaced by nucleic acid encoding a fusion protein of the present invention, rendering the retrovirus replication defective. The replication defective retrovirus is then packaged into virions which can be used to infect a target cell through the use of a helper virus by standard techniques. Protocols for producing recombinant retroviruses and for infecting cells *in vitro* or *in vivo* with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F.M. et al., (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are well known to those skilled in the art. A preferred retroviral vector is a pSR MSVtkNeo (Muller et al. (1991) Mol. Cell Biol. 11:1785 and pSR MSV(XbaI) (Sawyers et al. (1995) J. Exp. Med. 181:307) and derivatives thereof. For example, the unique BamHI sites in both of these vectors can be removed by digesting the vectors with BamHI, filling in with Klenow and religating to produce pSMTN2 and pSMTX2, respectively, as described in PCT/US96/09948 by Clackson et al. Examples of suitable packaging virus lines for preparing both ecotropic and amphotropic retroviral systems include Crip, Cre, 2 and Am.

Retroviruses have been used to introduce a variety of genes into many different cell types, including neural cells, epithelial cells, endothelial cells, lymphocytes, myoblasts, hepatocytes, bone marrow cells, *in vitro* and/or *in vivo* (see for example Eglitis et al., (1985) Science 230:1395-1398; Danos and Mulligan, (1988) PNAS USA 85:6460-6464; Wilson et al., (1988) PNAS USA 85:3014-3018; Armentano et al., (1990) PNAS USA 87:6141-6145; Huber et al., (1991) PNAS USA 88:8039-8043; Ferry et al., (1991) PNAS USA 88:8377-8381; Chowdhury et al., (1991) Science 254:1802-1805; van Beusechem et al., (1992) PNAS USA 89:7640-7644; Kay et al.,

(1992) Human Gene Therapy 3:641-647; Dai et al., (1992) PNAS USA 89:10892-10895; Hwu et al., (1993) J. Immunol. 150:4104-4115; U.S. Patent No. 4,868,116; U.S. Patent No. 4,980,286; PCT Application WO 89/07136; PCT Application WO 89/02468; PCT Application WO 89/05345; and PCT Application WO 92/07573).

5 Furthermore, it has been shown that it is possible to limit the infection spectrum of retroviruses and consequently of retroviral-based vectors, by modifying the viral packaging proteins on the surface of the virus (see, for example PCT publications WO93/25234, WO94/06920, and WO94/11524). For instance, strategies for the modification of the infection spectrum of retroviruses include:  
10 coupling antibodies specific for cell surface antigens to the viral env protein (Roux et al., (1989) PNAS USA 86:9079-9083; Julian et al., (1992) J. Gen Virol 73:3251-3255; and Goud et al., (1983) Virology 163:251-254); or coupling cell surface ligands to the viral env proteins (Neda et al., (1991) J. Biol. Chem. 266:14143-14146). Coupling can be in the form of the chemical cross-linking with a protein or other variety (e.g. lactose  
15 to convert the env protein to an asialoglycoprotein), as well as by generating fusion proteins (e.g. single-chain antibody/env fusion proteins). This technique, while useful to limit or otherwise direct the infection to certain tissue types, and can also be used to convert an ecotropic vector in to an amphotropic vector.

## 20 Other Viral Systems

Other viral systems that may have application in gene therapy have been derived from herpes virus, e.g., Herpes Simplex Virus (U.S. Patent No. 5,631,236 by Woo et al., issued May 20, 1997), vaccinia virus (Ridgeway (1988) Ridgeway, "Mammalian expression vectors," In: Rodriguez R L, Denhardt D T, ed. *Vectors: A*  
25 survey of molecular cloning vectors and their uses. Stoneham: Butterworth.; Baichwal and Sugden (1986) "Vectors for gene transfer derived from animal DNA viruses: Transient and stable expression of transferred genes," In: Kucherlapati R, ed. *Gene transfer*. New York: Plenum Press; Coupar et al. (1988) *Gene*, 68:1-10), and several RNA viruses. Preferred viruses include an alphavirus, a poxivirus, an arena virus, a  
30 vaccinia virus, a polio virus, and the like. In particular, herpes virus may provide a unique strategy for persistence of the recombinant gene in cells of the central nervous system and ocular tissue (Pepose et al., (1994) *Invest Ophthalmol Vis Sci* 35:2662-2666). They offer several attractive features for various mammalian cells (Friedmann (1989) *Science*, 244:1275-1281 ; Ridgeway, 1988, *supra*; Baichwal and Sugden, 1986,  
35 *supra*; Coupar et al., 1988; Horwitz et al.(1990) *J.Virol.*, 64:642-650).

With the recent recognition of defective hepatitis B viruses, new insight was gained into the structure-function relationship of different viral sequences. *In vitro* studies showed that the virus could retain the ability for helper-dependent packaging and reverse transcription despite the deletion of up to 80% of its genome (Horwitz et al., 1990, *supra*). This suggested that large portions of the genome could be replaced with foreign genetic material. The hepatotropism and persistence (integration) were particularly attractive properties for liver-directed gene transfer. Chang et al. recently introduced the chloramphenicol acetyltransferase (CAT) gene into duck hepatitis B virus genome in the place of the polymerase, surface, and pre-surface coding sequences. It was cotransfected with wild-type virus into an avian hepatoma cell line. Culture media containing high titers of the recombinant virus were used to infect primary duckling hepatocytes. Stable CAT gene expression was detected for at least 24 days after transfection (Chang et al. (1991) *Hepatology*, 14:124A).

15

#### **Administration of Viral Vectors**

Generally the viral particles are transferred to a biologically compatible solution or pharmaceutically acceptable delivery vehicle, such as sterile saline, or other aqueous or non-aqueous isotonic sterile injection solutions or suspensions, numerous examples of which are well known in the art, including Ringer's, phosphate buffered saline, or other similar vehicles. Delivery of the recombinant viral vector can be carried out via any of several routes of administration, including intramuscular injection, intravenous administration, subcutaneous injection, intrahepatic administration, catheterization (including cardiac catheterization), intracranial injection, nebulization/inhalation or by instillation via bronchoscopy.

Preferably, the DNA or recombinant virus is administered in sufficient amounts to transfect cells within the recipient's target cells, including without limitation, muscle cells, liver cells, various airway epithelial cells and smooth muscle cells, neurons, cardiac muscle cells, etc. and provide sufficient levels of transgene expression to provide for observable ligand-responsive secretion of a target protein, preferably at a level providing therapeutic benefit without undue adverse effects.

Optimal dosages of DNA or virus depends on a variety of factors, as discussed previously, and may thus vary somewhat from patient to patient. Again, therapeutically effective doses of viruses are considered to be in the range of about 20 to about 50 ml of saline solution containing concentrations of from about  $1 \times 10^7$  to about  $1 \times 10^{10}$  pfu of virus/ml, e.g. from  $1 \times 10^8$  to  $1 \times 10^9$  pfu of virus/ml.

### Host Cells

This invention is particularly useful for the engineering of animal cells and in applications involving the use of such engineered animal cells. The animal cells may be insect, worm or mammalian cells. While various mammalian cells may be used, including, by way of example, equine, bovine, ovine, canine, feline, murine, and non-human primate cells, human cells are of particular interest. Among the various species, various types of cells may be used, such as hematopoietic, neural, glial, mesenchymal, cutaneous, mucosal, stromal, muscle (including smooth muscle cells), spleen, reticuloendothelial, epithelial, endothelial, hepatic, kidney, gastrointestinal, pulmonary, fibroblast, and other cell types. Of particular interest are hematopoietic cells, which may include any of the nucleated cells which may be involved with the erythroid, lymphoid or myelomonocytic lineages, as well as myoblasts and fibroblasts. Also of interest are stem and progenitor cells, such as hematopoietic, neural, stromal, muscle, 10 hepatic, pulmonary, gastrointestinal and mesenchymal stem cells

The cells may be autologous cells, syngeneic cells, allogeneic cells and even in some cases, xenogeneic cells with respect to an intended host organism. The cells may be modified by changing the major histocompatibility complex ("MHC") profile, by inactivating  $\beta$ 2-microglobulin to prevent the formation of functional Class I MHC molecules, inactivation of Class II molecules, providing for expression of one or more MHC molecules, enhancing or inactivating cytotoxic capabilities by enhancing or inhibiting the expression of genes associated with the cytotoxic activity, or the like.

In some instances specific clones or oligoclonal cells may be of interest, where the cells have a particular specificity, such as T cells and B cells having a specific antigen specificity or homing target site specificity.

### Introduction of Constructs into Animals

Cells which have been modified ex vivo with the DNA constructs may be grown in culture under selective conditions and cells which are selected as having the desired construct(s) may then be expanded and further analyzed, using, for example, the polymerase chain reaction for determining the presence of the construct in the host cells and/or assays for the production of the desired gene product(s). Once modified host cells have been identified, they may then be used as planned, e.g. grown in culture or introduced into a host organism.

Depending upon the nature of the cells, the cells may be introduced into a host organism, e.g. a mammal, in a wide variety of ways. Hematopoietic cells may be

administered by injection into the vascular system, there being usually at least about 10<sup>4</sup> cells and generally not more than about 10<sup>10</sup> cells. The number of cells which are employed will depend upon a number of circumstances, the purpose for the introduction, the lifetime of the cells, the protocol to be used, for example, the number 5 of administrations, the ability of the cells to multiply, the stability of the therapeutic agent, the physiologic need for the therapeutic agent, and the like. Generally, for myoblasts or fibroblasts for example, the number of cells will be at least about 10<sup>4</sup> and not more than about 10<sup>9</sup> and may be applied as a dispersion, generally being injected at or near the site of interest. The cells will usually be in a physiologically- 10 acceptable medium.

Cells engineered in accordance with this invention may also be encapsulated, e.g. using conventional biocompatible materials and methods, prior to implantation into the host organism or patient for the production of a therapeutic protein. See e.g. Hguyen et al, Tissue Implant Systems and Methods for Sustaining viable High Cell 15 Densities within a Host, US Patent No. 5,314,471 (Baxter International, Inc.); Uludag and Sefton, 1993, J Biomed. Mater. Res. 27(10):1213-24 (HepG2 cells/hydroxyethyl methacrylate-methyl methacrylate membranes); Chang et al, 1993, Hum Gene Ther 4(4):433-40 (mouse Ltk- cells expressing hGH/immunoprotective perm-selective alginate microcapsules; Reddy et al, 1993, J Infect Dis 168(4):1082-3 (alginate); Tai 20 and Sun, 1993, FASEB J 7(11):1061-9 (mouse fibroblasts expressing hGH/alginate-poly-L-lysine-alginate membrane); Ao et al, 1995, Transplanataion Proc. 27(6):3349, 3350 (alginate); Rajotte et al, 1995, Transplantation Proc. 27(6):3389 (alginate); Lakey et al, 1995, Transplantation Proc. 27(6):3266 (alginate); Korbutt et al, 1995, Transplantation Proc. 27(6):3212 (alginate); Dorian et al, US Patent No. 5,429,821 25 (alginate); Emerich et al, 1993, Exp Neurol 122(1):37-47 (polymer-encapsulated PC12 cells); Sagen et al, 1993, J Neurosci 13(6):2415-23 (bovine chromaffin cells encapsulated in semipermeable polymer membrane and implanted into rat spinal subarachnoid space); Aebischer et al, 1994, Exp Neurol 126(2):151-8 (polymer-encapsulated rat PC12 cells implanted into monkeys; see also Aebischer, WO 30 92/19595); Savelkoul et al, 1994, J Immunol Methods 170(2):185-96 (encapsulated hybridomas producing antibodies; encapsulated transfected cell lines expressing various cytokines); Winn et al, 1994, PNAS USA 91(6):2324-8 (engineered BHK cells expressing human nerve growth factor encapsulated in an immunoisolation polymeric device and transplanted into rats); Emerich et al, 1994, Prog Neuropsychopharmacol 35 Biol Psychiatry 18(5):935-46 (polymer-encapsulated PC12 cells implanted into rats); Kordower et al, 1994, PNAS USA 91(23):10898-902 (polymer-encapsulated

engineered BHK cells expressing hNGF implanted into monkeys) and Butler et al WO 95/04521 (encapsulated device). The cells may then be introduced in encapsulated form into an animal host, preferably a mammal and more preferably a human subject in need thereof. Preferably the encapsulating material is semipermeable, permitting  
5 release into the host of secreted proteins produced by the encapsulated cells. In many embodiments the semipermeable encapsulation renders the encapsulated cells immunologically isolated from the host organism in which the encapsulated cells are introduced. In those embodiments the cells to be encapsulated may express one or more fusion proteins containing component domains derived from proteins of the host  
10 species and/or from viral proteins or proteins from species other than the host species. For example in such cases the fusion proteins may contain elements derived from GAL4 and VP16. The cells may be derived from one or more individuals other than the recipient and may be derived from a species other than that of the recipient organism or patient.

15 Instead of ex vivo modification of the cells, in many situations one may wish to modify cells in vivo. For this purpose, various techniques have been developed for modification of target tissue and cells in vivo. A number of viral vectors have been developed, such as adenovirus, adeno-associated virus, and retroviruses, as discussed above, which allow for transfection and, in some cases, integration of the virus into the  
20 host. See, for example, Dubensky et al. (1984) Proc. Natl. Acad. Sci. USA 81, 7529-7533; Kaneda et al., (1989) Science 243,375-378; Hiebert et al. (1989) Proc. Natl. Acad. Sci. USA 86, 3594-3598; Hatzoglu et al. (1990) J. Biol. Chem. 265, 17285-17293 and Ferry, et al. (1991) Proc. Natl. Acad. Sci. USA 88, 8377-8381. The vector may be administered by injection, e.g. intravascularly or intramuscularly, inhalation, or other  
25 parenteral mode. Non-viral delivery methods such as administration of the DNA via complexes with liposomes or by injection, catheter or biolistics may also be used.

In accordance with in vivo genetic modification, the manner of the modification will depend on the nature of the tissue, the efficiency of cellular modification required, the number of opportunities to modify the particular cells, the accessibility of the  
30 tissue to the DNA composition to be introduced, and the like. By employing an attenuated or modified retrovirus carrying a target transcription initiation region, if desired, one can activate the virus using one of the subject transcription factor constructs, so that the virus may be produced and transfect adjacent cells.

The DNA introduction need not result in integration in every case. In some  
35 situations, transient maintenance of the DNA introduced may be sufficient. In this way, one could have a short term effect, where cells could be introduced into the host

and then turned on after a predetermined time, for example, after the cells have been able to home to a particular site.

### Binding properties, Assays

5 FK506 is known to bind to the human protein, FKBP12 and to form a tripartite complex with the serine/threonine phosphatase, calcineurin. FK506 analogs may be characterized and compared to FK506 with respect to their ability to bind to human FKBP12 and/or to form tripartite complexes with fusion proteins containing human FKBP12 and CABs. See, for example, WO 96/41865 (Clackson et al). That  
10 application discloses various materials and methods which can be used to quantify the ability of a compound to bind to human FKBP12 or to form a tripartite complex with (*i.e.*, "heterodimerize") proteins comprising human FKBP12 and the FRB domain of human FRAP, respectively. Such assays include fluorescence polarization assays to measure binding. Also included are cell based transcription assays in which the ability  
15 of a compound to form the tripartite complex is measured indirectly by correlation with the observed level of reporter gene product produced by engineered mammalian cells in the presence of the compound. Corresponding cell-based assays may also be conducted in engineered yeast cells. See e.g. WO 95/33052 (Berlin et al).

It will often be preferred that the ligands of this invention be physiologically acceptable (*i.e.*, lack undue toxicity toward the cell or organism with which it is to be used), can be taken orally by animals (*i.e.*, is orally active in applications in whole animals, including gene therapy), and/or can cross cellular and other membranes, as necessary for a particular application.

In addition, preferred ligands are those which bind preferentially to mutant immunophilins (by way of non-limiting example, a human FKBP in which Phe36 is replaced with a different amino acid, preferably an amino acid with a less bulky R group such as valine or alanine) over native or naturally-occurring immunophilins. For example, such compounds may bind preferentially to mutant FKBP<sub>s</sub> at least an order of magnitude better than they bind to human FKBP12, and in some cases may bind to mutant FKBP<sub>s</sub> greater than 2 or even 3 or more orders of magnitude better than they do to human FKBP12, as determined by any scientifically valid or art-accepted assay methodology.

Binding affinities of various ligands of this invention with respect to human FKBP12, variants thereof or other immunophilin proteins may be determined by adaptation of known methods used in the case of FKBP. For instance, the practitioner may measure the ability of a compound of this invention to compete with the binding

of a known ligand to the protein of interest. See e.g. Sierkierka et al, 1989, *Nature* 341, 755-757 (test compound competes with binding of labeled FK506 derivative to FKBP).

One set of preferred ligands of this invention which binds, to human FKBP12, to a mutant thereof as discussed above, or to a fusion protein containing such FKBP domains, with a  $K_d$  value below about 200 nM, more preferably below about 50 nM, even more preferably below about 10 nM, and even more preferably below about 1 nM, as measured by direct binding measurement (e.g. fluorescence quenching), competition binding measurement (e.g. versus FK506), inhibition of FKBP enzyme activity (rotamase), or other assay methodology. In one subset of such compounds, 10 the FKBP domain is one in which phenylalanine at position 36 has been replaced with an amino acid having a less bulky side chain, e.g. alanine, valine, methionine or serine.

A Competitive Binding FP Assay is described in detail in the examples which follow. That assay permits the *in vitro* measurement of an IC<sub>50</sub> value for a given compound which reflects its ability to bind to an FKBP protein in competition with a 15 labeled FKBP ligand, such as, for example, FK506.

One preferred class of compounds of this invention are those ligands which have an IC<sub>50</sub> value in the Competitive Binding FP Assay better than 1000 nM, preferably better than 300 nM, more preferably better than 100 nM, and even more preferably better than 10 nM with respect to a given FKBP domain and ligand pair, 20 e.g. human FKBP12 or a variant thereof with up to 10, preferably up to 5 amino acid replacements, with a fluoresceinated FK506 standard. In one subset of that class, the FKBP domain has one of the abovementioned modifications at position 36.

The ability of the ligands to multimerize fusion proteins may be measured in cell-based assays by measuring the occurrence of an event triggered by such 25 multimerization. For instance, one may use cells containing and capable of expressing DNA encoding a first fusion protein comprising one or more FKBP- domains and one or more action domains as well as DNA encoding a second fusion protein containing an CAB domain and one or more action domains capable, upon multimerization, of actuating a biological response. We prefer to use cells which further contain a reporter 30 gene under the transcription control of a regulatory element (i.e., promoter) which is responsive to the multimerization of the fusion proteins. The design and preparation of illustrative components and their use in so engineered cells is described in WO96/41865 and the other international patent applications referred to in this and the foregoing section. The cells are grown or maintained in culture. A ligand is added 35 to the culture medium and after a suitable incubation period (to permit gene expression and secretion, e.g. several hours or overnight) the presence of the reporter

gene product is measured. Positive results, i.e., multimerization, correlates with transcription of the reporter gene as observed by the appearance of the reporter gene product. The reporter gene product may be a conveniently detectable protein (e.g. by ELISA) or may catalyze the production of a conveniently detectable product (e.g. colored). Materials and methods for producing appropriate cell lines for conducting such assays are disclosed in the international patent applications cited above in this section. Typically used target genes include by way of example SEAP, hGH, beta-galactosidase, Green Fluorescent Protein and luciferase, for which convenient assays are commercially available.

Another preferred class of compounds of this invention are those which are capable of inducing a detectable signal in a 2-hybrid transcription assay based on fusion proteins containing an FKBP domain. Preferably, the FKBP domain is an FKBP domain other than wild-type human FKBP12.

Another assay for measuring the ability of the ligands to multimerize fusion proteins, like the FKBP-based transcription assay, is a cell-based assay which measures the occurrence of an event triggered by such multimerization. In this case, one uses cells which constitutively express a detectable product. The cells also contain and are capable of expressing DNAs encoding fusion proteins comprising one or more immunophilin-derived ligand binding domains and one or more action domains, such as the intracellular domain of FAS, capable, upon multimerization, of triggering cell death. The design and preparation of illustrative components and their use in so engineering cells is described in WO95/02684. See also WO96/41865. The cells are maintained or cultured in a culture medium permitting cell growth or continued viability. The cells or medium are assayed for the presence of the constitutive cellular product, and a baseline level of reporter is thus established. One may use cells engineered for constitutive production of hGH or any other conveniently detectable product to serve as the reporter. The compound to be tested is added to the medium, the cells are incubated, and the cell lysate or medium is tested for the presence of reporter at one or more time points. Decrease in reporter production indicates cell death, an indirect measure of multimerization of the fusion proteins.

Another preferred class of compounds of this invention are those which are capable of inducing a detectable signal in such an FKBP/CAB-based apoptosis assay. Preferably, the FKBP domain is an FKBP domain other than wild-type human FKBP12. In some cases, the FKBP domain is modified, as discussed above. Also preferably, the CAB domain is a CAB domain other than wild-type CAB.

Conducting such assays permits the practitioner to select ligands possessing the desired IC<sub>50</sub> values and/or binding preference for a mutant FKBP over wild-type human FKBP12. The Competitive Binding FP Assay permits one to select monomers or ligands which possess the desired IC<sub>50</sub> values and/or binding preference for a mutant FKBP or wild-type FKBP relative to a control, such as FK506.

## Applications

The ligands and ligand binding domains can be used as described in WO94/18317, WO95/02684, WO96/20951, WO95/41865, e.g. to regulatably activate the transcription of a desired gene, delete a target gene, actuate apoptosis, or trigger other biological events in engineered cells growing in culture or in whole organisms, including in gene therapy applications. The following are non-limiting examples of applications of the subject invention.

1. **Regulated gene therapy.** In many instances, the ability to switch a therapeutic gene on and off at will or the ability to titrate expression with precision are important for therapeutic efficacy. This invention is particularly well suited for achieving regulated expression of a therapeutic target gene in the context of human gene therapy. One example uses a pair of fusion proteins of this invention (one containing at least one CAB domain, the other containing at least one FKBP domain), a ligand capable of dimerizing the fusion proteins, and a target gene construct to be expressed. One of the fusion proteins comprises a DNA-binding domain, preferably a composite DNA-binding domain as described in Pomerantz et al, *supra*, as the heterologous action domain. The second fusion protein comprises a transcription activating domain as the heterologous action domain. The improved ligand is capable of binding to both fusion proteins and thus of effectively cross-linking the fusion proteins. DNA molecules encoding and capable of directing the expression of these fusion proteins are introduced into the cells to be engineered. Also introduced into the cells is a target gene linked to a DNA sequence to which the DNA-binding domain is capable of binding. Contacting the engineered cells or their progeny with the improved ligand (by administering it to the animal or patient) leads to assembly of the transcription factor complex and hence to expression of the target gene. The design and use of similar components is disclosed in PCT/US93/01617 and in WO 96/41865 (Clackson et al). In practice, the level of target gene expression should be a function of the number or concentration of fusion transcription factor complexes,

which should in turn be a function of the concentration of the improved ligand. Dose (of improved ligand)-responsive gene expression is typically observed.

The improved ligand may be administered to the patient as desired to activate transcription of the target gene. Depending upon the binding affinity of the improved ligand, the response desired, the manner of administration, the biological half-life of the ligand and/or target gene mRNA, the number of engineered cells present, various protocols may be employed. The improved ligand may be administered by various routes, including parenterally or orally. The number of administrations will depend upon the factors described above. The improved ligand may be taken orally as a pill, powder, or dispersion; buccally; sublingually; injected intravascularly, intraperitoneally, intramuscularly, subcutaneously; by inhalation, or the like. The improved ligand (and monomeric antagonist compound) may be formulated using conventional methods and materials well known in the art for the various routes of administration. The precise dose and particular method of administration will depend upon the above factors and be determined by the attending physician or human or animal healthcare provider. For the most part, the manner of administration will be determined empirically.

In the event that transcription activation by the improved ligand is to be reversed or terminated, a monomeric compound which can compete with the improved ligand may be administered. Thus, in the case of an adverse reaction or the desire to terminate the therapeutic effect, an antagonist to the dimerizing agent can be administered in any convenient way, particularly intravascularly, if a rapid reversal is desired. Alternatively, one may provide for the presence of an inactivation domain (or transcription silencer) with a ligand binding domain. In another approach, cells may be eliminated through apoptosis via signalling through Fas or TNF receptor as described elsewhere. See International Patent Applications PCT/US94/01617 and PCT/US94/08008.

The particular dosage of the improved ligand for any application may be determined in accordance with the procedures used for therapeutic dosage monitoring, where maintenance of a particular level of expression is desired over an extended period of times, for example, greater than about two weeks, or where there is repetitive therapy, with individual or repeated doses of improved ligand over short periods of time, with extended intervals, for example, two weeks or more. A dose of the improved ligand within a predetermined range would be given and monitored for response, so as to obtain a time-expression level relationship, as well as observing therapeutic response. Depending on the levels observed during the time period and

the therapeutic response, one could provide a larger or smaller dose the next time, following the response. This process would be iteratively repeated until one obtained a dosage within the therapeutic range. Where the improved ligand is chronically administered, once the maintenance dosage of the improved ligand is determined, one could then do assays at extended intervals to be assured that the cellular system is providing the appropriate response and level of the expression product.

It should be appreciated that the system is subject to many variables, such as the cellular response to the improved ligand, the efficiency of expression and, as appropriate, the level of secretion, the activity of the expression product, the particular need of the patient, which may vary with time and circumstances, the rate of loss of the cellular activity as a result of loss of cells or expression activity of individual cells, and the like.

**2. Production of recombinant proteins and viruses.** Production of recombinant therapeutic proteins for commercial and investigational purposes is often achieved through the use of mammalian cell lines engineered to express the protein at high level. The use of mammalian cells, rather than bacteria or yeast, is indicated where the proper function of the protein requires post-translational modifications not generally performed by heterologous cells. Examples of proteins produced commercially this way include erythropoietin, tissue plasminogen activator, clotting factors such as Factor VIII:c, antibodies, etc. The cost of producing proteins in this fashion is directly related to the level of expression achieved in the engineered cells. A second limitation on the production of such proteins is toxicity to the host cell: Protein expression may prevent cells from growing to high density, sharply reducing production levels. Therefore, the ability to tightly control protein expression, as described for regulated gene therapy, permits cells to be grown to high density in the absence of protein production. Only after an optimum cell density is reached, is expression of the gene activated and the protein product subsequently harvested.

A similar problem is encountered in the construction and use of "packaging lines" for the production of recombinant viruses for commercial (e.g., gene therapy) and experimental use. These cell lines are engineered to produce viral proteins required for the assembly of infectious viral particles harboring defective recombinant genomes. Viral vectors that are dependent on such packaging lines include retrovirus, adenovirus, and adeno-associated virus. In the latter case, the titer of the virus stock obtained from a packaging line is directly related to the level of production of the viral rep and core proteins. But these proteins are highly toxic to the host cells. Therefore, it

has proven difficult to generate high-titer recombinant AAV viruses. This invention provides a solution to this problem, by allowing the construction of packaging lines in which the rep and core genes are placed under the control of regulatable transcription factors of the design described here. The packaging cell line can be grown to high density, infected with helper virus, and transfected with the recombinant viral genome. Then, expression of the viral proteins encoded by the packaging cells is induced by the addition of dimerizing agent to allow the production of virus at high titer.

10           **3. Biological research.** This invention is applicable to a wide range of biological experiments in which precise control over a target gene is desired. These include: (1) expression of a protein or RNA of interest for biochemical purification; (2) regulated expression of a protein or RNA of interest in tissue culture cells (or in vivo, via engineered cells) for the purposes of evaluating its biological function; (3) regulated expression of a protein or RNA of interest in transgenic animals for the purposes of evaluating its biological function; (4) regulating the expression of a gene encoding another regulatory protein, ribozyme or antisense molecule that acts on an endogenous gene for the purposes of evaluating the biological function of that gene. Transgenic animal models and other applications in which the components of this invention may be adapted include those disclosed in PCT/US95/10591.

20           This invention further provides kits useful for the foregoing applications. Such kits contain DNA constructs encoding and capable of directing the expression of fusion proteins of this invention (and may contain additional domains as discussed above) and, in embodiments involving regulated gene transcription, a target gene construct containing a target gene linked to one or more transcriptional control elements which are activated by the multimerization of the fusion proteins. Alternatively, the target gene construct may contain a cloning site for insertion of a desired target gene by the practitioner. Such kits may also contain a sample of a dimerizing agent capable of dimerizing the two recombinant proteins and activating transcription of the target gene.

30

#### **Formulations, dosage and administration**

By virtue of its capacity to promote protein-protein interactions, a ligand of this invention may be used in pharmaceutical compositions and methods for promoting formation of complexes of fusion proteins of this invention in a human or non-human mammal containing genetically engineered cells of this invention.

The preferred method of such treatment or prevention is by administering to the mammal an effective amount of the compound to promote measurable formation of such complexes in the engineered cells, or preferably, to promote measurable actuation of the desired biological event triggered by such complexation, e.g. transcription of a target gene, apoptosis of engineered cells, etc.

#### Therapeutic/Prophylactic Administration & Pharmaceutical Compositions

The ligands can exist in free form or, where appropriate, in salt form. Pharmaceutically acceptable salts of many types of compounds and their preparation 10 are well-known to those of skill in the art. The pharmaceutically acceptable salts of compounds of this invention include the conventional non-toxic salts or the quaternary ammonium salts of such compounds which are formed, for example, from inorganic or organic acids of bases.

The compounds of the invention may form hydrates or solvates. It is known to 15 those of skill in the art that charged compounds form hydrated species when lyophilized with water, or form solvated species when concentrated in a solution with an appropriate organic solvent.

This invention also relates to pharmaceutical compositions comprising a 20 therapeutically (or prophylactically) effective amount of the compound, and one or more pharmaceutically acceptable carriers and/or other excipients. Carriers include e.g. saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof, and are discussed in greater detail below. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. The composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, 25 sustained release formulation, or powder. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Formulation may involve mixing, granulating and compressing or 30 dissolving the ingredients as appropriate to the desired preparation.

The pharmaceutical carrier employed may be, for example, either a solid or liquid.

Illustrative solid carrier include lactose, terra alba, sucrose, talc, gelatin, agar, 35 pectin, acacia, magnesium stearate, stearic acid and the like. A solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or

tablet-disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions, and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.

Illustrative liquid carriers include syrup, peanut oil, olive oil, water, etc. Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are useful in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellant. Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. The compound can also be administered orally either in liquid or solid composition form.

The carrier or excipient may include time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate along or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylate and the like. When formulated for oral administration, 0.01% Tween 80 in PHOSAL PG-50 (phospholipid concentrate with 1,2-propylene glycol, A. Nattermann & Cie. GmbH) has been recognized as providing an acceptable oral formulation for other compounds, and may be adapted to formulations for various compounds of this invention.

A wide variety of pharmaceutical forms can be employed. If a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will vary widely but preferably will be from about 25 mg to about 1 g. If a liquid carrier is used,  
5 the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable solution or suspension in an ampule or vial or nonaqueous liquid suspension.

To obtain a stable water soluble dosage form, a pharmaceutically acceptable salt of the multimerizer may be dissolved in an aqueous solution of an organic or  
10 inorganic acid, such as a 0.3M solution of succinic acid or citric acid. Alternatively, acidic derivatives can be dissolved in suitable basic solutions. If a soluble salt form is not available, the compound is dissolved in a suitable cosolvent or combinations thereof. Examples of such suitable cosolvents include, but are not limited to, alcohol, propylene glycol, polyethylene glycol 300, polysorbate 80, glycerin, polyoxyethylated  
15 fatty acids, fatty alcohols or glycerin hydroxy fatty acids esters and the like in concentrations ranging from 0-60% of the total volume.

Various delivery systems are known and can be used to administer the multimerizer, or the various formulations thereof, including tablets, capsules, injectable solutions, encapsulation in liposomes, microparticles, microcapsules, etc. Methods of  
20 introduction include but are not limited to dermal, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, pulmonary, epidural, ocular and (as is usually preferred) oral routes. The compound may be administered by any convenient or otherwise appropriate route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal  
25 and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. For treatment or prophylaxis of nasal, bronchial or pulmonary conditions, preferred routes of administration are oral, nasal or via a bronchial aerosol or nebulizer.

In certain embodiments, it may be desirable to administer the compound  
30 locally to an area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, by injection, by means of a catheter, by means of a suppository, or by means of a skin patch or implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.

35 In a specific embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous

administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or 5 mixed together in unit dosage form, for example, as a lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by 10 injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

Administration to an individual of an effective amount of the compound can also be accomplished topically by administering the compound(s) directly to the affected area of the skin of the individual. For this purpose, the compound is 15 administered or applied in a composition including a pharmacologically acceptable topical carrier, such as a gel, an ointment, a lotion, or a cream, which includes, without limitation, such carriers as water, glycerol, alcohol, propylene glycol, fatty alcohols, triglycerides, fatty acid esters, or mineral oils.

Other topical carriers include liquid petroleum, isopropyl palmitate, 20 polyethylene glycol, ethanol (95%), polyoxyethylene monolaurate (5%) in water, or sodium lauryl sulfate (5%) in water. Other materials such as anti-oxidants, humectants, viscosity stabilizers, and similar agents may be added as necessary. Percutaneous penetration enhancers such as Azone may also be included.

In addition, in certain instances, it is expected that the compound may be 25 disposed within devices placed upon, in, or under the skin. Such devices include patches, implants, and injections which release the compound into the skin, by either passive or active release mechanisms.

Materials and methods for producing the various formulations are well known in the art and may be adapted for practicing the subject invention. See e.g. US Patent 30 Nos. 5,182,293 and 4,837,311 (tablets, capsules and other oral formulations as well as intravenous formulations) and European Patent Application Publication Nos. 0 649 659 (published April 26, 1995; illustrative formulation for IV administration) and 0 648 494 (published April 19, 1995; illustrative formulation for oral administration).

The effective dose of the compound will typically be in the range of about 0.01 35 to about 50 mg/kgs, preferably about 0.1 to about 10 mg/kg of mammalian body weight, administered in single or multiple doses. Generally, the compound may be

administered to patients in need of such treatment in a daily dose range of about 1 to about 2000 mg per patient.

The amount of compound which will be effective in the treatment or prevention of a particular disorder or condition will depend in part on the characteristics of the fusion proteins to be multimerized, the characteristics and location of the genetically engineered cells, and on the nature of the disorder or condition, which can be determined by standard clinical techniques. In addition, *in vitro* or *in vivo* assays may optionally be employed to help identify optimal dosage ranges. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems. The precise dosage level should be determined by the attending physician or other health care provider and will depend upon well known factors, including route of administration, and the age, body weight, sex and general health of the individual; the nature, severity and clinical stage of the disease; the use (or not) of concomitant therapies; and the nature and extent of genetic engineering of cells in the patient.

The invention also provides a pharmaceutical pack or kit comprising one or more containers containing one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceutical or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. The notice or package insert may contain instructions for use of an improved ligand of this invention, consistent with the disclosure herein.

## Examples

### Example 1: Construction of human CAB fusion proteins

5 All constructs were made in the pcDNA3/m.jy2 vector which was derived from the pcDNA3 vector by mutation of backbone SalI sites and insertion of a new polylinker region. (B. Stockwell, J. Yang). The plasmid contains an ampicillin resistance gene which allows for selection in E. coli and a cytomegalovirus promoter which allows for high plasmid gene expression. The pcDNA3/m.jy2 plasmid was  
10 chosen instead of PBJ5, a plasmid used in many of the other dimerization systems, because its restriction digest profile eased the cloning of the calcineurin constructs.

#### Polymerase Chain Reaction

15 Primers were designed for the 3' and 5' ends of all calcineurin constructs used in this project. The primers integrated specific restriction sites into the ends of each gene to facilitate ligation of the gene into the pcDNA3/m.jy2 vector. The primers were synthesized on a Perkin Elmer Applied Biosystems 394 DNA/RNA Synthesizer Machine and purified using a Perkin Elmer Purification Protocol.

20 PCR Reactions were carried out on an M5 Research Mini-Cycler. The general PCR protocol included incubation at 95°C for 5 minutes. 30 seconds were then allowed for annealing at 55°C. This was followed by extension for one minute at 72°C and then a one minute incubation at 95°C. The annealing, extension and incubation steps were repeated 25-30 times. The resulting reaction mixture was stored at 4°C until further work up. PCR products were purified using a Qiagen PCR  
25 Purification Kit and the protocol therein.

#### Oligos for construction of calcineurin A fragments:

CNA sequence is in bold

30

i hCNA 5' PCR Oligo Start at residue 12

Junk Xho1

5' cggg ccc ccc ctc gag **tct acg acc gac agg gtg gtg aaa gc** 3'

35

Note: g->t is a silent mutation that destroys the SalI site.

i hCNA 5' PCR Oligo Start at residue 340

5

Junk XbaI  
5' atat aaa tcg ctc gag **cca tac tgg ctt cca aat ttc atg g** 3'

10

i hCNA 5' PCR Oligo Start at Residue 350

15

i hCNA 3' PCR Oligo End at Residue 370

20

Junk See Note ApaI Junk SalI  
5' cca gta ggg tct aga tct ggg ccc acg ata taa gtc gac **gtt gag gac**  
**att tac cag c** 3'

25

Note: tct aga tct = overlapping XbaI and BglII sites.

30

See Note STP FLAG Peptide SalI  
5' tt aa tct aga tct tca ctt gtc atc gtc atc ttt ata gtc gac **ctc**  
**ttt ccg ggc tgc agc tg** 3'

35

Note: tct aga tct = overlapping XbaI and BglII sites.

Oligos Designed for Human calcineurin B:

(Bold portion is CNB sequence)

5

i hCNB 5' PCR Oligo Start at residue 2

10       Junk       XhoI5' atat aaa tcg ctc gag **gga aat gag gca agt tat cct ttg g** 3'

15       i hCNB 5' PCR Oligo Start at residue 3

Junk       XhoI5' atat aaa tcg ctc gag **aat gag gca agt tat cct ttg g** 3'

20

i hCNB 3' PCR Oligo with 3' FLAG peptide and Stop

See Note   Apal   STP   FLAG Peptide25       5' ttaa tct **aga tct ggg ccc tca ctt gtc atc gtc atc ttt ata**Sallgtc gac **cac atc tac cac cat c** 3'

30       Note: tct aga tct = overlapping XbaI and BglII sites.

Oligos Designed for Constructing CNA-CNB Linkers:

(Bold portion is CNA sequence)

35

i 3' PCR Primer for hCNA to Generate 24 Amino Acid Template Linker (to residue 370)

5      Junk    Apal    See Note    Linker

5' cga ttt atat ggg ccc tct aga tct aga acc aga acc aga acc aga

Linker

acc aga acc aga acc aga acc aga acc acc acc aga acc aga acc

10

acc gtt gag gac att tac cag c 3'

Note: tct aga tct = overlapping XbaI and BglII sites.

15

i 3' PCR Primer for Randomizing the Length of the CNA-CNB Linker  
(Register 1 oligo)

20

Junk    See Note    Apal    Junk    Sall  
5' gaatcgcaaa tctaga tctgggccc gtc atc tttata gtc gac acc

aga acc aga acc 3'

25

Note: tct aga tct = overlapping XbaI and BglII sites.

30 i 3' PCR Primer for Randomizing the Length of the CNA-CNB Linker  
(Register 2 oligo)

Junk      See Note      Apal      Junk      Sall

5' g aat cgc aaa tct aga tct ggg ccc gtc atc ttt ata gtc gac aga

35

acc aga acc aga 3'

Note: tct aga tct = overlapping XbaI and BglII sites.

5 PCR Conditions (for all CNA and CNB fragments):

	<u>Step</u>	<u>Temperature (°C)</u>	<u>Time (sec)</u>
10	1.	95	180
	2.	37	30
	3.	72	60
	4.	95	60
	5.	37	30
	6.	72	60
15	7.	Goto Step 4 9 times	
	8.	95	60
	9.	55	30
	10.	72	60
	11.	Goto Step 8 25 times	
20	12.	72	300
	13.	4	

25 PCR Conditions (for randomization of Linker Length):

	<u>Step</u>	<u>Temperature (°C)</u>	<u>Time (sec)</u>
30	1.	95	180
	2.	37	30
	3.	72	60
	4.	95	60
	5.	45	30
	6.	72	60
35	7.	Goto Step 4 9 times	
	8.	95	60
	9.	55	30
	10.	72	60
	11.	Goto step 8 25 times	

12 .	72	300
13	4	

5    **Example 2: Method of Linking Calcineurin A to Calcineurin B**

The method of linking calcineurin A to calcineurin B in the CABS falls into two categories. The first method used fragments of the gene encoding calcineurin A ( residues 12-370, 12-394, 340-370, 340-394, 350-370, or 350-394) generated by PCR to contain a 5' Xho1 restriction site directly before the codons for residues 12, 340, or 350 and a 3' Sal1 restriction site directly following the codons for residues 370 or 394. The fragments of the gene encoding calcineurin B (residues 2-170 or 3-170) were also generated by PCR to contain a 5' Xho1 restriction site directly before the codons for residues 2 or 3 and a 3' Sal1 restriction site directly following the codon for residue 170. Ligation of the two fragments were performed such that the fragment of calcineurin A is 5' to calcineurin B and the site of ligation is the result of a Sal1/Xho1 fusion (gtcgag). This results in two additional codons encoding a Valine and a Glutamate between the calcineurin A portion of the CABS and the calcineurin B portion of these CABS.

The second method of linking the CABS was to generate a pool of calcineurin A fragments with linkers, ranging in size from 6 to 24 amino acids, attached directly after residue 370. These fragments were PCR'ed such that they also contained a 5' Xho1 restriction site directly before the codons for residues 12, 340, 350 and a 3' Sal1 restriction site directly following the codons encoding the flexible linker. The calcineurin B fragments were the same as those described in the previous paragraph. The ligation was performed such that the fragment of calcineurin A is 5' to calcineurin B and the site of ligation is the result of a Sal1/Xho1 fusion (gtcgag). This results in two additional codons encoding a Valine and a Glutamate between the calcineurin A-linker portion of the CABS and the calcineurin B portion of these CABS.

Generation of the variously lengthed flexible linkers on calcineurin A was accomplished through a two step PCR procedure developed for this purpose. The following bases were added after the codon for residue 370 of calcineurin A by PCR:

CNA residue 370-

35    GGTGGTTCTGGTCTGGTGTTCTGGTTCTGGTTCTGGTTCTGGG  
TTCTGGTTCTGGTCTGGTTCTGGTTCTGGTTCTGGTTCTGGG

This encodes for the following flexible longest length linker:

GGSGSGGGSGSGSGSGSGSGS

PCR was then performed on the above template with two primers that contained the  
5 following complimentary sequence:

Primer 1:

5' GTC GAC AGA ACC AGA ACC AGA 3'

Primer 2:

5' GTC GAC ACC AGA ACC AGA ACC 3'

10 and a Sal I restriction site (gtc gac). Upon PCR with both primers that can anneal in many registers of the template calcineurin A, fragments of calcineurin A containing from 7 to 24 amino acids of the flexible linker were generated. Interestingly, all of the fragments contained the amino acids GGSGS followed by the appropriate number of single alternating Glycines and Serines. The predicted PCR products should have two  
15 GGSGS repeats, but we recovered only one in all of the clones. Moreover, this strategy also provided fragments that had longer linkers than what we had predicted because the second PCR step allows the linker to grow.

### Example 3: Construction of FKBP and CAB fusion proteins

20 All CNA constructs were derived from human calcineurin A (a isoform). All CNB constructs were derived from human calcineurin B. CNB<sub>M</sub> contains an N-terminal methionine, while CNB<sub>MG</sub> contains both a methionine and a glycine residue. Residues 1-147 from GAL4 are used for the GAL4 DNA binding domain (GE). Residues 413-490 from VP16 are used as the VP16 transactivation domain (VE). Each VE  
25 construct contains an N-terminal nuclear localization sequence (NLS) from SV40 large T antigen, while all GE constructs contain an NLS within the GAL4 sequence. All GE constructs contain a FLAG epitope tag and all VE constructs contain a FLU epitope tag. All FKBP constructs contain the entirety of the human coding sequence. The FRB construct contains residues 2025-2114 of the human FRAP protein. The UAS-SEAP  
30 reporter gene contains 5 upstream Gal4-binding sites (UAS sites) and a minimal interleukin 2 basic promoter and encodes SEcreted Alkaline Phosphatase, a heat-stable alkaline phosphatase.

The same basic digestion, ligation and transformation procedure was used to obtain each construct. Calcineurin A fragments were put into the pcDNA3/m.jy2  
35 vector by digesting the PCR product with Xhol and XbaI and ligating into vector that had been cut with the same enzymes. CNB was ligated into the vector using Xhol and

Apal restriction sites. FKBP3-VE and FKBP3-GE were ligated from PBJ5 into the pcDNA3/m.jy2 vector using the SacII and EcoRI enzymes. These basic parent vectors allowed for the generation of all future constructs since calcineurin A and calcineurin B fragments could be liberated by digestion with XhoI and SalI or XhoI and ApaI while  
5 VE could be liberated with SalI and ApaI. In addition, GE, CNA or CNB containing vectors could be created by digestion with SalI and ApaI. Since XhoI and SalI generate complementary sticky ends, all the calcineurin constructs used in this project could be created from different combinations of the digests described above and from digests of successive generations of constructs.

10 After vector and insert DNAs were digested with the appropriate restriction enzymes, the products were then run on either a 1% or 2% agarose gel (1% was used for all products greater than 300 basepairs). The desired DNA bands were then isolated using a Qiagen Gel Purification Kit and the protocol therein. Vector and insert bands were ligated from 4 hours to overnight at 16°C in an 11ml volume with 1  
15 ml T4 DNA ligase and 1 ml NEB ligation buffer and a 2:1 (or greater) ratio of insert to vector. The ligation reaction was then transformed into subcloning efficiency DH5a bacterial cells obtained from GIBCO BRL according to the protocol supplied with the cells. For certain inefficient ligations, such as SalI/ApaI ligations, maximum efficiency DH5a cells were used. Positive transformants were selected for using ampicillin. A  
20 few positive colonies from each ligation were chosen for further analysis. The Wizard Mini-Prep Kit and protocol therein were used to isolate plasmid DNA from these positive colonies. The DNA was subjected to restriction digest analysis to screen for false positive clones. DNA from true positive colonies was prepared using a Wizard Midi-Prep Kit and protocol therein. The prepared DNA was quantitated using the  
25 relation:

[double stranded DNA] = (50 mg/ml)\*(A260)  
where A260 equals the absorbance of the DNA sample at 260 nm wavelength light.

**Example 4: Reporter-based Assay for Activation of Transcription:**

30 The transcription assay that we utilize has been described in WO94/18317 and in Rivera et al., 1996 supra. The general assay is as follows.

10 million T-antigen transformed Jurkat T-cells growing in log phase at 37 degrees with 5% CO<sub>2</sub> in RPMI medium supplemented with 10% FBS, Penicillin and Streptomycin, and Glutamate are centrifuged for 5 minutes at 1000xg. This pellet is  
35 washed with RPMI without phenol-red and re-pelleted by centrifugation at 1000xg for 5 minutes. 200 microliters of phenol-free RPMI are used to resuspend each 10 million

cells. 200 microliters of these cells are then incubated for 10 minutes at room temperature with 1 microgram of the UAS-SEAP reporter, 1 microgram of the DNA binding domain containing construct, and 5 micrograms of the activation domain containing construct. Electroporation is performed at 250 mV, 129 Ohms on a BTX electroporator. The cells are allowed to recover at room temperature for another 10 minutes. They are then resuspended in 10 mLs of RPMI w/o phenol red supplemented with 10% FBS, penicillin, streptomycin, and Glutamate and returned to the 37 degree incubator with 5% CO<sub>2</sub> for 24 hrs.

After recovery, the cells are pelleted by centrifugation at 1000xg for 5 minutes and 10 resuspended in 5 mLs of RPMI w/o phenol red supplemented with 10% FBS, penecillin, streptomycin, and Glutamate. 100 microliters of this cell suspension is plated on a 96 well plate. Appropriate dilutions of the dimerizer from an ethanolic solution (2 micromolar to 0.2 nanomolar) are made in the same media that the cells were resuspended in such that the concentration of ethanol is less than 1%. 100 15 microliters of these dilutions in media are added to the wells containing cells in the 96 well plate. The cells are again placed in the 37% incubator with 5% CO<sub>2</sub> for 24-48 hrs.

After incubation with the dimerizer the 96 well plates containing cells are wrapped 20 in Saran Wrap and heated to 65-75 degrees C for two hours. After heat treatment, the plates are placed at room temperature until cool. 100 microliters of each of the wells was transferred to a new plate containing 100 microliters of the following solution. For each 96 well plate prepare 11mLs of 2M diethanolamine pH 10 (with CO<sub>2</sub>) with 25 132 microliters of a solution of 1 mL 2M diethanolamine pH 10 (with CO<sub>2</sub>) containing 25.6 milligrams of 4-MethylumbuliferylPhosphate (MUP). These plates are then 25 returned to 37 degrees for 1-24 hours and are read on a microplate reader using a standard FITC filter set. The maximal reading should not exceed 1-2000 as this indicates that the substrate is nearly used up.

#### Example 5: Activation of Transcription using CAB fusion proteins

The CABS have been extensively tested in a three-hybrid-like transcription assay 30 as described in Spencer et al, 1993, Science 262:1019-1024, in WO 94/18317, in Rivera et al.,1996, Nature Medicine 2, 1028-1032 and in WO 96/41865 (Clackson et al.). As described above, multimeric CABS, single full length or mini CABS or portions 35 of the CABS have been fused C-terminally to the Gal4-DNA binding domain and placed between an N-terminal NLS and a C-terminal VP16 activation domain. Three copies of FKBP act as the other dimerization domain and are fused to either the C-

terminus of Gal4 or between an N terminal NLS and the VP16 activation domain. The reporter contains the upstream activating sequence of GAL4 (12 tandem copies) followed by the secreted alkaline phosphatase gene (SEAP). FK506 titration was used to elicit dimerizer dependent transcription activation of SEAP which was detected on a fluorescence plate reader using methylumblyleriferyl-phosphate (MUP) as a substrate. The vector used for expression is a version of pCDNA3 from Pharmacia Biotech that has had its Xho1 and Sal1 restriction sites destroyed and a new polylinker inserted for ease of cloning. The cells used in these experiments are T-antigen transformed Jurkat T-cells.

The summary of our data in this transcription assay is as follows. The full length CABS (residues 12-394 of calcineurin A fused to residue 2 or to residue 3 of Calcineurin B) are functional when fused to VP16 or to GAL4. They have an EC50 of ~ 1 nanoMolar.

We identified residues 340-370 of calcineurin A as being sufficient to form a complex with calcineurin B; residues 350-370 fail to complex with calcineurin B. This is also reflected in the fusion proteins using the mini-CABS, which all function to varying degrees with respect to total level of activation but behave almost identically with respect to EC50.

The linker length does seem to be able to modulate the amount of activity elicited by the CABS, but not the EC50s of the CABS, in the following way. The smallest linkers (7 or 8 amino acids) and the longest linkers (16-18 amino acids) tested appear to be the best with a total activation of around 8-10 fold and are comparable to the direct fusion between residues 340-394 of calcineurin A and residues 2 or 3-170 of calcineurin B.

The two versions of calcineurin B differ slightly in two respects. Calcineurin B from residues 3-370 seems to give a higher overall activation by about 10 % but also seem to have a slightly higher background association with "free" calcineurin B and calcineurin A. Calcineurin B from residues 2-370 has a slightly lower overall activation but seems to interact less with free calcineurin A or "free" calcineurin B. It should be noted that this interaction with "free" calcineurin A or calcineurin B is extremely minimal. The average EC50 for activation for all of these constructs is between 1 and 3 nanoMolar.

The multimers of minicabs (340-394 of CNA and 3-170 of CNB) have been tested as fusions to VP16. 3, and 4 tandem CABS function identically to the best single CABS mentioned above when recruited to Gal4 fused to 3 FKBP. 2 tandem CABS

function twice as well with regard to total activation (~20 fold) and have an EC<sub>50</sub> that is shifted to between 0.1 and 0.3 nanoMolar with FK506.

#### Example 6: Creation and Testing of miniCAB Proteins

Our analysis suggested that the N-terminal region of the CNA domain of CAB could be removed and the resulting protein could still be expected to bind FK506-FKBP. Four such minimal CAB proteins were created by PCR and ligation. Two of the miniCABs contained CNA residues 340-394 fused to either CNB<sub>MG</sub> or CNB<sub>M</sub> (340miniCABs). The other two miniCABs contained CNA residues 350-394 fused to either CNB<sub>MG</sub> or CNB<sub>M</sub> (350miniCABs). Each of these miniCABs was also fused to the VP16 transactivation domain.

Both of the 340miniCAB-VE constructs were able to stimulate SEAP activity when cotransfected with FKBP<sub>3</sub>-GE in an FK506-dependent manner under standard SEAP assay conditions. Consistent with the relative activity of CNB<sub>MG</sub> and CNB<sub>M</sub>, 340miniCAB<sub>MG</sub>-VE was able to induce higher SEAP activity than 340miniCAB<sub>M</sub>-VE. In contrast, neither of the 350miniCABs were able to stimulate SEAP activity in similar experiments. These results indicate that residues 340-394 of CNA represent a minimal domain of CNA that is able to form functional interactions with both CNB and FKBP-FK506 at the resolution detected by the SEAP assay.

The 340miniCAB<sub>MG</sub>-VE construct also stimulates higher SEAP activity (6.5 0.6 fold) than the corresponding full length CAB<sub>MG</sub>-VE (4.0 0.4 fold). The finding that the miniCABs produce higher SEAP activation than the full CABs might be attributable to the smaller miniCAB proteins being more stable or more efficiently translated or folded than the larger full length CAB proteins. The EC<sub>50</sub> of the miniCABs is about 3 nM, an order of magnitude greater than for full length CAB<sub>MG</sub>-VE. This result is understandable given the fact that the full length CAB-VE is able to make more binding contacts with FK506-FKBP than the 340miniCABs.

As with the full length CABs, assays were done to study whether the miniCABs were working through an inter- or intra- molecular mechanism. Like the full length CABs, the 340miniCAB-VEs showed only slight interaction with CNA-GE. In addition, both 340miniCAB-VE's showed only slight interaction with CNB-GE. This is in contrast to full CAB<sub>MG</sub>-VE which shows a high level of interaction with CNB-GE. Perhaps the less bulky CNA domain of the 340miniCAB-VE is less efficient in finding intermolecular binding partners than the

larger CNA domain of the full CAB. These are promising results for the use of miniCABs as dimerization domains since they imply that both miniCAB-VE proteins, unlike full CAB<sub>MG</sub>-VE, do not participate in unwanted intermolecular interactions which could lower the efficiency of the miniCAB proteins or cause them to interfere with the functioning of other proteins. Since the miniCABs do not seem to participate significantly in intermolecular interactions, this implies that the CNA and CNB domains of these proteins work together, and not independently in an intramolecular fashion, to form an FK506-FKBP binding site.

The results obtained imply that the 340miniCAB-VEs function as efficient dimerization domains in an intramolecular fashion, as designed. In addition, the 340miniCAB-VEs lack the catalytic domain of the full length CABs and, at 24 kDa, are approximately 35 kDa smaller.

#### *Improving the miniCAB System by Placing Multiple Dimerization Domains in Series*

In previous dimerization systems, it had been observed that multiple dimerization domains fused to both the GAL4 DNA binding domain and the VP16 transactivation domain could increase the maximal amount of SEAP activity induced by the CID. For example, it was found that three FKBP molecules fused in tandem led to higher SEAP activity than did one, two or four FKBP molecules in series (Belshaw, PJ. et al. "Controlling Protein Association and Subcellular Localization with a Synthetic Ligand that Induces Heterodimerization of Proteins". PNAS. 1996. 93:4604-4607.) This is why FKBP<sub>3</sub> constructs have been used for all the experiments above. The optimal number of dimerization domains in tandem may be different for each domain. Multiple dimerization domains in series in a protein would increase the number of ligand binding sites on that protein. This would increase the effective affinity of a ligand for that protein. Too many dimerization domains in series would add excess bulk to the fusion protein and cause it to have unfavorable steric interactions with its environment. The balance between these factors determines the ideal number of dimerization domains to put in series for a particular construct.

In an effort to improve the miniCAB dimerization system, constructs with one, two, three or four 340miniCABs in series fused to VE were created through ligations of existing constructs (called (340miniCAB)<sub>n</sub>-VE where n = 1,2,3,4). There was a 2 residue linker between each 340miniCAB subunit due to the restriction profile of the miniCAB constructs. The multiple 340miniCAB constructs were only made with

CNB<sub>MG</sub> containing miniCABs since these gave the best signal in the dimerization assay.

Figure 4 shows that two 340miniCAB domains in series give rise to the highest SEAP activity (9.9 0.4 fold) in the presence of FK506 when cotransfected with FKBP<sub>3</sub>-GE. One and three 340miniCABs in series result in similar levels of SEAP activity while four miniCABs give a very low signal. The EC<sub>50</sub> of two and three miniCABs in series is similar with a value of approximately 1.3 nM and is lower than that for one miniCAB. Like 340miniCAB<sub>MG</sub>-VE, (340miniCAB<sub>MG</sub>)<sub>2</sub>-VE shows little intermolecular association with CNA-GE or CNB<sub>MG</sub>-GE, thereby implying that the activity of this construct is due to its CNA and CNB domains working together in an intramolecular fashion.

Currently, the (340miniCAB<sub>MG</sub>)<sub>2</sub> domain represents the most optimized CAB dimerization reagent.

**15      Example 7: Implementing CAB Mediated Dimerization in Contexts Other than CAB-VE**

In order to show that CAB truly represents a useful new dimerization domain, it must function in the context of activation domains other than VP16. A simple test of CAB versatility would be to create a new transcription activation system in which CAB-GE could be shown to heterodimerize with FKBP-VE. This is the same as the original CAB-VE system except that the activation domains to which CAB and FKBP are fused have been swapped. To implement the new system, six CAB-GE constructs were made. Two of these were full length CABs with either CNB<sub>MG</sub> or CNB<sub>M</sub>. The other four were 340miniCABs and 350miniCABs with either form of CNB. In order to test these proteins, an FKBP-VE fusion protein was needed. As with FKBP<sub>3</sub>-GE, FKBP<sub>3</sub>-VE was already available in a PBJ5 vector and was easily transferred to the pcDNA3/m.jy2 vector used for all constructs in this project.

We found that the CAB-GE's work similarly to the CAB-VE constructs. However, the full length CAB<sub>MG</sub>-GE protein only enhance SEAP activity 2.0 fold whereas the full length CAB<sub>MG</sub>-VE protein could enhance it by approximately 4 fold. Both full CAB-GE and CAB-VE are able to stimulate SEAP activity when heterodimerized to FKBP<sub>3</sub>-GE, demonstrating the versatility of the full CAB domain. In addition, they do not stimulate activity in the absence of FK506. This result implies that the presence of an intact phosphatase active site on the full length CABs

is not responsible for enhanced SEAP activity, a concern raised initially by the constitutive association experiments between CNA and CNB described above.

The 340miniCAB-GE constructs enhance SEAP activity to the same level as the 340miniCAB-VE constructs. No difference was seen between 340miniCAB<sub>MG</sub>-GE and 340miniCAB<sub>M</sub>-GE. Like 340miniCAB-VE, 340miniCAB<sub>MG</sub>-GE does not show significant constitutive activity with CNA or CNB and thus, seems to work through an intramolecular mechanism as opposed to an intermolecular mechanism.

Example 8: Probing the Difference between full length CAB-GE and  
miniCAB-GE

Further experiments were done to explore why the full length CAB<sub>MG</sub>-GE construct was not working as well as its 340miniCAB<sub>MG</sub>-GE counterpart (a trend also observed with the VE CAB proteins). The normal SEAP assay protocol calls for transfecting a 1:5 ratio of GE construct DNA to VE construct DNA. This ratio has been empirically determined to give the best results for the FK1012 and rapamycin dimerization systems. Presumably, the ratio of transfected DNA affects the ratio of translated GE and VE containing proteins. A series of SEAP assays were performed with full CAB<sub>MG</sub>-GE in which the ratio of transfected GE DNA to VE DNA was changed from 1:5 (normal) to 1:1 to 5:1 while keeping the total amount of transfected DNA constant. As the amount of full CAB<sub>MG</sub>-GE DNA was increased the enhancement of SEAP activity increased as well.

A similar series of experiments was performed for 340miniCAB<sub>MG</sub>-GE, but changes in the GE DNA to VE DNA transfection ratio did not affect maximum induced SEAP activity as significantly as for the full CAB<sub>MG</sub>-GE construct. Interestingly, in the 5:1 GE DNA to VE DNA experiment, the maximum amount of SEAP activity induced by full length CAB<sub>MG</sub>-GE was equal to that produced by 340miniCAB<sub>MG</sub>-GE. Even though protein expression levels were never directly examined, these results suggest that greater expression of full CAB<sub>MG</sub>-GE, assuming more transfected DNA leads to higher levels of expression, increases its performance as a dimerization domain up to the level achieved by 340miniCAB<sub>MG</sub>-GE. This finding supports the previously presented suggestion that miniCABs perform better than full CABs because their smaller size makes them more stable or more efficiently translated or folded than the larger full length CAB proteins.

**Example 9: Synthesis of C40 bumped FK506****Extraction/Purification of FK506**

Powder from Prograft<sup>TM</sup> brand pharmaceutical tacrolimus capsules was suspended  
5 in water and FK506 was extracted using 3/7 volume of EtOAc and collected by rotary evaporation. Crude FK506 extract was purified by size exclusion chromatography using a Japan Analytical Industries LC- 908 recycling preparative HPLC equipped with tandem J14 and J11 9C13 columns (hereafter referred to as "Sizing JAI"). The identity of this material was confirmed by TLC, FAB-MS, and  
10 proton NMR.

**Synthesis of C40-phenyl-FK506**

12mg of purified FK506 was sealed with a stir bar in a flame-dried 20ml roundbottom flask and the flask purged with argon. 12ml of CH<sub>2</sub>Cl<sub>2</sub>, freshly  
15 distilled over CaH<sub>2</sub>, was injected and stirred briefly to solubilize the FK506. 0.25mL of styrene (150 eq.) was injected, along with 2.2ml CHCl<sub>2</sub> containing 3.6mg (0.3 eq) of the Grubbs catalyst, bis-tricyclohexylphosphine benzylidene ruthenium chloride. The final reaction concentration of FK506 was thus about 1 mM. This reaction mixture was stirred under argon for 24h at room temperature. Products and  
20 unreacted SM were collected by rotary evaporation, solubilized in ethyl acetate, and filtered through Celite. At this point, fresh solvent, styrene, and catalyst were added in the same proportions and the reaction repeated for an additional 24h.

**Purification of C40-phenyl-FK506**

25 Following rotary evaporation and filtration as described above, the product/SM mixture was resuspended in CH<sub>2</sub>Cl<sub>2</sub> and separated by flash chromatography using a stepwise gradient of a) CH<sub>2</sub>Cl<sub>2</sub>, b) 18:1:1 CH<sub>2</sub>Cl<sub>2</sub>: iPrOH:PhH, c) 12:1:1 CH<sub>2</sub>Cl<sub>2</sub>:iPrOH:PhH, and d) 9:2:2 CH<sub>2</sub>Cl<sub>2</sub>:iPrOH:PhH. Column fractions were analyzed by TLC and compared with standards to facilitate pooling into three major  
30 fractions which were analyzed by FAB-MS. Fraction I contained styrene and stilbene, fraction II contained FK506 and C40-phenyl-FK506, and fraction III contained FK1012 (the FK506 self-metathesis product). The components of fraction II were separated by two rounds of HPLC. First, the mixture was separated by affinity  
35 HPLC using a Japan Analytical Industries LC-908 recycling preparative

HPLC equipped with two tandem JAIGel GS310 columns (hereafter referred to as "Affinity JAI"). Crude C40-phenyl-FK506 as well as crude recovered FK506 were obtained in this fashion. Second, each crude fraction from the Affinity JAI was purified to homogeneity by Sizing JAI as described above. The identity of each purified compound was confirmed by FAB-MS and proton-NMR analysis.

Synthesis/Purification of other C40-derivatized FK506s

In each case, the synthetic route to preparing these derivatives is essentially that described above, using the appropriate terminal olefin compound (usually a substituted styrene) instead of styrene itself. For example, p-phenoxystyrene was used in the synthesis of C40-p-phenyoxy-phenyl-FK506, and m-fluorostyrene was used in the synthesis of C40- m-fluorophenyl-FK506. The principal means of following reaction progress was FAB-MS, with emphasis on the appearance of a parent ion peak which corresponds to the desired product. During purification, FAB-MS was also used to quickly identify the components of JAI fractions. In this case, however, emphasis was placed upon the absence of the parent ion peak corresponding to FK506. This focus is necessary since FK506 is competitive with each product in biological applications, so its absolute absence was considered more important than was maximizing product yields. In some cases, the sequence of JAI purification steps were reversed (i.e. Sizing JAI first, then Affinity JAI), or more such steps were added, in pursuit of this goal.

Example 10: Construction of CAB/p65 fusion proteins

CAB/p65 fusion proteins were prepared in the pBJ5.2X vector, which contains an SV40 origin of replication for high-copy number in mammalian cells transformed with the large tumor antigen. This version of pBJ5 does not contain a selection cassette for mammalian cells and contains the ampicillin-resistance cassette for selection in bacterial cells. This plasmid contains an SRa promoter for high-level expression in mammalian cells. The polylinker sequence of this plasmid consists of the following elements (HA is the hemagglutinin epitope tag):

**NotI/SacII—Kozak—ATG—XhoI—SalI—HA—SpeI—TAA**

Primers containing restriction sites were prepared in order to amplify two different fragments of calcineurin A, corresponding to the full-length CAB (fCAB) and the

minimal CAB (mCAB). These PCR fragments were subcloned directionally into the polylinker to generate the following constructs:

ATG—XhoI—CnA (12-394) —SalI—SpeI—TAA—EcoRI

5 ATG—XhoI—CnA (340-394) —SalI—SpeI—TAA—EcoRI

Primers containing restriction sites were prepared in order to amplify the fragment of calcineurin B corresponding to residues 3-170 of this protein. These PCR fragments were subcloned directionally into the constructs already containing calcineurin A 10 fragments, producing the following CAB constructs (S\X represents a fusion of complementart SalI and XhoI restriction sites which can no longer be cut by either enzyme):

ATG—XhoI—CnA (12-394)—(S\X)—Cn B (3-170)—SalI—HA—SpeI—TAA

15 ATG—XhoI—CnA (340-394) —(S\X)—Cn B (3-170)—SalI—HA—SpeI—TAA

To study the ability of the CABs to mediate transcriptional activation in the context of FKBP:FK506, a (XhoI/SpeI) fragment containing the transcriptional activation domain of the p65 subunit of NF- $\kappa$ B was inserted into (SalI/SpeI) digested mCAB constructs. This fusion results in another (SalI/XhoI) fusion which cannot be cut by 20 either enzyme. A similar strategy is possible to generate multimers of the CAB domain, greatly facilitating the production of these reagents. Since all of the restriction enzymes within the coding region are 6-base cutters, they preserve the reading frame for protein synthesis. The mature CAB should have the following 25 amino acid sequence:

NH<sub>2</sub>-Met-Leu-Glu-(CnA frag)-Val-Glu-(CnB frag)-Val-Asp-Thr-Ser-COOH

New mCAB-p65 constructs were verified by sequence analysis.

30

**Example 11: Demonstration of FK506-derivatives as "bumps" by calcineurin inhibition assay.**

To demonstrate that the FK506 derivatives are less effective at binding 35 calcineurin than is FK506 itself, we performed reporter gene assays that are sensitive to the action of FK506 on calcineurin. In particular, we transfected human TAg

Jurkat T cells with a reporter construct, NFAT-SEAP, which consists of 12 copies of the NFAT response element fused upstream of the gene for secreted alkaline phosphatase (SEAP). Following transfection, the cells were exposed to phorbol myristate acetate (PMA) and ionomycin (IO), which together are able to activate NFAT-SEAP reporter activity. FK506, by inhibiting calcineurin, antagonizes the effect of PMA+IO in a dose-dependent manner. Specifically, ten million Jurkat cells per condition were transfected with 500ng of NFAT-SEAP reporter construct by electroporation (40ms pulse) and aliquoted at  $0.3 \times 10^6$ /well into a 96-well microtiter plate. PMA (50ng/mL) and IO (1 $\mu$ M) were added to all cells, and serial dilutions of FK506, FK506 derivative, or vehicle, were added. Cells were incubated 36 hours in a tissue culture incubator, then heat-inactivated for 2 hours at 65°C. Following heating, 100 $\mu$ L of cell supernatants were transferred to a replica plate containing 100 $\mu$ L of assay buffer (120 $\mu$ M 4-methylumbelliferyl phosphate in 2M diethanolamine bicarbonate, pH 10). Assays were incubated 8 hours before reading on a Fluoroskan plate reader. The results of these experiments are shown in Figure 7.

We assumed that the reduced ability of the FK506 derivatives (as judged by their higher IC<sub>50</sub> in this assay) to antagonize reporter gene activity is due to an impairment in the ability of the FKBP:ligand complex to bind calcineurin. Other possibilities for the reduced activity of derivatives in this assay are 1) compound insolubility in tissue culture media, 2) inability of compound to penetrate the cell membrane, or 3) inability of compound to bind to FKBP. To rule out these other possibilities, we tested two of the derivatives for their ability to suppress a rapamycin-dependent effect in mink lung cells (Paul A Clemons and Brent Stockwell, unpublished observations). As both the phenyl and phenoxyphenyl derivatives were able to suppress the effects of rapamycin in this context, we believe that each is soluble, cell-permeant, and able to bind FKBP.

**Example 12: Effect of overexpression of full-length CABs (fCABs) on reporter gene activity.**

In contrast to the assay described in the previous section, we wanted to test the ability of the bumped compounds to inhibit the phosphatase activity of the full length CABs (fCABs) upon transient transfection of these constructs. Initial experiments involved the co-transfection of 500-5000ng of fCAB construct DNA along with 500ng of NFAT-SEAP reporter gene. Figure 8 shows the results of these experiments, in which a high level of fCAB overexpression overcame the ability of

FK506 or its derivatives to inhibit reporter gene activity. Also shown is a Western blot corresponding to each concentration of construct DNA transfected.

To tune the phosphatase assay in the context of transiently transfected fCABs, we performed SEAP assays as described above while varying the concentration of fCAB construct DNA between 3.2ng and 320ng. The results of these experiments are shown in Figure 9.

Example 13: Optimization of CAB transcription system based on mCAB-p65 constructs.

In order to screen for mutants CABs which can restore binding to FK506 derivatives, we prepared fusions of the mCAB module to the N-terminus of the activation domain of p65, as described above. Our rationale for the use of this activation domain was that the original transcription construct, with the mCAB fused to VP16, gave low signal amplitudes in the transcription assay. We hoped that changing activation domains would improve this signal and give a stable EC<sub>50</sub> for transcriptional activation. Both of these are required for effective screening of pools of mutants using the transcription assay.

Briefly, we transfected human TAg Jurkat T cells with a reporter construct (GRE-SEAP) containing 12 copies of the Gal4 response element upstream of the gene for SEAP, along with Gal4-(FKBP)<sub>3</sub> and the mCAB-p65 fusion. FK506, a derivative, or vehicle were added to cells in a 96-well plate as with the NFAT-SEAP assay. Initial trials gave very promising results, so we undertook to optimize the transcription system by systematic variation of DNA concentrations for each of the three constructs. In three successive experiments, we found the following optimal DNA concentrations for these transfections:

GRE-SEAP reporter gene	500ng
Gal4-(FKBP) <sub>3</sub> DB fusion	1500ng
mCAB-p65 AD fusion	500ng

Following optimization of DNA concentrations, we tested FK506 and two derivatives in the transcription assay. The results of this experiment are shown in Figure 10A. The amplitudes of activation in these experiments are sufficient to warrant an attempt to screen pools of CAB mutants for compensatory binding.

To address the stability of the dose response in these cells, we carried out a finer titration of FK506 and phenyl-FK506. These data are shown in Figure 10B,

which illustrates this property and indicates that the transcription system comprises a viable assay for screening pools of CAB mutants for compensatory binding.

**Example 14: Mutagenesis strategies for CAB "hole" discovery.**

5 As described above, we envision the use of the improved transcription system to screen pools of mutants for compensatory binding to FK506 derivatives. Put simply, this involves transfection of mixtures of DNA species corresponding to mCAB-p65 mutants, then looking for leftward shifts in the dose-response curves depicted in Figure 10.

10 To mutagenize the mCAB-p65 constructs, we prepared degenerate, internal primer pairs at each of the amino acid positions to be mutagenized. These primers are fully degenerate at the codon corresponding to their respective amino acid position (the positions are the same six positions outlined in the original document). Using each primer and the corresponding (antiparallel) primer outside the coding 15 region (in the vector arms), two degenerate, overlapping PCR products were generated. In a secondary PCR reaction, these two fragments were used as template and amplified by overlap extension using the two external primers. These final products were digested and placed back into the pBJ5.2X host vector. It is these libraries that will be screened in the transcription assay for compensatory mutants.

20 Another strategy for identifying potential compensatory mutants is one involving a yeast three-hybrid system. In such a system, yeast are transformed with a DNA-binding fusion to one dimerization domain and an activation domain fusion to the other dimerization domain, along with an appropriately responsive reporter which drives expression of a nutritional marker gene. Yeast transformants are 25 screened for the recovery of growth at a concentration of FK506 or derivative which does not permit growth of yeast harboring the "wild-type" mCAB-p65 construct. The advantage of such a system is that many more clones can be screened simultaneously, allowing multiple amino acid positions in the mCAB to be randomized simultaneously. Use of such three-hybrid systems for screening 30 mutagenized libraries of FKBP and FRB domains are described in USSN 5,830,462 and WO 96/41865.

The system used to screen CAB libraries is based on the MatchMaker LexA Two-Hybrid System from Clonetech (Catalog # K1609-1). It utilizes two vectors, pLex-A and pB42AD, that contain a DNA binding domain from Lex-A and an 35 activation domain (B42), respectively. In addition, the yeast strain EGY48 contains an integrated LEU2 reporter under the control of the LexA<sub>op(X6)</sub>-Leu2 operator

enabling one to directly screen for LexA induced reporter activation on LEU2 dropout plates.

The normal polylinker from pB42AD was removed and replaced with the polylinker described below. I have fused single copies of FKBP and the CABS C-terminal to both domains.

LexA-miniCAB-E (E = Flag epitope tag)  
B42AD-FKBP-E (E = Flag epitope tag)

Using this system, ~5 million different mutant mCABS can be screened simultaneously on a single petri dish using very small amounts of compounds. Some or all of the residues that will putatively be in contact with the allyl sidechain, or a substituent on the allyl sidechain, of FK506 can be mutated individually or simultaneously by PCR with the oligonucleotides indicated below. These libraries are then ligated into the Lex-A-miniCAB-E construct and electroporated into DH5-alpha e-coli electrocompetent cells from Gibco BRL. The DNA is amplified in DH5-alphas, purified, and transformed into the yeast strain EGY48 that are expressing B42AD-FKBP-E. The library will be further amplified in yeast by growth on -HIS-TRP plates with Glucose as the sugar source (for selection of both the LexA-mCAB and B42AD-FKBP constructs) then plated onto -HIS-TRP-LEU Galactose/Raffinose plates containing 100nM concentrations of each of the bump compounds. Colonies that grow will be checked by plating onto -HIS-TRP-LEU Galactose/Raffinose plates in the absence of compounds to distinguish between mutants that allow constitutive association (ie. False positives) from those that facilitate drug induced association. The colonies that do not grow on the previous control will then be re-plated onto -HIS-TRP-LEU +Galactose/Raffinose with 100 nM of each of the individual bump compounds to be sure that the compounds induce growth. Those that grow will then be compared by plating them onto -HIS-TRP-LEU +Galactose/Raffinose plates with 3 fold dilutions of the bump compounds. The clones that allow the lowest concentration of drug to induce growth will be further analyzed. The DNA from the best positive clones will be rescued or PCR'd to give template for sequencing of the positive hits. These mutants will then be tested in one or more of the assays (ie. transcription assay with mCABS) that we have developed in cell culture for verification of the improvement of affinity of the miniCABS for the bump compound in the context of FKBP. The shuttling of these mutant miniCABS

into these other systems can be accomplished by a simple ligation since they all contain a 5' Xho1 site and a 3' Sal 1 site and a 3' Apa1 site.

**Preparation of the Constructs:**

5

A. pB42AD constructs.

The pB42AD vector was digested with EcoR1 and Xho1, gel purified and ligated to the following polylinker to give pB42AD-PL3. All of the constructs made with

10 pB42AD are in this pB42AD-PL3 vector.

Polylinker Oligos for pB42AD:

The following two oligonucleotides were phosphorylated with polynucleotide  
15 kinase, annealed, and ligated into pB42AD that had been digested with EcoR1 and Xho 1 to give a new polylinker with the following restriction sites in order.

5' Xho1-Spacer-Sal1-Nco1-BstEII-BspEI-AfI-III-ApaI-EcoR1 3'

20

5' tcg acg aat tcg ggc ccc tta agt ccg gag gtc acc cat ggg tcg acg tcg gtc gta gac  
tcg aga 3'

25

5' aat ttc tcg agt cta cga ccg acg tcg acc cat ggg tga cct ccg gac tta agg ggc ccg  
aat tcg 3'

The miniCABS and FKBP from previously reported constructs were then  
digested with Xho1 and EcoR1 and ligated directly into pB42AD-PL.

30

B. pLexA constructs.

The following oligos were used with standard PCR conditions to generate an  
FKBP fragment with a 5' EcoR1 and a 3' BamHI. pLexA and this fragment were  
35 digested with EcoR1 and BamH1, gel purified, and ligated.

FKBP oligos:

5 1. FKBP Y2H<sup>ex</sup> 5' (5' oligo for FKBP with EcoR1 and Xho1 restriction sites

EcoR1 Xho1 Met

5' c ggg ccc ccc gaa ttc ctc gag atg ggc gtg cag gtg gag ac 3'

10 2. FKBP Y2H<sup>sb</sup> 3' (3' oligo for FKBP with 3'Sal 1 and BamH1 restriction sites. No stop codon)

BamH1 Sal1 E

5' ggg tct gga tcc gtg gac ttc cag ttt tag aag ctc g 3'

15

Construction of the miniCABS for pLexA:

mCABS were PCR'd with standard PCR conditions off of my original miniCAB template with the followin oligos and digested with NcoI and BamHI. This 20 gel purified fragment was ligated to gel purified pLexA digested with BamHI and NcoI.

3. mCAB Y2H<sup>ex</sup> 5' (5' oligo for mCAB starting at residue 340 of CNA with 5' BamH1 and Xho1 sites.)

25

BamH1 Xho1 Pro340

5' a tat aaa tcg gga tc cgt ctc gag cca tac tgg ctt cca aat ttc atg g 3'

4. mCAB Y2H<sup>s<sub>flag</sub></sup> 3' (3' oligo for mCAB with 3' Sal1, Flag, Stop, Apa1, Not1, and 30 Nco1)

Nco1 Not1 Apa1 stp -----Flag----- Sal1

5' tct tt aa cca tgg cgg ccg c ggg ccc tca ctt gtc atc gtc atc ttt ata gtc gac cac atc tac cac cat c 3'

35

C. Mutagenic Oligos for mCABs. The following are the oligonucleotides used to generate the libraries of mutant mCABS. They were constructed with the codon NN(G/C) (N= G, A, T, or C) at each of the following positions that we mutagenized. The numbering scheme from each of the independent proteins in the mCAB is retained.

For the CNB portion an overlap mutagenesis strategy was employed. An N-terminal fragment without mutations was PCR'd from my original miniCAB template. This has a region that will anneal with a C-terminal fragment generated by PCR with the indicated oligonucleotides. These two fragments were mixed and subjected to PCR with standard conditions to generate a fragment with an N-terminal Pflm1 site and a C-terminal Apa1 site. Since this reaction generated a visible fragment of the proper size it was then further amplified with oligo 4. above (mCAB Y2H<sup>stann</sup> 3') and the Pflm1 oligo below to generate a significant amount of product. This was then digested with Pflm1 and Nco1 and ligated into pLexA-mCAB-E that had been digested with Pflm1 and Nco1 and gel purified. The CNA portion of the mCABS was mutagenized with the oligos under 2. below by PCR to generate a small fragment of the mCAB with a 3' Pflm1 site and a 5'Xho site. This was ligated into pLexA-mCABE digested with Pflm1 and Xho1. To generate the 5 position library this can be ligated into pLexA-mCABE library with the 3 positions mutagenized.

1. Overlap extension mutagenesis of the CNB portion of the mCABS.

25 5' oligo for generation of the N-terminal portion of CNB for overlap.

Pflm1

5' ct tgg tcc ctt cca ttt gtt ggg gaa aaa gtg act gag 3'

30 3' oligo for generation of the N-terminal portion of CNB for overlap.

5' ggg aac aat ctg aaa gat aca cag tta cag c 3'

35 5' mutagenic oligo for generation of C-terminal portion of CNB for overlap.

Val119    Met118                Leu115  
 5' gctg taa ctg tgt atc ttt cag att gtt ccc (g/c)NN (g/c)NN cat ctt  
 (g/c)NN tac ctg gaa gag ttc ccc 3'

5                                    3' mutagenic oligo for generation of C-terminal portion of CNB for overlap.

XbaI BglII ApaI Stp -----FLAG----- Sall    170  
 5' ttaa tct aga tct ggg ccc tca ctt gtc atc gtc atc ttt ata gtc gac cac atc  
 tac cac cat c 3'

10

2. Mutagenic oligos for the CNA portion of mCABS.

5' Mutagenic oligo with 5' Xho I site.

15                                    XhoI 340

5' atat aaa tcg ctc gag cca tac tgg ctt cca aat ttc atg g 3'

3' Mutagenic oligo

20                                    PflM1                353                352

5' ctc agt cac ttt ttc ccc aac aaa tgg aag (g/c)NN (g/c)NN agt aaa aac atc  
 cat g 3'

25    **Example 15: Use of the CAB domain in complex with multiple binding partners**

In order to engineer a cell containing both FKBP/FK506/CAB complexes as well as cyclophilin/cyclosporin/CAB complexes, one would first test the ability of the CAB domain to form cyclophilin/cyclosporin/CAB complexes by replacing FKBP directly with cyclophilin in the transcription assay described in example 4.

30    Thus, the cell would be transfected with a first fusion protein containing cyclophilin and a DNA binding domain such as GAL4, and a second fusion protein containing a CAB domain fused to a transcription activation domain such as p65. Reporter gene expression would be detected following addition of cyclosporin to the cells. Such experiments have been described in WO 98/08956, especially in Example 3. Once formation of cyclophilin/cyclosporin/CAB complexes is demonstrated, one would

then show that cells containing both cyclophilin and FKBP fusion proteins could form the appropriate complexes upon addition of the correct ligand.

A proof of principle experiment for each of the modes of CAB function illustrated in figure 5 would involve fluorescent proteins. To demonstrate the recruitment of either FRB or CAB to the same (FKBP) dock, we would make fusions of each of these modules to a different fluorescent protein, such as BFP and GFP, then cotransfect these constructs with a nuclear (or membrane-localized) FKBP construct. Treatment with rapamycin, FK506, or both should result in translocation of either or both of the fluorescence signals to the nucleus (or membrane). To demonstrate the docking of CAB with either FKBP or cyclophilin, we would make fusions of each of these immunophilins to a different localization signal sequence, such as those for nuclear or membrane localization, then cotransfect these constructs with CAB-GFP. Treatment with FK506, cyclosporin, or both, should result in translocation of green fluorescence signal to the appropriate location. These experiments would ideally be backed up immunoprecipitation studies. For example, one could use an antibody to calcineurin or the CAB domain to immunoprecipitate the CAB domain in the presence of FK506 or cyclosporin. One would then run the immunoprecipitates on SDS-page, perform a Western transfer and detect the complex formation by blotting with antibodies to either FKBP or cyclophilin.

A use for this system has been envisioned in the conditional regulation of the protein kinases Akt and PDK1. These kinases are regulated by their proximity to each other and to the membrane in a complex way. Using the first mode of localization discussed above, but replacing each of BFP and GFP with one of these kinases, we could perform order of addition experiments with rapamycin and FK506 in which we monitor treated cells for readouts known to be downstream of one or the other of these kinases. Because these kinases impinge, directly or indirectly, on pathways involving the cellular targets of both rapamycin and FK506, one would preferably have "bump-hole" solutions for each of these immunophilin-ligand complexes in order to carry out these experiments.



The full disclosure of each of the patent documents and scientific papers cited herein is hereby incorporated by reference. Those documents serve to illustrate the state of the art in various aspects of this invention. Numerous modifications and variations of the present invention should be apparent to one of skill in the art. Such modifications and variations, including design choices in selecting a heterologous action domain, improved ligand, fusion protein design, DNA formulation, viral vector or other DNA delivery means, manner and route of transgene administration, etc. are intended to be encompassed by the scope of the invention and of the appended claims.

## Claims:

1. A recombinant nucleic acid encoding a CAB domain, comprising a portion of calcineurin A and a portion of calcineurin B, wherein the CAB domain forms a tripartite complex with an FKBP/CAB ligand and an FKBP domain.

5 2. The recombinant nucleic acid of claim 1 wherein the calcineurin A portion of the CAB domain comprises a peptide sequence selected from any of the following 10 peptide sequences: residues 12-394 of human calcineurin A, residues 12-370 of human calcineurin A or residues 340-394 of human calcineurin A.

15 3. The recombinant nucleic acid of claim 1 wherein the calcineurin B portion of the CAB domain comprises residues 3-170 of human calcineurin B.

4. The recombinant nucleic acid of claim 1, 2 or 3 comprising a nucleic acid sequence encoding a calcineurin A and/or calcineurin B peptide sequence which differs from a naturally occurring calcineurin peptide sequence by up to ten amino acid substitutions, deletions or insertions.

20 5. A recombinant nucleic acid encoding a fusion protein comprising at least one CAB domain of claim 1 and at least one additional domain that is heterologous thereto.

25 6. The recombinant nucleic acid of claim 5 wherein the heterologous domain is selected from the group comprising a DNA binding domain, a transcription regulatory domain, a cellular localizing domain and a signaling domain.

30 7. The recombinant nucleic acid of claim 6 wherein the heterologous domain is or is derived from a lexA, GAL4 or composite DNA binding domain.

8. The recombinant nucleic acid of claim 6 wherein the heterologous domain is or is derived from a p65, VP16 or AP domain.

35 9. The recombinant nucleic acid of claim 6 wherein the heterologous domain is or is derived from a KRAB domain or a ssn-6/TUP-1 domain.

10. The recombinant nucleic acid of claim 6 wherein the heterologous domain is or is derived from an intracellular domain of a cell surface receptor.

5 11. A recombinant nucleic acid encoding a fusion protein containing one or more CAB domains which form a tripartite complex with an FKBP domain-containing protein and a non-naturally occurring FKBP/CAB ligand preferentially over FK506.

10 12. A nucleic acid composition, comprising a first recombinant nucleic acid of any of claims 5-11 and a second recombinant nucleic acid encoding a fusion protein comprising at least one FKBP domain and at least one additional domain that is heterologous thereto.

15 13. A nucleic acid composition of claim 12 wherein the second nucleic acid encodes a fusion protein containing a heterologous domain that is the same or different from the heterologous domain on the first fusion protein.

20 14. The nucleic acid composition of claim 13 wherein the first fusion protein comprises a CAB domain and a transcription activation domain and the second fusion protein comprises an FKBP domain and a DNA binding domain.

25 15. The nucleic acid composition of claim 13 wherein the first fusion protein comprises a CAB domain and a DNA binding domain and the second fusion protein comprises an FKBP domain and a transcription activation domain.

16. A nucleic acid composition of claim 12 wherein the first and second fusion proteins form a ligand dependent complex in the presence of ligand, and wherein the complex initiates a detectable biological signal.

30 17. The nucleic acid composition of claim 16 wherein the biological signal is selected from the group comprising transcription, cell proliferation, cell differentiation, apoptosis.

35 18. The nucleic acid composition of claim 12 wherein the composition further comprises a target gene construct.

19. A fusion protein encoded by the recombinant nucleic acid of any of claims 5-11.
20. A vector comprising a recombinant nucleic acid of any of claims 1-3 or 5-11.  
5
21. A vector comprising a recombinant nucleic acid of claim 4.
22. A vector comprising a nucleic acid composition of claim 12.
- 10 23. The vector of claim 20 wherein the vector is a viral vector.
24. The vector of claim 22 wherein the vector is a viral vector.
25. The vector of claim 23 or 24 wherein the viral vector is selected from the  
15 group consisting of adenovirus, AAV, herpesvirus, retrovirus, hybrid adenovirus/AAV, poxvirus, lentivirus.
26. A host cell comprising a recombinant nucleic acid of any of claims 1-3 or 5-11.  
20
27. A host cell comprising a nucleic acid composition of claim 12.
28. A host cell cell of claim 26 which is of human origin.
- 25 29. A host cell cell of claim 27 which is of human origin.
30. A host cell of claim 26 which is encapsulated within a biocompatible material.
- 30 31. A host cell of claim 27 which is encapsulated within a biocompatible material.
32. A non-human animal containing host cells of claim 26.
- 35 33. A non-human animal containing host cells of claim 27.

34. A method for producing genetically engineered host cells comprising introducing into the cells a recombinant nucleic acid of any of claims 1-3 or 5-11 under conditions permitting DNA uptake by cells.

5 35. A method for producing genetically engineered host cells comprising introducing into the cells the nucleic acid compositions of any of claims 12-18 under conditions permitting DNA uptake by cells.

10 36. The method of claim 34 wherein the nucleic acids are introduced ex vivo.

37. The method of claim 35 wherein the nucleic acids are introduced ex vivo.

38. The method of claim 34 wherein the cells are present within an organism.

15 39. The method of claim 35 wherein the cells are present within an organism.

40. A method for multimerizing fusion proteins in the cell of claim 27 which comprises contacting the cells with an effective amount of a ligand under conditions permitting it to form a complex with the fusion proteins.

20 41. A method for initiating a detectable biological signal in cells of claim 27 which comprises contacting the cells with a ligand capable of forming a complex with the fusion proteins, in an effective amount permitting gene expression.

25 42. A method of claim 40 or 41 wherein the cells are grown in a culture medium and the contacting is effected by adding the ligand to the culture medium.

30 43. A method of claim 40 or 41 wherein the cells are present within a host organism and the contacting is effected by administering the ligand to the host organism.

35 44. A method of claim 43 wherein the host organism is a mammal and the ligand is administered by oral, bucal, sublingual, transdermal, subcutaneous, intramuscular, intravenous, intra-joint or inhalation administration in an appropriate vehicle therefor.

45. A method for providing animal cells responsive to a ligand which comprises introducing into host animal cells a nucleic acid composition of any of claims 12-18.
46. A kit which comprises the nucleic acid composition of any of claims 12-18 with an appropriate package insert.
47. A kit of claim 46 which further comprises a ligand capable of forming a complex with the fusion proteins.
- 10 48. A kit of claim 47 which further comprises a multimerization antagonist.
49. A kit of claim 46 in which one or more of the DNA constructs contains a cloning site in place of a heterologous domain.
- 15 50. A kit of claim 46 in which the target gene construct contains a cloning site in place of a target gene.

20

Figure 1

FKBP <sub>3</sub> -VE	NLS	FKBP	FKBP	FKBP	VP16	Flu
-----------------------	-----	------	------	------	------	-----

full CAB-VE	NLS	CNA 12-394	CNB	VP16	Flu
-------------	-----	------------	-----	------	-----

mini CAB-VE	NLS	CNA	CNB	VP16	Flu	CNA 340-394
-------------	-----	-----	-----	------	-----	-------------

FKBP <sub>3</sub> -GE	GAL4	FKBP	FKBP	FKBP	Flag
-----------------------	------	------	------	------	------

full CAB-GE	GAL4	CNA 12-394	CNB	Flag
-------------	------	------------	-----	------

mini CAB-VE	GAL4	CNA	CNB	Flag	CNA 340-394
-------------	------	-----	-----	------	-------------

full CAB-p65	NLS	CNA 12-394	CNB	p65	Flu
--------------	-----	------------	-----	-----	-----

mini CAB-p65	NLS	CNA	CNB	p65	Flu	CNA 340-394
--------------	-----	-----	-----	-----	-----	-------------

Figure 2

Initial reaction scheme for direct synthesis of (*E/Z*)-C40-phenyl-FK506.





Figure 3

**Styrene and its analogs to be used in cross-metathesis reaction with FK506.**



			1    Allyltrimethylsilane
			2    4-Vinylbenzoic acid
			3    4-Sulfamidostyrene
			4    2-Fluorostyrene
			5    3-Fluorostyrene
			6    4-Fluorostyrene
			7    3-Bromostyrene
			8    2-Bromostyrene
			9    4-Iodostyrene
			10    4-Vinylbiphenyl
			11    4-Phenoxystyrene
			12    2-Vinylnaphthalene
			13    2,5-Dimethylstyrene
			14    2,4-Dimethylstyrene
			15    9-Vinylanthracene

Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10

